



(86) **Date de dépôt PCT/PCT Filing Date:** 2007/12/20  
(87) **Date publication PCT/PCT Publication Date:** 2008/07/03  
(45) **Date de délivrance/Issue Date:** 2015/08/04  
(85) **Entrée phase nationale/National Entry:** 2009/06/17  
(86) **N° demande PCT/PCT Application No.:** US 2007/088473  
(87) **N° publication PCT/PCT Publication No.:** 2008/080029  
(30) **Priorité/Priority:** 2006/12/21 (US60/871,451)

(51) **Cl.Int./Int.Cl. C12P 19/34** (2006.01),  
**C07H 21/00** (2006.01), **C12Q 1/68** (2006.01)

(72) **Inventeurs/Inventors:**  
BRENTANO, STEVEN T., US;  
CARLSON, JAMES D., US;  
LYAKHOV, DMITRY, US;  
NELSON, NORMAN C., US;  
ARNOLD, LYLE J., JR., US;  
BECKER, MICHAEL M., US

(73) **Propriétaire/Owner:**  
GEN-PROBE INCORPORATED, US

(74) **Agent:** SMART & BIGGAR

(54) **Titre : PROCÉDES ET COMPOSITIONS POUR L'AMPLIFICATION D'ACIDE NUCLEIQUE**  
(54) **Title: METHODS AND COMPOSITIONS FOR NUCLEIC ACID AMPLIFICATION**

(57) **Abrésumé/Abstract:**

Compositions that are used in nucleic acid amplification in vitro are disclosed, which include a target specific universal (TSU) promoter primer or promoter provider oligonucleotide that includes a target specific (TS) sequence that hybridizes specifically to a target sequence that is amplified and a universal (U) sequence that is introduced into the sequence that is amplified, by using a primer for the universal sequence. Methods of nucleic acid amplification in vitro are disclosed that use one or more TSU oligonucleotides to attached a U sequence to a target nucleic acid in a target capture step and then use a primer for a U sequence in subsequent amplification steps performed in substantially isothermal conditions to make amplification products that contain a U sequence that indicates the presence of the target nucleic acid in a sample.



## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
3 July 2008 (03.07.2008)

PCT

(10) International Publication Number  
**WO 2008/080029 A3**

(51) International Patent Classification:  
*C12P 19/34* (2006.01)

(21) International Application Number:  
PCT/US2007/088473

(22) International Filing Date:  
20 December 2007 (20.12.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/871,451 21 December 2006 (21.12.2006) US

(71) Applicant: **GEN-PROBE INCORPORATED** [US/US];  
10210 Genetic Center Drive, San Diego, California 92121  
(US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BRENTANO, Steven T.** [US/US]; 8426 Mesa Ridge Road, Santee, California 92071 (US). **CARLSON, James D.** [US/US]; 1461 Missouri Street, Apt. 1, San Diego, California 92109 (US). **LYAKHOV, Dmitry** [RU/US]; 13908 Capewood Lane, Apt.327, San Diego, California 92128 (US). **NELSON, Norman C.** [US/US]; 3639 Marlesta Drive, San Diego, California 92111 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH,

CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

## Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- with sequence listing part of description published separately in electronic form and available upon request from the International Bureau

(88) Date of publication of the international search report:  
16 October 2008

(15) Information about Correction:

Previous Correction:  
see Notice of 14 August 2008

(54) Title: METHODS AND COMPOSITIONS FOR NUCLEIC ACID AMPLIFICATION

(57) Abstract: Compositions that are used in nucleic acid amplification in vitro are disclosed, which include a target specific universal (TSU) promoter primer or promoter provider oligonucleotide that includes a target specific (TS) sequence that hybridizes specifically to a target sequence that is amplified and a universal (U) sequence that is introduced into the sequence that is amplified, by using a primer for the universal sequence. Methods of nucleic acid amplification in vitro are disclosed that use one or more TSU oligonucleotides to attached a U sequence to a target nucleic acid in a target capture step and then use a primer for a U sequence in subsequent amplification steps performed in substantially isothermal conditions to make amplification products that contain a U sequence that indicates the presence of the target nucleic acid in a sample.

WO 2008/080029 A3

## METHODS AND COMPOSITIONS FOR NUCLEIC ACID AMPLIFICATION

### FIELD OF THE INVENTION

This invention relates to molecular biology, more specifically to *in vitro* amplification of nucleic acids which is useful for increasing the number of copies of a nucleic acid sequence to provide sufficient copies to be readily detected.

### BACKGROUND

Nucleic acid amplification provides a means for making more copies of a nucleic acid sequence that is relatively rare or unknown, for identifying the source of nucleic acids, or for making sufficient nucleic acid to provide a readily detectable amount. Amplification is useful in many applications, for example, in diagnostics, drug development, forensic investigations, environmental analysis, and food testing.

Many methods for amplifying nucleic acid sequences *in vitro* are known, including polymerase chain reaction (PCR), ligase chain reaction (LCR), replicase-mediated amplification, strand-displacement amplification (SDA), "rolling circle" types of amplification, and various transcription associated amplification methods. These known methods use different techniques to make amplified sequences, which usually are detected by using a variety of methods. PCR amplification uses a DNA polymerase, oligonucleotide primers, and thermal cycling to synthesize multiple copies of both strands of a double-stranded DNA (dsDNA) or dsDNA made from a cDNA (US Pats. 4,683,195, 4,683,202, and 4,800,159, Mullis et al.). LCR amplification uses an excess of two complementary pairs of single-stranded probes that hybridize to contiguous target sequences and are ligated to form fused probes complementary to the original target, which allows the fused probes to serve as a template for further fusions in multiple cycles of hybridization, ligation, and denaturation (US Pat. 5,516,663 and EP 0320308 B1, Backman et al.). Replicase-mediated amplification uses a self-replicating RNA sequence attached to the analyte sequence and a replicase, such as Q $\beta$ -replicase, to synthesize copies of the self-replicating sequence specific for the chosen replicase, such as a Q $\beta$  viral sequence (US Pat. 4,786,600, Kramer et al.). The amplified sequence is detected as a substitute or reporter molecule for the analyte sequence. SDA uses a primer that contains a recognition site for a restriction endonuclease which allows the endonuclease to nick one strand of a hemimodified dsDNA that includes the target sequence, followed by a series of primer extension and strand displacement steps (US Pat. 5,422,252A, Walker et al., and US Pat. 5,547,861, Nadeau et al.). Rolling circle types of amplification rely on a circular or concatenated nucleic acid structure that serves as a template used to

5 enzymatically replicate multiple single-stranded copies from the template (e.g., US Pat. 5,714,320, Kool, and US Pat. 5,834,252, Stemmer et al.). Transcription associated amplification refers to methods that amplify a sequence by producing multiple transcripts from a nucleic acid template. Such methods generally use one or more oligonucleotides, of which one provides a promoter sequence, and enzymes with RNA polymerase and DNA polymerase activities to make a functional promoter sequence near the  
10 target sequence and then transcribe the target sequence from the promoter (e.g., US Pats. 5,399,491 and 5,554,516, Kacian et al., US Pat. 5,437,990, Burg et al., WO 1988010315 A1, Gingeras et al., US Pat. 5,130,238, Malek et al., US Pats. 4,868,105 and 5,124,246, Urdea et al., and US 2006-0046265 A1, Becker et al.). Nucleic acid amplification methods may amplify a specific target sequence (e.g., a gene sequence), a group of related target sequences, or a surrogate sequence, which may be referred to as  
15 a tag or reporter sequence that is amplified and detected in place of the analyte sequence. The surrogate sequence is only amplified if the analyte target sequence is present at some point during the reaction.

Modified nucleic acid amplification methods may amplify more than one potential target sequence by using "universal" primer(s) or universal priming. One form of PCR amplification uses  
20 universal primers that bind to conserved sequences to amplify related sequences in a PCR reaction (Okamoto et al., 1992, *J. Gen. Virol.* 73(Pt. 3):673-9, Persing et al, 1992, *J. Clin. Microbiol.* 30(8):2097-103). Methods that use universal primers often are paired with use of a species-specific, gene-specific or type-specific primer or primers to generate an amplified sequence that is unique to a species, genetic variant, or viral type, which may be identified by sequencing or detecting some other  
25 characteristic of the amplified nucleic acid. For example, a method may use one universal primer and one specific primer in the same amplification step. For another example, a method may use "nested" PCR in which a pair of universal primers are used in an initial amplification step to amplify many potential target sequences, followed by use of a pair of specific primers in subsequent amplification steps to amplify one or more specific target sequences contained in the initial amplicons.

30 Anchored PCR is another modified PCR method that uses a universal primer or an "adapter" primer to amplify a sequence which is only partially known. Anchored PCR introduces an "adaptor" or "universal" sequence into a cDNA and then uses a primer that binds to the introduced sequence in subsequent amplification steps. Generally, anchored-PCR uses a primer directed to a known sequence to make a cDNA, adds a known sequence (e.g., poly-G) to the cDNA or uses a common  
35 sequence in the cDNA (e.g., poly-T), and performs PCR by using a universal primer that binds to the

added or common sequence in the cDNA and a downstream target-specific primer (Loh et al., 1989, *Science* 243(4888):217-20; Lin et al., 1990, *Mol. Cell. Biol.* 10(4):1818-21). Nested PCR may use primer(s) that contain a universal sequence unrelated to the analyte target sequence to amplify nucleic acid from unknown target sequences in a reaction (Sullivan et al, 1991, *Electrophoresis* 12(1):17-21;

5 Sugimoto et al., 1991, *Agric. Biol. Chem.* 55(11):2687-92).

Other forms of amplification use a probe or probe set to introduce universal priming sites located upstream and downstream of a target-specific sequence and adapter sequence(s), which may be referred to as molecular zip-codes. The upstream and downstream priming sites are used to amplify a nucleic acid that contains the adapter sequence(s) which are detected, usually on an array, to identify the target present in the reaction (US Patent Nos. 6,812,005 and 6,890,741, Fan et al.). The two probes that bind in close proximity on a target sequence may be ligated together before being amplified by using the upstream and downstream universal priming sites.

Alternative assay methods may use probe hybridization and linear signal amplification by using a common sequence that is included in a variety of analyte-specific probes (e.g., US 20070111200, Hudson et al.). This method uses a labeled cassette that contains a sequence complementary to the common sequence to detect multiple analytes.

#### SUMMARY OF THE INVENTION

Various embodiments of this invention provide a method of amplifying a target nucleic acid comprising the steps of: a. mixing a target nucleic acid with a target specific universal (TSU) primer complex made up of i. a TSU promoter primer oligonucleotide comprising a 5' promoter sequence, an internal first universal sequence (U1), and a 3' first target specific sequence (TS1) that binds specifically to a target sequence contained in a target nucleic acid, and a 3' terminus that is capable of being extended by a polymerase, joined to ii. a TSU non-promoter primer oligonucleotide comprising a 5' second universal sequence (U2) and a 3' second target specific sequence (TS2) which is different from the TS1, b. hybridizing the TSU promoter primer oligonucleotide of the TSU primer complex to a target sequence in the target nucleic acid via the TS1 sequence in the TSU promoter primer, c. isolating the target nucleic acid with hybridized TSU complex away unhybridized TSU primer complexes and other sample components, d. synthetically extending the 3' terminus of the TS1 by using a polymerase *in vitro* nucleic acid synthesis in which the target nucleic acid is a template to make a first cDNA strand, e. hybridizing the TSU non-promoter primer oligonucleotide of the TSU primer complex to the first cDNA strand by specific hybridization of the TS2 sequence to its target sequence contained in the first cDNA

strand, f. synthetically extending the 3' terminus of the TS2 sequence hybridized to the first cDNA strand by a polymerase *in vitro* nucleic acid synthesis to make a second DNA strand, thereby making a substantially double-stranded DNA that contains a functional promoter sequence and the U1 sequence, g. enzymatically transcribing RNA transcripts from the functional promoter sequence of the substantially double-stranded DNA to make RNA transcripts that contain a 5' U1 region sequence, a TS1 sequence, a complement of the second target specific sequence (TS2'), and a 3' universal sequence that is complementary to the U2 sequence (U2'), h. hybridizing a universal primer oligonucleotide (UP2) that contains a universal sequence U2 to the RNA transcript at the U2' sequence, i. synthetically extending the 3' terminus of the UP2 by enzymatic *in vitro* nucleic acid synthesis to make a cDNA strand, j. hybridizing a universal promoter primer oligonucleotide (UP1) that contains a universal sequence U1 to the cDNA made in the previous step at the U1' sequence, k. synthetically extending at least the 3' terminus of the DNA strand made in step i, by enzymatic *in vitro* nucleic acid synthesis to make a functional promoter, and l. transcribing multiple RNA transcripts from the functional promoter, which transcripts are amplification products that may serve as templates for further enzymatic *in vitro* nucleic acid synthesis.

Various embodiments of this invention provide a method of amplifying a target nucleic acid comprising the steps of: a. mixing a target nucleic acid with a target specific universal (TSU) complex made up of i. a TSU promoter oligonucleotide comprising a 5' promoter sequence, an internal first universal sequence (U1), and a 3' first target specific sequence (TS1) that binds specifically to its target sequence, wherein the TSU promoter oligonucleotide is a TSU promoter provider oligonucleotide that has a blocked 3' terminus that is incapable of being extended by a polymerase, joined to ii. a TSU non-promoter primer oligonucleotide comprising a 5' second universal sequence (U2) and a 3' second target specific sequence (TS2) which is different from the TS1, b. hybridizing the TSU non-promoter primer oligonucleotide of the TSU complex to a target sequence in the target nucleic acid via the TS2 sequence in the TSU non-promoter primer, c. optionally hybridizing a blocker oligonucleotide to a sequence on the target nucleic acid, wherein said blocker comprises a blocked 3' terminus to prevent extension of the blocker by a polymerase and wherein the blocker oligomer is hybridized to the target nucleic acid at a position to terminate polymerase extension of the TSU non-promoter primer, d. isolating the target nucleic acid with hybridized TSU complex away unhybridized TSU primer complexes and other sample components, e. synthetically extending the 3' terminus of the TSU non-promoter primer hybridized to the target nucleic acid by using a polymerase *in vitro* nucleic acid synthesis in which the target nucleic acid is a template to make a first cDNA strand, f. hybridizing the TSU promoter provider oligonucleotide of the TSU complex to the first cDNA strand by specific hybridization of the TS1 sequence in the TSU promoter provider oligonucleotide to a target sequence contained in the first cDNA strand, g. synthetically extending the 3' terminus of the first cDNA by using the TSU promoter provider as a template to make a substantially double-stranded DNA that contains a functional

promoter sequence and the U1 sequence, h. enzymatically transcribing RNA transcripts from the functional promoter sequence to make RNA transcripts that contain a 5' U1 region sequence, a TS1 sequence, a complement of the second target specific sequence (TS2'), and a 3' universal sequence that is complementary to the U2 sequence (U2'), i. hybridizing a universal primer oligonucleotide (UP2) that contains a universal sequence U2 to the RNA transcript at the U2' sequence, j. synthetically extending the 3' terminus of the UP2 by enzymatic *in vitro* nucleic acid synthesis to make a cDNA strand, k. hybridizing to the U1' sequence a universal promoter oligonucleotide (UP1) that contains a promoter sequence, a universal sequence U1, and a 3' blocked end to the cDNA made in step j, l. synthetically extending the 3' terminus of the DNA strand made in step j using the UP1 oligonucleotide as a template to make a functional double-stranded promoter using enzymatic *in vitro* nucleic acid synthesis, and m. transcribing multiple RNA transcripts from the functional promoter, which transcripts are amplification products that may serve as templates for further enzymatic *in vitro* nucleic acid synthesis.

Various embodiments of this invention provide a method of amplifying a target nucleic acid comprising the steps of: a. mixing a target nucleic acid with a target specific universal (TSU) promoter primer oligonucleotide comprising a 5' promoter sequence, an internal first universal sequence (U1), and a 3' first target specific sequence (TS1) that binds specifically to a target sequence contained in a target nucleic acid, and a 3' terminus of the TS1 is capable of being extended by a polymerase, b. hybridizing the TSU promoter primer oligonucleotide to its target sequence in a target nucleic acid via the TS1 sequence of the TSU promoter primer and then synthetically extending the 3' terminus of the TSU promoter primer oligonucleotide hybridized to the target nucleic acid by using a polymerase *in vitro* nucleic acid synthesis in which the target nucleic acid is a template to make a first cDNA strand, c. isolating the target nucleic acid with hybridized TSU complex away unhybridized TSU primer complexes and other sample components, d. hybridizing a target specific (TS) non-promoter primer oligonucleotide, comprising a second target specific sequence (TS2) that is different from TS1, to the first cDNA strand by specific hybridization of the TS2 sequence to its target sequence contained in the first cDNA strand, e. synthetically extending the 3' terminus of the TS non-promoter primer oligonucleotide hybridized to the first cDNA strand by a polymerase *in vitro* nucleic acid synthesis to make a second DNA strand, thereby making a substantially double-stranded DNA that contains a functional promoter sequence and the U1 sequence, f. enzymatically transcribing RNA transcripts from the functional promoter sequence of the substantially double-stranded DNA to make RNA transcripts that contain a 5' U1 region sequence, a first target specific sequence (TS1) and, a complement of the second target specific sequence (TS2'), g. hybridizing a TS non-promoter primer to the TS2' sequence of an RNA transcript made in step f and extending the 3' terminus of the TS non-promoter primer to make a cDNA strand, h. hybridizing a universal promoter primer oligonucleotide that contains a universal sequence U1 to the U1' sequence of the

DNA strand generated in step g, i. synthetically extending at least the 3' terminus of the DNA strand by enzymatic *in vitro* nucleic acid synthesis to make a functional promoter sequence, and j. transcribing multiple RNA transcripts from the functional promoter, which transcripts are amplification products that may serve as templates for further enzymatic *in vitro* nucleic acid synthesis.

5           Various embodiments of this invention provide a method of amplifying a target nucleic acid comprising the steps of: a. mixing a target nucleic acid with a TSU non-promoter primer oligonucleotide comprising a 5' universal sequence (U2) and a 3' target specific sequence (TS2), b. hybridizing the TSU non-promoter primer oligonucleotide to a target sequence in the target nucleic acid via the TS2 sequence to a complementary sequence in the target nucleic acid, c. optionally hybridizing a blocker oligonucleotide to a  
10           sequence on the target nucleic acid, wherein said blocker comprises a blocked 3' terminus to prevent extension of the blocker by a polymerase and wherein the blocker oligomer is hybridized to the target nucleic acid at a position to terminate polymerase extension of the TSU non-promoter primer, d. isolating the target nucleic acid with hybridized TSU complex away unhybridized TSU primer complexes and other sample components, e. synthetically extending the 3' terminus of the TSU non-promoter primer hybridized to the  
15           target nucleic acid by using a polymerase *in vitro* nucleic acid synthesis in which the target nucleic acid is a template to make a first cDNA strand, f. hybridizing to the first cDNA strand a target specific (TS) promoter provider oligonucleotide comprising a 5' promoter sequence and a 3' target specific sequence (TS1) that binds specifically to a target sequence contained in a target nucleic acid and a blocked 3' terminus that is incapable of being extended by a polymerase, wherein the TS promoter provider is hybridized to the first cDNA strand by  
20           specific hybridization of the TS1 sequence to a complementary sequence in the first cDNA strand, g. synthetically extending the 3' terminus of the first cDNA by using the TS promoter provider as a template to make a substantially double-stranded DNA that contains a functional promoter sequence and a TS1 sequence, h. enzymatically transcribing RNA transcripts from the functional promoter sequence to make RNA transcripts that contain a 5' target specific sequence TS1, a complement of the target specific sequence (TS2')  
25           and a complement of the universal sequence (U2'), i. hybridizing a universal primer oligonucleotide (UP2) that contains a universal sequence U2 to the RNA transcript at the U2' sequence, j. synthetically extending the 3' terminus of the UP2 by enzymatic *in vitro* nucleic acid synthesis to made a cDNA strand, k. hybridizing a TS promoter provider oligonucleotide that contains a promoter sequence and a 3' blocked end to the cDNA made in the previous step, l. synthetically extending the 3' terminus of the cDNA to make a functional double-  
30           stranded promoter using enzymatic *in vitro* nucleic acid synthesis, and m. transcribing multiple RNA transcripts from the functional promoter, which transcripts are amplification products that may serve as templates for further enzymatic *in vitro* nucleic acid synthesis.

Various embodiments of this invention provide a method of amplifying a target nucleic acid comprising the steps of:

a. mixing a target nucleic acid with a target specific universal (TSU) primer complex made up of

i. a TSU promoter oligonucleotide comprising a 5' promoter sequence, an internal first

5 universal sequence (U1), and a 3' first target specific sequence (TS1) that binds specifically to a target sequence contained in a target nucleic acid, wherein the TSU promoter oligonucleotide is a TSU promoter primer oligonucleotide that has a 3' terminus that is capable of being extended by a polymerase, directly or indirectly joined to

ii. a TSU non-promoter primer oligonucleotide comprising a 5' second universal sequence (U2)

and a 3' second target specific sequence (TS2) which is different from the TS1,

10 wherein the TSU promoter primer oligonucleotide is joined to the TSU non-promoter primer oligonucleotide via:

A. a covalent linkage,

15 B. a non-covalent linkage of members of a binding pair to join the TSU promoter primer oligonucleotide and the TSU non-promoter primer oligonucleotide to a support, wherein one member of the binding pair is present on the TSU promoter primer oligonucleotide or the TSU non-promoter primer oligonucleotide and the other member of the binding pair is attached to the support,

20 C. a hybridization complex between a first sequence on the TSU promoter primer oligonucleotide and a second sequence on the TSU non-promoter primer oligonucleotide that is complementary to the first sequence on the TSU promoter primer oligonucleotide, or

25 D. a hybridization complex that includes an S-oligonucleotide that contains a first sequence complementary to a sequence in the TSU promoter primer oligonucleotide and a second sequence complementary to a sequence in the TSU non-promoter primer oligonucleotide,

b. hybridizing the TSU promoter primer oligonucleotide of the TSU primer complex to a target sequence in the target nucleic acid via the TS1 sequence in the TSU promoter primer,

c. isolating the target nucleic acid with hybridized TSU complex away from unhybridized TSU primer complexes and other sample components,

30 d. synthetically extending the 3' terminus of the TS1 by using a polymerase *in vitro* nucleic acid synthesis in which the target nucleic acid is a template to make a first cDNA strand,

e. hybridizing the TSU non-promoter primer oligonucleotide of the TSU primer complex to the first cDNA strand by specific hybridization of the TS2 sequence to its target sequence contained in the first cDNA strand,

f. synthetically extending the 3' terminus of the TS2 sequence hybridized to the first cDNA strand by a polymerase *in vitro* nucleic acid synthesis to make a second DNA strand, thereby making a substantially double-stranded DNA that contains a functional promoter sequence and the U1 sequence,

g. enzymatically transcribing RNA transcripts from the functional promoter sequence of the substantially double-stranded DNA to make RNA transcripts that contain a 5' U1 region sequence, a TS1 sequence, a complement of the second target specific sequence (TS2'), and a 3' universal sequence that is complementary to the U2 sequence (U2'),

h. hybridizing a universal primer oligonucleotide (UP2) that contains a universal sequence U2 to the RNA transcript at the U2' sequence,

i. synthetically extending the 3' terminus of the UP2 by enzymatic *in vitro* nucleic acid synthesis to make a cDNA strand,

j. hybridizing a universal promoter primer oligonucleotide (UP1) that contains a universal sequence U1 to the cDNA made in the previous step at the U1' sequence,

k. synthetically extending at least the 3' terminus of the DNA strand made in step i, by enzymatic *in vitro* nucleic acid synthesis to make a functional promoter, and

l. transcribing multiple RNA transcripts from the functional promoter, which transcripts are amplification products that may serve as templates for further enzymatic *in vitro* nucleic acid synthesis.

Various embodiments of this invention provide a method of amplifying a target nucleic acid comprising the steps of:

a. mixing a target nucleic acid with a target specific universal (TSU) complex made up of  
i. a TSU promoter oligonucleotide comprising a 5' promoter sequence, an internal first universal sequence (U1), and a 3' first target specific sequence (TS1) that binds specifically to its target sequence, wherein the TSU promoter oligonucleotide is a TSU promoter provider oligonucleotide that has a blocked 3' terminus that is incapable of being extended by a polymerase, directly or indirectly joined to

ii. a TSU non-promoter primer oligonucleotide comprising a 5' second universal sequence (U2) and a 3' second target specific sequence (TS2) which is different from the TS1,

wherein the TSU promoter provider oligonucleotide is joined to the TSU non-promoter primer oligonucleotide via:

A. a covalent linkage,

B. a non-covalent linkage of members of a binding pair to join the TSU promoter provider oligonucleotide and the TSU non-promoter primer oligonucleotide to a support, wherein one member of the binding pair is present on the TSU promoter provider oligonucleotide or the TSU non-promoter primer oligonucleotide and the other member of the binding pair is attached to the support,

- 5 C. a hybridization complex between a first sequence on the TSU promoter provider oligonucleotide and a second sequence on the TSU non-promoter primer oligonucleotide that is complementary to the first sequence on the TSU promoter provider oligonucleotide, or
- 10 D. a hybridization complex that includes an S-oligonucleotide that contains a first sequence complementary to a sequence in the TSU promoter provider oligonucleotide and a second sequence complementary to a sequence in the TSU non-promoter primer oligonucleotide,
- 15 b. hybridizing the TSU non-promoter primer oligonucleotide of the TSU complex to a target sequence in the target nucleic acid via the TS2 sequence in the TSU non-promoter primer,
- c. optionally hybridizing a blocker oligonucleotide to a sequence on the target nucleic acid, wherein said blocker comprises a blocked 3' terminus to prevent extension of the blocker by a polymerase and wherein the blocker oligomer is hybridized to the target nucleic acid at a position to terminate polymerase extension of the TSU non-promoter primer,
- 20 d. isolating the target nucleic acid with hybridized TSU complex away from unhybridized TSU primer complexes and other sample components,
- e. synthetically extending the 3' terminus of the TSU non-promoter primer hybridized to the target nucleic acid by using a polymerase *in vitro* nucleic acid synthesis in which the target nucleic acid is a template to make a first cDNA strand,
- 25 f. hybridizing the TSU promoter provider oligonucleotide of the TSU complex to the first cDNA strand by specific hybridization of the TS1 sequence in the TSU promoter provider oligonucleotide to a target sequence contained in the first cDNA strand,
- g. synthetically extending the 3' terminus of the first cDNA by using the TSU promoter provider as a template to make a substantially double-stranded DNA that contains a functional promoter sequence and the U1 sequence,
- 30 h. enzymatically transcribing RNA transcripts from the functional promoter sequence to make RNA transcripts that contain a 5' U1 region sequence, a TS1 sequence, a complement of the second target specific sequence (TS2'), and a 3' universal sequence that is complementary to the U2 sequence (U2'),
- i. hybridizing a universal primer oligonucleotide (UP2) that contains a universal sequence U2 to the RNA transcript at the U2' sequence,
- j. synthetically extending the 3' terminus of the UP2 by enzymatic *in vitro* nucleic acid synthesis to make a cDNA strand,
- k. hybridizing to the U1' sequence a universal promoter oligonucleotide (UP1) that contains a promoter sequence, a universal sequence U1, and a 3' blocked end to the cDNA made in step j,

l. synthetically extending the 3' terminus of the DNA strand made in step j using the UP1 oligonucleotide as a template to make a functional double-stranded promoter using enzymatic *in vitro* nucleic acid synthesis, and

m. transcribing multiple RNA transcripts from the functional promoter, which transcripts are amplification products that may serve as templates for further enzymatic *in vitro* nucleic acid synthesis.

5

Various embodiments of this invention provide a composition comprising: a TSU promoter oligonucleotide that includes a 5' promoter sequence, an internal first universal sequence (U1), and a 3' first target specific sequence (TS1) that binds specifically to a target sequence contained in a target nucleic acid, wherein the TSU promoter oligonucleotide is a TSU promoter primer that has a 3' terminus that is capable of being extended by a polymerase, or is a TSU promoter provider oligonucleotide that has a blocked 3' terminus that is incapable of being extended by a polymerase, a TSU non-promoter primer oligonucleotide made up of a 5' second universal sequence (U2) and a 3' second target specific sequence (TS2) which is different from the TS1, and a means for directly or indirectly joining the TSU promoter oligonucleotide to the TSU non-promoter primer oligonucleotide, thereby forming a target specific universal (TSU) primer complex, wherein said joining means is selected from a covalent linkage,

10

15

a non-covalent linkage of members of a binding pair to join the TSU promoter oligonucleotide and the TSU non-promoter primer oligonucleotide to a support, wherein one member of the binding pair is present on the TSU promoter oligonucleotide or the TSU non-promoter primer oligonucleotide and the other member of the binding pair is attached to the support, a hybridization complex between a first sequence on the TSU promoter oligonucleotide and a second sequence on the TSU non-promoter primer that is complementary to the first sequence on the TSU promoter oligonucleotide, and a hybridization complex that includes an S-oligonucleotide that contains a first sequence complementary to a sequence in the TSU promoter oligonucleotide and a second sequence complementary to a sequence in the TSU non-promoter primer oligonucleotide.

20

25

A composition is disclosed that includes a TSU promoter oligonucleotide that includes a 5' promoter sequence, an internal first universal sequence (U1), and a 3' first target specific sequence (TS1) that binds specifically to a target sequence contained in a target nucleic acid, wherein the TSU promoter oligonucleotide is a TSU promoter primer that has a 3' terminus that is capable of being extended by a polymerase, or is a TSU promoter provider oligonucleotide that has a blocked 3' terminus that is incapable of being extended by a polymerase, a TSU non-promoter primer oligonucleotide made up of a 5' second universal sequence (U2) and a 3' second target specific sequence (TS2) which is different from the TS1, and a means for directly or indirectly joining the TSU promoter oligonucleotide to the TSU non-promoter primer oligonucleotide, thereby forming a target specific universal (TSU) primer complex. In one embodiment, the means for directly joining the TSU promoter oligonucleotide to the TSU non-promoter primer oligonucleotide is a covalent linkage. In another embodiment, the covalent linkage is formed via a polynucleotide linker sequence, which may be a covalent linkage formed via a non-nucleotide abasic linker compound. Another embodiment uses a means for indirectly joining the TSU promoter oligonucleotide to the TSU non-promoter primer

30

5 oligonucleotide that is a non-covalent linkage of members of a binding pair to join the TSU promoter oligonucleotide and the TSU non-promoter primer oligonucleotide to a support, in which one member of the binding pair is present on the TSU promoter oligonucleotide or the TSU non-promoter primer oligonucleotide and the other member of the binding pair is attached to the support. In another embodiment, the means for directly joining the TSU promoter oligonucleotide to the TSU non-promoter primer oligonucleotide is a hybridization complex between a first sequence on the the TSU promoter oligonucleotide and a second sequence on the TSU non-promoter primer that is complementary to the first sequence on the TSU promoter oligonucleotide. The means for indirectly joining the TSU promoter oligonucleotide to the TSU non-promoter primer oligonucleotide may be a hybridization complex that includes an S-oligonucleotide that contains a first sequence complementary to a sequence in the TSU promoter oligonucleotide and a second sequence complementary to a sequence in the TSU non-promoter primer oligonucleotide. In one embodiment the S-oligonucleotide contains a first sequence complementary to the universal sequence in the TSU promoter oligonucleotide and the the S-oligonucleotide contains a second sequence complementary to the universal sequence in the TSU non-promoter primer oligonucleotide. The composition may also include a target specific capture oligonucleotide that contains a sequence that hybridizes specifically to a sequence in the target nucleic acid of the TSU promoter oligonucleotide and the TSU non-promoter primer at a sequence that is different from the sequence in the target nucleic acid that hybridizes to the TS sequence of the TSU promoter oligonucleotide or the TS sequence of the TSU non-promoter primer, and contains a means for binding the target nucleic acid to a support. The composition may also include a universal promoter primer made up a 5' promoter sequence and a 3' universal sequence that is the same as the universal sequence of the TSU promoter oligonucleotide. Another embodiment is a composition that further includes a universal primer made up a universal sequence that is the same as the universal sequence of the TSU non-promoter primer oligonucleotide. The composition may also include a blocker oligonucleotide that hybridizes specifically to a sequence in a target nucleic acid strand that is different than the sequence that the TS sequence of the TSU promoter oligonucleotide or the TS sequence of the TSU non-promoter primer oligonucleotide binds to in the target nucleic acid strand, wherein the blocker oligonucleotide has a 3' blocked terminus that is not capable of being extended by a polymerase. In some embodiments that include an S-oligonucleotide, it is made up of (1) a first terminal region sequence that is complementary to the U1 sequence of the TSU promoter primer and (2) a second terminal region sequence that is complementary to the U2 sequence of the TSU non-

5 promoter primer, and (3) a linking moiety that links the first and second terminal region sequences. The linking moiety may be a non-nucleic acid chemical compound that covalently links the first and second terminal region sequences. The composition may also include at least one universal promoter primer made up of a 5' promoter sequence and a 3' U1 sequence and at least one target specific primer (TSP) made up of a sequence that is complementary to a sequence contained in an RNA  
10 transcript made from a double stranded DNA that contains a cDNA sequence made from synthetic extension of the 3' end of the TSU promoter primer oligonucleotide.

Also disclosed is a method of amplifying a target nucleic acid comprising the steps of: isolating a target nucleic acid from a mixture by binding to the target nucleic acid a target capture probe that binds specifically to the target nucleic acid and provides a means for attaching the bound target nucleic  
15 acid to a support that is separated from the mixture and further hybridizing to the target nucleic acid in the mixture a target specific universal (TSU) primer complex made up of (1) a TSU promoter primer oligonucleotide that includes a 5' promoter sequence, an internal first universal sequence (U1), and a 3' first target specific sequence (TS1) that binds specifically to a target sequence contained in a target nucleic acid, and a 3' terminus that is capable of being extended by a polymerase, (2) a TSU non-  
20 promoter primer oligonucleotide made up of a 5' second universal sequence (U2) and a 3' second target specific sequence (TS2) which is different from the TS1, and (3) a means for directly or indirectly joining the TSU promoter oligonucleotide to the TSU non-promoter primer oligonucleotide. The method includes hybridizing the TSU promoter primer oligonucleotide to a target sequence in the target nucleic acid via a TS sequence in the TSU promoter primer, synthetically extending the 3' terminus of the TSU  
25 promoter primer oligonucleotide hybridized to the target nucleic acid by using a polymerase *in vitro* nucleic acid synthesis in which the target nucleic acid is a template to make a first cDNA strand, hybridizing the TSU non-promoter primer oligonucleotide to the first cDNA strand by specific hybridization of the TS sequence in the TSU non-promoter primer oligonucleotide to a target sequence contained in the first cDNA strand, synthetically extending the 3' terminus of the TSU non-promoter  
30 primer oligonucleotide hybridized to the first cDNA strand by a polymerase *in vitro* nucleic acid synthesis to make a second DNA strand, thereby making a substantially double-stranded DNA that contains a functional promoter sequence and the U1 sequence, enzymatically transcribing RNA transcripts from the functional promoter sequence of the substantially double-stranded DNA to make RNA transcripts that contain a 5' U1 region sequence, a first target specific sequence (TS1), a second  
35 target specific sequence (TS2'), and a 3' universal sequence (U2') that is complementary to the U2

5 sequence, hybridizing a universal primer oligonucleotide (UP2) that contains a universal sequence U2 to the RNA transcript at the U2' sequence, under isothermal conditions, synthetically extending the 3' terminus of the UP2 by enzymatic *in vitro* nucleic acid synthesis to make a cDNA strand, and enzymatically removing the RNA transcript strand, hybridizing a universal promoter primer oligonucleotide (UP1) that contains a universal sequence U1 to the cDNA made in the previous step at  
10 the U1' sequence, under isothermal conditions, synthetically extending the 3' terminus of the UP1 by enzymatic *in vitro* nucleic acid synthesis to make a dsDNA that contains a functional promoter, and transcribing multiple RNA transcripts from the functional promoter of the dsDNA, which transcripts are amplification products that may serve as templates for further enzymatic *in vitro* nucleic acid synthesis under isothermal conditions by binding the UP2 primer and repeating the synthetic steps. The method  
15 may also include the step of detecting the amplification products to indicate the presence of an analyte in the mixture from which the target nucleic acid was isolated.

Another disclosed method of amplifying a target nucleic acid includes isolating a target nucleic acid from a mixture by binding to the target nucleic acid a target capture probe that binds specifically to the target nucleic acid and provides a means for attaching the bound target nucleic acid to a support  
20 that is separated from the mixture and further hybridizing to the target nucleic acid in the mixture a target specific universal (TSU) primer complex made up of (1) a TSU promoter oligonucleotide that includes a 5' promoter sequence, an internal first universal sequence (U1), and a 3' first target specific sequence (TS1) that binds specifically to a target sequence contained in a target nucleic acid, wherein the TSU promoter oligonucleotide is a TSU promoter provider oligonucleotide that has a blocked 3'  
25 terminus that is incapable of being extended by a polymerase, (2) a TSU non-promoter primer oligonucleotide made up of a 5' second universal sequence (U2) and a 3' second target specific sequence (TS2) which is different from the TS1, and (3) a means for directly or indirectly joining the TSU promoter oligonucleotide to the TSU non-promoter primer oligonucleotide. The method steps also include hybridizing the TSU non-promoter primer oligonucleotide to a target sequence in the target  
30 nucleic acid via the TS sequence in the TSU non-promoter primer, optionally hybridizing a blocker oligonucleotide with a 3' blocked end that is incapable of being extended synthetically by a polymerase to a sequence on the target nucleic acid that is downstream from the position that the TSU non-promoter primer oligonucleotide hybridizes in the target nucleic acid, synthetically extending the 3' terminus of the TSU non-promoter primer hybridized to the target nucleic acid by using a polymerase *in vitro* nucleic acid synthesis in which the target nucleic acid is a template to make a first cDNA strand,  
35

5 hybridizing the TSU promoter primer oligonucleotide to the first cDNA strand by specific hybridization of the TS sequence in the TSU promoter primer oligonucleotide to a target sequence contained in the first cDNA strand, synthetically extending the 3' terminus of the first cDNA by using sequence in the TSU promoter primer as a template to make a substantially double-stranded DNA that contains a functional promoter sequence and the U1 sequence, enzymatically transcribing RNA transcripts from  
10 the functional promoter sequence to make RNA transcripts that contain a 5' U1 region sequence, a first target specific sequence (TS1), a second target specific sequence (TS2'), and a 3' universal sequence (U2') that is complementary to the U2 sequence, hybridizing a universal primer oligonucleotide (UP2) that contains a universal sequence U2 to the RNA transcript at the U2' sequence, under isothermal conditions, synthetically extending the 3' terminus of the UP2 by enzymatic *in vitro* nucleic acid  
15 synthesis to make a cDNA strand, and enzymatically removing the RNA transcript strand, hybridizing a universal promoter oligonucleotide (UP1) that contains a promoter sequence, a universal sequence U1, and a 3' blocked end to the cDNA made in the previous step at the U1' sequence, under isothermal conditions, synthetically extending the 3' terminus of the cDNA to make a functional double-stranded promoter by using the UP1 oligonucleotide as a template and by enzymatic *in vitro* nucleic acid  
20 synthesis to make a dsDNA that contains a functional promoter, and transcribing multiple RNA transcripts from the functional promoter of the dsDNA, which transcripts are amplification products that may serve as templates for further enzymatic *in vitro* nucleic acid synthesis under isothermal conditions by binding the UP2 primer and repeating the synthetic steps. The method may further include the step of detecting the amplification products to indicate the presence of an analyte in the sample from which  
25 the target nucleic acid was isolated.

Also disclosed is a method of amplifying a target nucleic acid that includes steps of isolating a target nucleic acid from a mixture by binding to the target nucleic acid a target capture probe that binds specifically to the target nucleic acid and provides a means for attaching the bound target nucleic acid to a support that is separated from the mixture and further hybridizing to the target nucleic acid in the  
30 mixture a target specific universal (TSU) promoter primer oligonucleotide that includes a 5' promoter sequence, an internal first universal sequence (U1), and a 3' first target specific sequence (TS1) that binds specifically to a target sequence contained in a target nucleic acid, and a 3' terminus that is capable of being extended by a polymerase, synthetically extending the 3' terminus of the TSU promoter primer oligonucleotide hybridized to the target nucleic acid by using a polymerase *in vitro*  
35 nucleic acid synthesis in which the target nucleic acid is a template to make a first cDNA strand, adding

5 to the amplification reaction mixture a target specific (TS) non-promoter primer that contains a second target specific sequence (TS2) which is different from the TS1, hybridizing the TS non-promoter primer oligonucleotide to the first cDNA strand by specific hybridization of the TS2 sequence to a target sequence contained in the first cDNA strand, synthetically extending the 3' terminus of the TS non-promoter primer oligonucleotide hybridized to the first cDNA strand by a polymerase *in vitro* nucleic acid synthesis to make a second DNA strand, thereby making a substantially double-stranded DNA that contains a functional promoter sequence and the U1 sequence, enzymatically transcribing RNA transcripts from the functional promoter sequence of the substantially double-stranded DNA to make RNA transcripts that contain a 5' U1 region sequence, a first target specific sequence (TS1), a second target specific sequence (TS2'), hybridizing a universal promoter primer oligonucleotide that contains a universal sequence U1' to the RNA transcript at the U1 sequence, under isothermal conditions, synthetically extending the 3' terminus of the universal promoter primer by enzymatic *in vitro* nucleic acid synthesis to make a cDNA strand, and enzymatically removing the RNA transcript strand, hybridizing a TS non-promoter primer oligonucleotide to a specific sequence in the cDNA made in the previous step, under isothermal conditions, synthetically extending the 3' terminus of the TS non-promoter primer by enzymatic *in vitro* nucleic acid synthesis to make a dsDNA that contains a functional promoter, and transcribing multiple RNA transcripts from the functional promoter of the dsDNA, which transcripts are amplification products that may serve as templates for further enzymatic *in vitro* nucleic acid synthesis under isothermal conditions by repeating the synthetic steps. The method may further include detecting the amplification products to indicate the presence of an analyte in the mixture from which the target nucleic acid was isolated.

Another disclosed method of amplifying a target nucleic acid includes the steps of isolating a target nucleic acid from a mixture by binding to the target nucleic acid a target capture probe that binds specifically to the target nucleic acid and provides a means for attaching the bound target nucleic acid to a support that is separated from the mixture and further hybridizing to the target nucleic acid in the mixture a TSU non-promoter primer oligonucleotide made up of a 5' universal sequence (U2) and a 3' target specific sequence (TS2), hybridizing the TSU non-promoter primer oligonucleotide to a target sequence in the target nucleic acid via the TS2 sequence to a complementary sequence in the target nucleic acid, hybridizing a blocker oligonucleotide with a 3' blocked end that is incapable of being extended synthetically by a polymerase to a sequence on the target nucleic acid that is downstream from the position that the TSU non-promoter primer oligonucleotide hybridizes in the target nucleic

5 acid, synthetically extending the 3' terminus of the TSU non-promoter primer hybridized to the target nucleic acid by using a polymerase *in vitro* nucleic acid synthesis in which the target nucleic acid is a template to make a first cDNA strand, hybridizing to the first cDNA strand a target specific TS promoter  
10 provider oligonucleotide that includes a 5' promoter sequence and a 3' target specific sequence (TS1) that binds specifically to a target sequence contained in a target nucleic acid, and a blocked 3' terminus that is incapable of being extended by a polymerase, by specific hybridization of the TS1  
15 sequence to a complementary sequence in the first cDNA strand, synthetically extending the 3' terminus of the first cDNA by using sequence in the TS promoter provider as a template to make a substantially double-stranded DNA that contains a functional promoter sequence and a TS1 sequence, enzymatically transcribing RNA transcripts from the functional promoter sequence to make RNA  
20 transcripts that contain a 5' target specific sequence TS1, a target specific sequence TS2' and a U2' sequence, hybridizing a universal primer oligonucleotide (UP2) that contains a universal sequence U2 to the RNA transcript at the U2' sequence, under isothermal conditions, synthetically extending the 3' terminus of the UP2 by enzymatic *in vitro* nucleic acid synthesis to make a cDNA strand, and enzymatically removing the RNA transcript strand, hybridizing a TS promoter provider oligonucleotide  
25 that contains a promoter sequence and a 3' blocked end to the cDNA made in the previous step, under isothermal conditions, synthetically extending the 3' terminus of the cDNA to make a functional double-stranded promoter by using the TS promoter provider oligonucleotide as a template and by enzymatic *in vitro* nucleic acid synthesis to make a dsDNA that contains a functional promoter, and transcribing multiple RNA transcripts from the functional promoter of the dsDNA, which transcripts are amplification  
30 products that may serve as templates for further enzymatic *in vitro* nucleic acid synthesis under isothermal conditions by repeating the synthetic steps. The method may also include detecting the amplification products to indicate the presence of an analyte in the sample from which the target nucleic acid was isolated.

30 The accompanying drawings, which constitute a part of the specification, illustrate some embodiments of the invention. These drawings, together with the description, serve to explain and illustrate the principles of the invention.

#### BRIEF DESCRIPTION OF THE DRAWINGS

35 FIG. 1 is a schematic drawing showing: a three-component target-specific universal (TSU) primer complex that includes a TSU promoter primer made up of a 5' promoter sequence (solid line) labeled P, a universal sequence (dashed line) labeled U1, and a 3' target-specific sequence (double

lines) labeled TS1, which is hybridized to an S-oligonucleotide (S-shaped dotted line) that includes a 5' universal sequence labeled U1' and a 3' universal sequence labeled U2', which is hybridized to a TSU non-promoter primer made up of a 5' universal sequence (dashed line) labeled U2 and a 3' target-specific sequence (double line) labeled TS2; a target-specific capture oligonucleotide made up of a 5' target-specific sequence (double line) labeled TS3 and a 3' binding pair member (triple line) labeled BPM ; a universal promoter primer (UP1) made up of a 5' promoter sequence (solid line) labeled P and a 3' universal sequence (dashed line) labeled U1; and a universal non-promoter primer (UP2) made up of a universal sequence (dashed line) labeled U2.

FIG. 2 is a schematic drawing illustrating target capture in which: (1) target capture reagent (TCR) contains multiple three-component target-specific universal (TSU) primer complexes (see FIG. 1) specific for three different targets (labeled TSUa, TSUb, TSUc) and capture probes specific for the three different targets in which the BPM is shown as poly-A sequences (AAA) and the target-specific sequences are labeled TSa, TSb, and TSc; (2) TCR is mixed with a sample that contains "Target a", which allows the TSUa primer complex to hybridize to Target a and the TSa capture probe to hybridize to Target a; (3) the poly-A sequence of the TSa capture probe hybridizes to an immobilized probe (poly-T sequence shown as TTTT) which is attached to a support (shaded circle), which allows the complex attached to the support to be separated from the mixture to retrieve the captured target and TSU primer complex; and (4) the portion containing the unbound TSU primer complexes (labeled TSUb and TSUc) is discarded as waste.

FIG. 3 is a schematic drawing that illustrates a three-component TSU primer complex which is attached to a target strand via hybridization of the TS1 sequence of the TSU promoter primer to a complementary TS1' sequence in the target nucleic acid, which is attached to a support (shaded circle) via hybridization of the target specific TS3 sequence of a capture probe to a complementary TS3' sequence of the target nucleic acid and the poly-A portion of the capture probe is hybridized to an immobilized poly-T probe that is attached to the support. Vertical connecting lines (| | | |) indicate sequence hybridization. The TSU primer complex is made up of the TSU non-promoter primer hybridized at its U2 sequence region to the complementary U2' sequence region of the S-oligonucleotide which has a 3' blocked end ( $\ominus$ ) and a 5' region that is hybridized at its U1' sequence region to a complementary U1 sequence region in the TSU promoter primer that includes a 5' promoter sequence region (solid line P) and a 3' target specific sequence region (TS1) which is complementary to the TS1' sequence in the target strand. The target strand also contains another target specific

5 sequence region (TS2) which is the same as the TS2 region of the TSU non-promoter primer. The capture probe contains a 5' target specific sequence (TS3) that is complementary to part of the target strand (sequence TS3') and a 3' poly-A sequence that is complementary to a poly-T sequence that serves as the BPM of the immobilized probe.

10 FIG. 4 is a schematic drawing that illustrates a TSU primer complex in which the upper strand is a TSU non-promoter primer made up of a 3' target specific region (TS2) and a 5' universal sequence region, labeled U2(+), which is hybridized to a complementary 3' U2' sequence region of the S-oligonucleotide (labeled S-oligo) which contains an abasic spacer that links the 3' U2' sequence to a 5' U1' sequence region that is the complement of and hybridized to the U1(-) sequence region in the TSU promoter primer that includes a 5' promoter sequence (P) and a 3' target specific sequence region (TS1). The illustrated S-oligonucleotide includes a 3' blocked end in which terminal bases are joined by a 3' to 3' linkage (labeled 3'-3'C) and an internal abasic compound (e.g., (C9)<sub>2</sub> or (C9)<sub>3</sub>) that is a spacer that covalently joins the 5' U1' sequence and the 3' U2' sequence.

20 FIG. 5 is a schematic drawing that illustrates the product that results from an initial synthetic step of the initial amplification phase in which the 3' end of the TSU promoter primer, hybridized via its TS1 sequence to the complementary TS1' sequence in an RNA template strand (narrow solid line), has been synthetically extended to make a first strand cDNA (wider solid line) by using a reverse transcriptase (RT) polymerase. The RNA template strand also contains a TS2 sequence that is complementary to the TS2' sequence made in the first strand cDNA.

25 FIG. 6 is a schematic drawing that illustrates the first strand cDNA product (as shown in FIG. 5) following degradation of the RNA template strand that was shown in FIG. 5, in which the cDNA contains a 5' promoter sequence (P), a universal sequence (U1), a target-specific sequence (TS1), a cDNA sequence that was made from the template strand and that contains a second target-specific sequence (TS2').

30 FIG. 7 is a schematic drawing that illustrates the product that results from a second synthetic step in the initial phase of amplification. This product results from hybridization of the TSU non-promoter primer to the first strand cDNA product (see FIG. 6) by hybridizing the TS2 sequence of the TSU non-promoter primer to the complementary TS2' sequence of the cDNA and extending the 3' end of the TSU non-promoter primer by using a DNA polymerase (shaded rectangle) to make a complementary second strand of DNA. The second strand contains the primer's 5' U2 sequence and TS2 sequence, the complementary sequence to the first strand cDNA which includes a target specific

35

5 sequence TS1', a universal sequence U1' and a 3' sequence that is complementary to the promoter sequence of the cDNA, thus making a double-stranded DNA that contains a functional promoter sequence.

FIG. 8 is a schematic drawing that illustrates the substantially dsDNA made up of the first strand cDNA and the second strand DNA (see FIG. 7) and three RNA transcripts (broader lines) above the dsDNA. RNA transcripts are made by transcription that initiates at the functional double-stranded promoter sequence (P) by using its respective RNA polymerase (shaded area labeled RNA Pol). RNA transcripts include, in a 5' to 3' direction, a 5' U1 sequence, a TS1 sequence, a transcript from the target strand, a TS2' sequence, and a 3' U2' sequence.

FIG. 9 is a schematic drawing showing a single RNA transcript, as illustrated in FIG. 8, from the first phase of isothermal amplification with terminal universal sequences, U1 and U2', which flank the target specific sequences TS1 and TS2', which flank the transcript of other target strand sequence, and a universal primer (UP2) that includes sequence U2 that is complementary to sequence U2' in the transcript.

FIG. 10 is a schematic drawing showing the steps in the second phase of isothermal amplification in which RNA transcripts (as illustrated in FIG. 9) enter the system at the lower left where the RNA transcript hybridizes to the universal primer UP2 via complementary pairing of the U2' and U2 sequences (hybridization shown by vertical lines ||||) and reverse transcriptase enzyme (open circle labeled RT) attaches to UP2 and uses its RNA directed DNA polymerase activity to enzymatically extend the UP2 primer by using the RNA transcript as a template. The next step, after the arrow pointing to the right, shows the resulting cDNA (lower strand) hybridized to the RNA template (upper strand), which after the upward pointing arrow, is digested by RNase H activity of the RT enzyme that leaves the cDNA strand. After the next upward pointing arrow, the cDNA is hybridized via its U1' sequence to the complementary U1 sequence of the universal promoter primer (UP1) which includes a 5' promoter sequence (P) and the UP1 primer is extended by DNA directed DNA polymerase activity of the RT enzyme to make a dsDNA that is illustrated at the top of the circle, above the arrow pointing upward and leftward. The dsDNA contains two universal sequences per strand (U1 and U2' on the upper strand and U1' and U2 on the lower strand) which flank target specific sequences (TS1, TS2' and the intervening sequence on the upper strand and TS1' and TS2 and the intervening sequence on the lower strand), and a functional promoter (P). Following the arrow downward to the left, the functional promoter interacts with a RNA polymerase (oval labeled RNA Pol) specific for the promoter

5 sequence to make transcripts from the dsDNA, which are shown after the next downward pointing arrow, to result in 100 to 1000 transcripts or RNA amplicons which contain two universal sequences (U1 and U2') and target specific sequences (TS1 and TS2' and the intervening sequence). Following the next arrow downward and to the right, these RNA transcripts enter the amplification system and are used as templates for further isothermal amplification in a cyclic manner as shown, repeating the steps  
 10 as described above for the first phase RNA transcripts.

FIG. 11 is a schematic drawing of two embodiments of TSU primers that do not include an S-oligonucleotide but which may be used in the first phase of isothermal amplification which is performed using TSU primers attached to a support, followed by the second phase of isothermal amplification performed in solution phase by using the universal primers (UP1 and UP2). In Embodiment 1, a TSU  
 15 non-promoter primer and a TSU promoter primer are linked together, covalently or non-covalently, and attached to a support via a first binding pair member (shaded arrow labeled BPM1) which binds specifically to a second binding pair member (dark chevron labeled BPM2) attached to the support (shaded rectangle). In Embodiment 2, the TSU non-promoter primer and TSU promoter primer are separate oligonucleotides which are separately attached to the same support via a BPM1 attached to  
 20 each oligomer, which binds specifically to a separate binding pair member, BPM2, attached to the support (shaded circle). For both Embodiment 1 and 2, universal primers (UP1 and UP2) are provided in solution phase and are unattached to a support.

FIG. 12 is a schematic drawing showing structures used in a target capture (TC) step with initial primer attachment (left side, labeled A.) and primers used in the second phase of isothermal  
 25 amplification (right side, labeled B.), for Embodiment 1 (upper half above the line) and Embodiment 2 (lower half below the line). In Embodiment 1, the TC step (left side, upper half) includes a capture complex made up of the target nucleic acid attached to a support, via a target specific capture probe that hybridizes to the target strand (shown by vertical lines between a short horizontal line and the longer horizontal line representing the target strand) and also hybridizes via a poly-A sequence to an  
 30 immobilize poly-T sequence attached to the support (shaded circle). The target nucleic acid is attached at another location to a TSU primer complex that includes the TSU promoter primer hybridized specifically to a sequence in the target strand and to an S-oligonucleotide that is hybridized to a TSU non-promoter primer (substantially as shown in FIG. 3). In Embodiment 1, the second phase of amplification (right side, upper half) uses two universal primers: a universal promoter primer (UP1)  
 35 and a universal non-promoter primer (UP2) which hybridizes to a complementary sequence introduced

5 in the RNA transcript by use of the TSU primer complex. In Embodiment 2, the TC step (left side, lower half) includes the capture complex as shown for Embodiment 1 and only the TSU promoter primer hybridized via a target-specific sequence at another location on the target strand, and the second phase of amplification (right side, lower half) uses one universal promoter primer (UP1) and one target specific primer (TSP).

10 FIG. 13 is a schematic drawing showing the steps in the second phase of isothermal amplification substantially as shown in FIG. 10, except that RNA transcripts from the first and/or second phases (lower left) are hybridized to a target specific primer (TSP) that is extended by RT to synthesize the cDNA strand (lower right) using the RNA transcripts as templates, and no U2 or U2' universal sequences are present.

15 FIG. 14 is a schematic drawing showing an embodiment in which (lower left) a TSU promoter primer used in a first phase of amplification is attached to a support via a first binding pair member (BPM1) that binds specifically to a second binding pair member (BPM2) attached to the support (shaded circle), and a mixture of universal promoter primers (UP1) and target specific primers (TSP) in solution phase are used in the second phase of amplification.

20 FIG. 15 is a schematic drawing showing components in an embodiment in which the top portion of the diagram shows a hybridization complex made in the Target Capture step, made up of the Target nucleic acid strand hybridized to a target capture (TC) probe that has an unbound poly-A tail and a TS sequence hybridized to a 5' portion of the target strand, a Blocker oligonucleotide hybridized to the target strand downstream from the position hybridized to the TC probe, and a TSU primer  
25 hybridized to a 3' portion of the target strand via a TS sequence with an unhybridized universal (U) sequence; and the lower portion of the diagram shows that the nucleic acids present in single-primer isothermal amplification which include (1) the target amplicon consisting of a 5' U sequence, an internal TS sequence, and a 3' sequence copied from the target strand by extension of the TSU primer, (2) a TS promoter provider that includes a 5' promoter (P) sequence, a 3' TS sequence, and a blocked 3' end (⊗), and (3) a universal primer consisting of a universal sequence (U') complementary to the  
30 universal sequence of the target amplicon.

FIG. 16 is a schematic drawing showing components in an embodiment in which the top portion of the diagram shows a hybridization complex made in the Target Capture step, made up of the Target nucleic acid strand hybridized to a target capture (TC) probe that has an unbound poly-A tail  
35 and a TS sequence hybridized to a 5' portion of the target strand, a Blocker oligonucleotide hybridized

5 to the target strand downstream from the position hybridized to the TC probe, and a TSU primer complex made up of (top strand) a TSU promoter provider with a 3' blocked end ( $\otimes$ ), an S-oligomer (middle strand, substantially as in FIG. 3), and a TSU primer (lower strand) hybridized to a 3' portion of the target strand via a TS sequence with its universal (U2) sequence hybridized to a complementary (U2') sequence in the S-oligomer; and the lower portion of the diagram shows that nucleic acids  
 10 present in single-primer isothermal amplification which include (1) the TSU promoter provider hybridized via its TS1 sequence to the extension product made by extension of the TS2 sequence of the TSU primer which includes its U2 universal sequence, (2) a promoter provider oligonucleotide that includes a 5' promoter (P) sequence, a 3' U1' universal sequence, and a blocked 3' end ( $\otimes$ ), and (3) a universal primer consisting of a universal sequence (U2') complementary to the U2 universal  
 15 sequence.

FIG. 17 is a schematic drawing of an embodiment showing two TSU oligonucleotides in a hybridization complex that is hybridized to a target strand via the TS1 sequence of a TSU primer which also includes a U1 sequence and a promoter complementary sequence (P'), which is hybridized to a TSU promoter provider oligonucleotide via hybridization of the complementary P' sequence and the P  
 20 sequence of the TSU promoter provider oligonucleotide which also contains a U2 sequence, a TS2 sequence and a blocked 3' end.

FIG. 18 is a schematic drawing of an embodiment showing two TSU oligonucleotides joined covalently via a non-nucleotide linker ( $-C_9-C_9-$ ). This forms a complex made up of a TSU promoter provider that includes a blocked 3' end, and TS2, U2 and promoter (P) sequences in a 3' to 5'  
 25 orientation linked to a TSU primer that includes U1 and TS1 sequences in a 5' to 3' orientation, providing one extendable 3' terminus in the complex which is hybridized to a target strand via the TS1 sequence of the TSU primer. Also shown hybridized to the Target strand are a blocker oligonucleotide and a TC probe, hybridized to the target via its TS sequence and shown with an unhybridized tail sequence.

30 FIG. 19 shows data obtained from an isothermal amplification of a single target ("PCA3 uniplex" panel) present in samples at  $10^2$ ,  $10^4$  and  $10^6$  copies per reaction, and of two targets ("PCA3/PSA duplex (oligos)" panel) present in samples at  $10^6$  copies per reaction, in which amplification products were detected in real time by using a fluorescent-labeled probe. For both panels, the x-axis shows cycles of amplification and the y-axis shows fluorescence units.

5

## DETAILED DESCRIPTION

10

15

20

The invention encompasses compositions that include one or more target-specific universal (TSU) oligonucleotide primers that include both a target-specific sequence and a universal sequence in the same oligonucleotide. TSU primers described herein include at least one TSU promoter primer oligonucleotide made up of a 5' promoter sequence, an internal first universal sequence (U1) and a 3' first target specific sequence (TS1) that binds specifically to a target sequence contained in a target nucleic acid. Such compositions may further include at least one TSU non-promoter primer oligonucleotide made up of a 5' second universal sequence (U2) and a 3' second target specific sequence (TS2) which is different from the TS1. The TSU promoter primer and TSU non-promoter primer may be linked in a complex by using an S-oligonucleotide that links the universal sequences of the TSU primers via hybridization to complementary terminal sequences of the S-oligonucleotide. The compositions may further include at least one universal promoter primer made up of a 5' promoter sequence and a 3' U1 sequence, and may also include at least one universal primer made up of a universal sequence that is substantially identical to that of the second universal sequence (U2). These compositions do not require any particular sequence be used for any particular component of an oligonucleotide so long as the structural and functional aspects of the oligonucleotides are present in the selected sequences chosen for synthesis of them.

25

30

35

The invention encompasses isothermal amplification methods that use one or more of the TSU primers as described herein, which include at least one TSU promoter primer oligonucleotide made up of a 5' promoter sequence, an internal first universal sequence (U1) and a 3' first target specific sequence (TS1) that binds specifically to a target sequence contained in a target nucleic acid. The methods make use of steps that bind a TSU primer to the target nucleic acid in a target capture step whereby the target nucleic acid with the attached TSU primer is separated from other mixture components before amplification is initiated. The isothermal amplification includes a first phase in which RNA transcripts are made that include at least one universal sequence or two universal sequences flanking at least one target specific sequence. The isothermal amplification includes a second phase in which the RNA transcripts from the first phase are used as templates by using at least one universal primer and enzymatic in vitro nucleic acid synthesis to make a dsDNA that contains a functional promoter used to transcribe additional RNA transcripts which are the amplification products that may be further cycled in the isothermal amplification reaction or used to provide a detectable signal that indicates that the target nucleic acid was present in the tested sample.

5           Methods and compositions are disclosed that are useful for amplifying target nucleic acid sequences *in vitro* in substantially isothermal conditions to produce amplified sequences that can be detected to indicate the presence of the target nucleic acid in a sample. The methods and compositions are useful for synthesizing amplified nucleic acids to provide useful information for making diagnoses and/or prognoses of medical conditions, detecting the purity or quality of  
10           environmental and/or food samples, or investigating forensic evidence. The methods and compositions are advantageous because they allow synthesis of a variety of nucleic acids to provide highly sensitive assays over a wide dynamic range that are relatively rapid and inexpensive to perform, making them suitable for use in high throughput and/or automated systems. The methods and compositions are useful for assays that simultaneously analyze multiple different genetic sequences,  
15           i.e., multiplex amplification systems. Preferred compositions are provided in kits that include defined assay components that are useful because they allow a user to efficiently perform methods that use the components together in an assay to amplify desired targets.

          The disclosed compositions and methods increase the efficiency of isothermal amplification of nucleic acids, which is particularly useful in multiplex assays that amplify multiple analytes in a single  
20           reaction mixture, e.g., for array-based assays. Multiplex isothermal transcription based amplification assays are often limited to amplification of about six or fewer analyte targets in a single reaction because of primer interactions result in inefficient amplification of one or more of the targets, which decreases assay sensitivity. Although design and testing of many different primers and primer combinations may result in increased amplification efficiency in multiplex assays, the disclosed  
25           systems minimize primer interactions by use of target-specific primers in an initial phase of amplification followed by use of universal primers to amplify all of target amplicons in a second phase of amplification. Thus, amplification efficiency increases while the need to design and test many individual primers or primer combinations in multiplex reactions decreases. The disclosed compositions and methods provide the advantages that the system can amplify one or many desired  
30           targets present in a complex mixture, including one or more internal control or internal calibrator targets that provide information that the assay was performed properly or is used to quantitate the results. Besides simplifying multiplex assay design, the disclosed compositions and methods provide advantages of simplifying both the manufacture of assay reagents the performance of assay steps a limited number of reagents are used for each desired target. That is, for each desired target only one  
35           or a pair of target-specific universal (TSU) primers unique to the desired target are designed for use in

5 an initial amplification phase, and a subsequent amplification phase uses universal reagents that are used in common for amplification of many targets. TSU primers include both a target-specific (TS) sequence and a universal (U) sequence in the same oligonucleotide, although TSU primers may include additional sequences, such as a promoter sequence. The disclosed methods are versatile and may be used to detect a single target or multiple different targets, all amplified in a single reaction, from  
10 which amplification products may be detected at the end of a reaction (end-point detection) or during the reaction (real-time detection). Typically, the target-specific universal (TSU) primers are provided in a target capture reagent (TCR) so that the TSU primer is hybridized to an isolated target nucleic acid that is use in an initial phase of amplification, and universal primers specific for the universal sequences introduced by the TSU primers are used in a subsequent amplification reaction mixture.

15 Unless otherwise described, scientific and technical terms used herein have the same meaning as commonly understood by those skilled in the art of molecular biology based on technical literature, e.g., *Dictionary of Microbiology and Molecular Biology*, 2nd ed. (Singleton et al., 1994, John Wiley & Sons, New York, NY), or other well known technical publications related to molecular biology. Unless otherwise described, techniques employed or contemplated herein are standard methods well  
20 known in the art of molecular biology. To aid in understanding aspects of the disclosed methods and compositions, some terms are described in more detail or illustrated by embodiments described herein.

Nucleic acid refers to a polynucleotide compound, which includes oligonucleotides, comprising nucleosides or nucleoside analogs that have nitrogenous heterocyclic bases or base analogs, covalently linked by standard phosphodiester bonds or other linkages. Nucleic acids include RNA,  
25 DNA, chimeric DNA-RNA polymers or analogs thereof. In a nucleic acid, the backbone may be made up of a variety of linkages, including one or more of sugar-phosphodiester linkages, peptide-nucleic acid (PNA) linkages (PCT No. WO 95/32305), phosphorothioate linkages, methylphosphonate linkages, or combinations thereof. Sugar moieties in a nucleic acid may be ribose, deoxyribose, or similar compounds with substitutions, e.g., 2' methoxy and 2' halide (e.g., 2'-F) substitutions.

30 Nitrogenous bases may be conventional bases (A, G, C, T, U), analogs thereof (e.g., inosine; *The Biochemistry of the Nucleic Acids* 5-36, Adams et al., ed., 11<sup>th</sup> ed., 1992), derivatives of purine or pyrimidine bases (e.g., N<sup>4</sup>-methyl deoxygaunosine, deaza- or aza-purines, deaza- or aza-pyrimidines, pyrimidines or purines with altered or replacement substituent groups at any of a variety of chemical positions, e.g., 2-amino-6-methylaminopurine, O<sup>6</sup>-methylguanine, 4-thio-pyrimidines, 4-amino-  
35 pyrimidines, 4-dimethylhydrazine-pyrimidines, and O<sup>4</sup>-alkyl-pyrimidines, or pyrazolo-compounds, such

5 as unsubstituted or 3-substituted pyrazolo[3,4-d]pyrimidine (e.g. US Pat. Nos. 5,378,825, 6,949,367 and PCT No. WO 93/13121). Nucleic acids may include "abasic" positions in which the backbone does not have a nitrogenous base at one or more locations (US Pat. No. 5,585,481, Arnold et al.), e.g., one or more abasic positions may form a linker region that joins separate oligonucleotide sequences together. A nucleic acid may comprise only conventional sugars, bases, and linkages as found in  
10 conventional RNA and DNA, or may include conventional components and substitutions (e.g., conventional bases linked by a 2' methoxy backbone, or a polymer containing a mixture of conventional bases and one or more analogs). The term includes "locked nucleic acids" (LNA), which contain one or more LNA nucleotide monomers with a bicyclic furanose unit locked in a RNA mimicking sugar conformation, which enhances hybridization affinity for complementary sequences in ssRNA,  
15 ssDNA, or dsDNA (Vester et al., 2004, *Biochemistry* 43(42):13233-41).

The interchangeable terms "oligonucleotide" and "oligomer" refer to nucleic acid polymers generally made of less than 1,000 nucleotide (nt), including those in a size range having a lower limit of about 2 to 5 nt and an upper limit of about 500 to 900 nt. Preferred oligomers are in a size range having a 5 to 15 nt lower limit and a 50 to 500 nt upper limit, and particularly preferred embodiments  
20 are in a size range having a 10 to 20 nt lower limit and a 25 to 150 nt upper limit. Preferred oligonucleotides are made synthetically by using any well known *in vitro* chemical or enzymatic method, and may be purified after synthesis by using standard methods, e.g., high-performance liquid chromatography (HPLC).

Amplification oligonucleotides include primers and oligonucleotides that are not extended  
25 enzymatically, hybridize to a target nucleic acid, or its complement, and participate in an *in vitro* nucleic acid amplification reaction in which new nucleic acid strands are synthesized from a template strand by using an end of a primer as an initiation point for synthesis, which generally is catalyzed by enzymatic polymerase activity. Amplification oligonucleotides that are extended enzymatically include primers and promoter-primers which include TSU primers that contain a target-specific (TS) sequence that is  
30 identical or completely complementary to a sequence contained in an analyte (target) nucleic acid sequence, and a universal (U) sequence that is not contained in or complementary to an analyte sequence but is introduced to serve as a surrogate or tag for an analyte sequence. The U sequence may be linked to an analyte or TS sequence and is amplified and/or detected in place of the analyte sequence to indicate the presence of one or more analytes in a mixture. Embodiments of TSU primers  
35 may include additional sequence information, such a promoter sequence, resulting in a TSU primer

5 referred to as a TSU promoter primer. A TSU primer that does not include a promoter sequence may be referred to as a TSU non-promoter primer to distinguish it from a TSU promoter primer. Embodiments of amplification oligonucleotides that are generally referred to as universal primers (UP) contain a sequence used to amplify a universal or tag sequence that has been linked to an analyte sequence to serve as a surrogate for the analyte in subsequent assay steps. Universal primers (UP) 10 may contain only a universal sequence and may contain no analyte-specific sequence, but a UP may also contain additional functional sequences, such as a promoter sequence. Terms such as "universal non-promoter primer" or "universal promoter primer" may be used to distinguish between different UP types. Amplification oligonucleotides that are not extended enzymatically typically have a chemically or structurally blocked 3' end that inhibits or prevents them from being used to initiate enzymatic 15 polymerization but these oligonucleotides functionally participate in amplification. Examples of amplification oligonucleotides that are not extended enzymatically include TSU promoter provider oligonucleotides and blocker oligonucleotides that bind to a target strand to inhibit or prevent strand extension from a primer to proceed beyond the location on the target strand where the blocker oligonucleotide is bound.

20 Sizes of the amplification oligonucleotides are generally determined by the function portions that are included in the oligonucleotide. Component portions of a promoter primer or promoter provider oligonucleotide include a promoter sequence specific for a RNA polymerase (RNP). RNP and their corresponding promoter sequences are well known and may be purified from or made synthetically *in vitro* by using materials derived from a variety of sources, e.g., viruses, bacteriophages, fungi, yeast, 25 bacteria, animal, plant or human cells. Examples of RNP and promoters include RNA polymerase III and its promoter (US Pat. 7,241,618, Agami et al.), bacteriophage T7 RNA polymerase and its promoter or mutants thereof (US Pats. 7,229,765, Ziman et al. and 7,078,170, Haydock), RNA polymerase and promoter from *Thermus thermophilus* (US Pat. 7,186,525, Sakanyan et al.), RNA polymerases from HIV-1 or HCV, and plant directed RNPs (US Pat. 7,060,813, Odell et al.). A 30 promoter primer or provider oligonucleotide includes a promoter sequence that is linked functionally to the chosen RNP. Preferred embodiments of promoter primer or promoter provider oligonucleotides include a T7 promoter sequence that is used with T7 RNP, where the promoter sequence is in the range of 25 to 30 nt, such as a promoter sequence of SEQ ID Nos. 67 or 68 (SEQ ID NO:67, aatttaatacgactcactatagggaga; SEQ ID NO:68, gaaattaata cgactcactatagggaga). Amplification 35 oligonucleotides that include a universal (U) portion typically include a U sequence in a range of 5 to 40

5 nt, with preferred embodiments in a range of 10 to 25 nt, or 10 to 30 nt, or 15 to 30 nt. Amplification oligonucleotides that include a target specific (TS) portion typically include a TS sequence in a range of 10 to 45 nt, with preferred embodiments in a range of 10 to 35 nt or 20 to 30 nt. Amplification oligonucleotides that include multiple U sequences and/or multiple TS sequences will be in a size range that is determined by the length of its individual functional sequences, e.g., a promoter primer or  
10 provider oligonucleotide that includes a U sequence and a TS sequence will be the sum of the sizes of the promoter, U and TS sequences, and may optionally include linking nucleotides or non-nucleotide portions (e.g., abasic linkers). Amplification oligonucleotides made up of multiple functional components as described herein may be covalently linked by standard phosphodiester linkages, nucleic acid analog linkages, or non-nucleic acid linkages directly between the different functional  
15 portions or may be covalently linked together by using additional nucleic acid sequences or non-nucleic (e.g., abasic linkages) compounds that serve as spacers between functional portions. Some embodiments of amplification oligonucleotides may be linked together to form a complex by using non-covalent linkages, such as by using interactions of binding pair members between the oligonucleotides, which includes direct hybridization of complementary sequences contained in two or more  
20 oligonucleotides, or via a linking component to which the individual binding pair member of an oligonucleotide binds (e.g., a binding pair member for each oligonucleotide attached to a support).

In addition to primers, other amplification oligomers may include blocked oligonucleotides and promoter provider oligomers (e.g., US Pats. 5,399,491, 5,554,516 and 5,824,518, Kacian et al.; US Pats. 4,683,195, 4,683,202 and 4,800,159, Mullis et al., and US 2006-0046265 A1, Becker et al.). A  
25 blocked oligonucleotide refers to an oligonucleotide that includes a chemical and/or structural modification, usually near or at the 3' terminus, that prevents or impedes initiation of DNA synthesis from the oligonucleotide by enzymatic means. Examples of such modifications include use of a 3'2'-dideoxynucleotide base, a 3' non-nucleotide moiety that prevents enzymatic extension, or attachment of a short sequence in 3' to 5' orientation to the oligonucleotide to make a final oligonucleotide with two  
30 5' termini (i.e., a first 5' to 3' oligonucleotide attached to a second, usually shorter, 5' to 3' oligonucleotide by covalently joining the oligonucleotides at their 3' termini). Another example of a modification is a "cap" made up of a sequence that is complementary to at least 3 nt at the 3'-end of the oligonucleotide such that the 5'-terminal base of the cap is complementary to the 3'-terminal base of the oligonucleotide. Although blocked oligonucleotides are not extended synthetically, they may  
35 participate in nucleic acid amplification, e.g., by hybridizing to a specific location on a nucleic acid

5 template strand to impede synthesis of a complementary strand beyond the position at which the  
blocked oligonucleotide is bound. A promoter provider oligonucleotide refers to an oligonucleotide that  
contains a promoter sequence usually on an oligonucleotide that includes a first region that hybridizes  
to a 3'-region of a DNA primer extension product (e.g., a cDNA) to form a hybridization complex  
between the promoter provider oligonucleotide and the extension product, and a second region,  
10 located 5' to the first region, that is a promoter sequence for an RNA polymerase. By forming the  
hybridization complex with the extension product, the promoter provider oligonucleotide can serve as a  
template for making a dsDNA that includes a functional promoter when the extension product or cDNA  
is used as a template for further strand synthesis, i.e., by extending a newly synthesized strand made  
from using the cDNA as a template and using the promoter sequence of the promoter provider  
15 oligonucleotide as a template, a substantially double-stranded structure that contains a functional  
promoter is synthesized *in vitro*.

Amplification of a nucleic acid refers to the process of creating *in vitro* nucleic acid strands that  
are identical or complementary to a complete or portion of a target nucleic acid sequence, or a  
universal or tag sequence that serves as a surrogate for the target nucleic acid sequence, all of which  
20 are only made if the target nucleic acid is present in a sample. Typically, nucleic acid amplification  
uses one or more nucleic acid polymerase and/or transcriptase enzymes to produce multiple copies of  
a target polynucleotide or fragments thereof, or of a sequence complementary to the target  
polynucleotide or fragments thereof, or of a universal or tag sequence that has been introduced into  
the amplification system to serve as a surrogate for the target polynucleotide, such as in a detection  
25 step, to indicate the presence of the target polynucleotide at some point in the assay. *In vitro* nucleic  
acid amplification techniques are well known and include transcription-associated amplification  
methods, such as transcription mediated amplification (TMA) or nucleic acid sequence based  
amplification (NASBA), and other methods such as the Polymerase Chain Reaction (PCR), reverse  
transcriptase-PCR, replicase mediated amplification, and the Ligase Chain Reaction (LCR).

30 To aid in understanding some of the embodiments disclosed herein, the TMA method that has  
been described in detail previously (e.g., US Pats. 5,399,491, 5,554,516 and 5,824,518, Kacian et al.)  
is briefly summarized. In TMA, a target nucleic acid that contains the sequence to be amplified is  
provided as single stranded nucleic acid (e.g., ssRNA or ssDNA). Any conventional method of  
converting a double stranded nucleic acid (e.g., dsDNA) to a single-stranded nucleic acid may be used.  
35 A promoter primer binds specifically to the target nucleic acid at its target sequence and a reverse

5 transcriptase (RT) extends the 3' end of the promoter primer using the target strand as a template to create a cDNA copy, resulting in a RNA:cDNA duplex. RNase activity (e.g., RNaseH of RT enzyme) digests the RNA of the RNA:cDNA duplex and a second primer binds specifically to its target sequence in the cDNA, downstream from the promoter-primer end. Then RT synthesizes a new DNA strand by extending the 3' end of the second primer using the cDNA as a template to create a dsDNA that  
10 contains a functional promoter sequence. RNA polymerase specific for the functional promoter initiates transcription to produce about 100 to 1000 RNA transcripts (amplified copies or amplicons) of the initial target strand. The second primer binds specifically to its target sequence in each amplicon and RT creates a cDNA from the amplicon RNA template to produce a RNA:cDNA duplex. RNase digests the amplicon RNA from the RNA:cDNA duplex and the target-specific sequence of the promoter primer  
15 binds to its complementary sequence in the newly synthesized DNA and RT extends the 3' end of the promoter primer to create a dsDNA that contains a functional promoter to which the RNA polymerase binds and transcribes additional amplicons that are complementary to the target strand. Autocatalytic cycles that use these steps repeatedly during the reaction produce about a billion-fold amplification of the initial target sequence. Amplicons may be detected during amplification (real-time detection) or at  
20 an end point of the reaction (end-point detection) by using a probe that binds specifically to a sequence contained in the amplicons. Detection of a signal resulting from the bound probes indicates the presence of the target nucleic acid in the sample.

Another form of transcription associated amplification that uses a single primer and one or more additional amplification oligomers to amplify nucleic acids *in vitro* by making transcripts that  
25 indicate the presence of the target nucleic acid has been described in detail previously (US 20060046265, Becker et al.). Briefly, this single-primer method uses a priming oligomer, a promoter oligomer (or promoter provider oligonucleotide) that is modified to prevent the initiation of DNA synthesis from its 3' end and, optionally, a binding molecule (e.g., a 3'-blocked oligomer) to terminate elongation of a cDNA from the target strand. The method synthesizes multiple copies of a target  
30 sequence by treating a target nucleic acid that includes a RNA target sequence with (i) a priming oligonucleotide which hybridizes to the 3'-end of the target sequence such that a primer extension reaction can be initiated therefrom and (ii) a binding molecule that binds to the target nucleic acid adjacent to or near the 5'-end of the target sequence. The priming oligonucleotide is extended in a primer extension reaction by using a DNA polymerase to give a DNA primer extension product  
35 complementary to the target sequence, in which the DNA primer extension product has a 3' end

5 determined by the binding molecule and which is complementary to the 5'-end of the target sequence. The method then separates the DNA primer extension product from the target sequence by using an enzyme which selectively degrades the target sequence and treats the DNA primer extension product with a promoter oligonucleotide made up of a first region that hybridizes to a 3'-region of the DNA primer extension product to form a promoter oligonucleotide:DNA primer extension product hybrid, and  
10 a second region that is a promoter for an RNA polymerase which is situated 5' to the first region, wherein the promoter oligonucleotide is modified to prevent the initiation of DNA synthesis from the promoter oligonucleotide. The method extends the 3'-end of the DNA primer extension product in the promoter oligonucleotide:DNA primer extension product hybrid to add a sequence complementary to the second region of the promoter oligonucleotide, which is used to transcribe multiple RNA products  
15 complementary to the DNA primer extension product using an RNA polymerase which recognizes the promoter and initiates transcription therefrom. This method produces RNA transcripts that are substantially identical to the target sequence.

An embodiment of the one-primer transcription mediated amplification method synthesizes multiple copies of a RNA target sequence by hybridizing to the target RNA a primer at a location in the  
20 3' portion of the target sequence and a 3' blocked oligomer (i.e., the binding molecule) at a location in the 5' portion of the target sequence. Then the DNA polymerase activity of RT initiates extensions from the 3' end of the primer to produce a cDNA in a duplex with the template strand (a RNA:cDNA duplex). The 3' blocked oligomer binds to the target strand at a position adjacent to the intended 5' end of the sequence to be amplified because the bound 3' blocked oligomer impedes extension of the  
25 cDNA beyond that location. That is, the 3' end of the cDNA is determined by the position of the binding molecule because polymerization stops when the extension product reaches the blocking molecule bound to the target strand. The RNA:cDNA duplex is separated by RNase activity (RNase H of RT) that degrades the RNA, although those skilled in the art will appreciate that any form of strand separation may be used. A promoter provider oligomer includes a 5' promoter sequence for an RNA  
30 polymerase and a 3' sequence complementary to a sequence in the 3' region of the cDNA to which it hybridizes. The promoter provider oligomer has a modified 3' end that includes a blocking moiety to prevent initiation of DNA synthesis from the 3' end of the promoter provider oligomer. In the duplex made of the promoter provider hybridized to the cDNA, the 3'-end of the cDNA is extended by using DNA polymerase activity of RT and the promoter provider oligomer serves as a template to add a  
35 promoter sequence to the 3' end of the cDNA, which creates a functional double-stranded promoter

5 made up of the sequence on the promoter provider oligomer and the complementary cDNA sequence made from the promoter provider template. RNA polymerase specific for the promoter sequence binds to the functional promoter and transcribes multiple RNA transcripts that are complementary to the cDNA and substantially identical to the target sequence of the initial target RNA strand. The resulting amplified RNA can cycle through the process again by binding the primer and serving as a template for  
10 further cDNA production, ultimately producing many amplicons from the initial target nucleic acid present in the sample. Embodiments of the single primer transcription associated amplification method do not require use of the 3' blocked oligomer that serves as a binding molecule and, if a binding molecule is not included the cDNA product made from the primer has an indeterminate 3' end, but amplification proceeds substantially the same as described above. Due to the nature of this  
15 amplification method, it is performed under substantially isothermal conditions, i.e., without cycles of raising and lowering incubation temperatures to separate strands or allow hybridization of primers as is used in PCR-based methods.

Detection of the amplified products may be accomplished by using any known method. For example, the amplified nucleic acids may be associated with a surface that results in a detectable  
20 physical change, e.g., an electrical change. Amplified nucleic acids may be detected in solution phase or by concentrating them in or on a matrix and detecting labels associated with them (e.g., an intercalating agent such as ethidium bromide or cyber green). Other detection methods use probes complementary to a sequence in the amplified product and detect the presence of the probe:product complex, or use a complex of probes to amplify the signal detected from amplified products (e.g., US  
25 Pat. Nos. 5,424,413 and 5,451,503, Hogan et al., US Pat. No. 5,849,481, Urdea et al.). Other detection methods use a probe in which signal production is linked to the presence of the target sequence because a change in signal results only when the labeled probe binds to amplified product, such as in a molecular beacon, molecular torch, or hybridization switch probe (e.g., US Pat. Nos.  
5,118,801 and 5,312,728, Lizardi et al., US Pat. Nos. 5,925,517 and 6,150,097, Tyagi et al., US Pat.  
30 Nos. 6,849,412, 6,835,542, 6,534,274, and 6,361,945, Becker et al., US 2006-0068417 A1, Becker et al., and US 2006-0194240 A1, Arnold et al.). Such probes typically use a label (e.g., fluorophore) attached to one end of the probe and an interacting compound (e.g., quencher) attached to another location of the probe to inhibit signal production from the label when the probe is in one conformation ("closed") that indicates it is not hybridized to amplified product, but a detectable signal is produced  
35 when the probe is hybridized to the amplified product which changes its conformation (to "open").

5 Detection of a signal from directly or indirectly labeled probes that specifically associate with the amplified product indicates the presence of the target nucleic acid that was amplified.

Members of a specific binding pair (or binding partners) are moieties that specifically recognize and bind each other. Members may be referred to as a first binding pair member (BPM1) and second binding pair member (BPM2), which represent a variety of moieties that specifically bind together.

10 Specific binding pairs are exemplified by a receptor and its ligand, enzyme and its substrate, cofactor or coenzyme, an antibody or Fab fragment and its antigen or ligand, a sugar and lectin, biotin and streptavidin or avidin, a ligand and chelating agent, a protein or amino acid and its specific binding metal such as histidine and nickel, substantially complementary polynucleotide sequences, which include completely or partially complementary sequences, and complementary homopolymeric  
15 sequences. Specific binding pairs may be naturally occurring (e.g., enzyme and substrate), synthetic (e.g., synthetic receptor and synthetic ligand), or a combination of a naturally occurring BPM and a synthetic BPM.

Target capture refers to selectively separating a target nucleic acid from other components of a sample mixture, such as cellular fragments, organelles, proteins, lipids, carbohydrates, or other nucleic  
20 acids. A target capture system may be specific and selectively separate a predetermined target nucleic acid from other sample components, e.g., by using a sequence specific to the intended target nucleic acid, or it may be nonspecific and selectively separate a target nucleic acid from other sample components by using other characteristics of the target, e.g., a physical trait of the target nucleic acid that distinguishes it from other sample components which do not exhibit that physical characteristic.  
25 Preferred target capture methods and compositions have been previously described in detail (US Patent Nos. 6,110,678 and 6,534,273, Weisburg et al., and US Ser. No. 11/832,367, Becker et al.). Preferred target capture embodiments use a capture probe in solution phase and an immobilized probe attached to a support to form a complex with the target nucleic acid and separate the captured target from other components.

30 A capture probe refers to at least one nucleic acid oligomer that joins a target nucleic acid and an immobilized probe by using binding pair members which may be complementary nucleic acid sequences. One capture probe embodiment binds nonspecifically to a target nucleic acid and links it to a support for separation from the sample, whereas another embodiment includes a target specific (TS) sequence that binds specifically to a sequence in the target nucleic acid and an immobilized  
35 probe-binding region that binds to an immobilized probe, e.g., by specific binding pair interaction. In

embodiments in which the TS sequence and immobilized probe-binding region are both nucleic acid sequences, they may be covalently joined or may be on different oligonucleotides joined by one or more linkers. Immobilized probe refers to a moiety attached to a support that joins the capture probe to a support, directly or indirectly, e.g., by joining members of a specific binding pair, which includes non-nucleic acid binding (e.g., avidin with biotin) and nucleic acid sequence hybridization. Immobilized probes include an oligonucleotide attached to a support to facilitate separation of bound target from unbound material, such as other sample components and/or other oligonucleotides included in a target capture reaction mixture. A target capture (TC) complex includes the capture probe's TS sequence hybridized specifically to a sequence in the target nucleic acid and the capture probe's immobilized probe-binding region bound to an immobilized probe on a support.

Support refers to known materials, such as matrices or particles dispersed in solution, which may be made of nitrocellulose, nylon, glass, polyacrylate, mixed polymers, polystyrene, silane, metal or polypropylene. Preferred supports are magnetically attractable particles, e.g., monodisperse magnetic spheres of uniform size  $\pm 5\%$  to provide consistent results, to which an immobilized probe is joined directly (via covalent linkage, chelation, or ionic interaction), or indirectly (via one or more linkers), to provide stable attachment of the immobilized probe to the support in conditions used in the target capture reaction.

Separating or purifying refers to removal of one or more components of a mixture, such as a sample, from one or more other components in the mixture. Sample components include nucleic acids in a generally aqueous solution phase which may include cellular fragments, proteins, carbohydrates, lipids, and other compounds. Preferred embodiments separate or remove at least 70% to 80%, and more preferably about 95%, of the target nucleic acid from other components in the mixture.

Label refers to a molecular moiety or compound that can be detected or lead to a detectable response, which may be joined directly or indirectly to a nucleic acid probe. Direct labeling may use bonds or interactions to link label and probe, which includes covalent bonds, non-covalent interactions (hydrogen bonds, hydrophobic and ionic interactions), or chelates or coordination complexes. Indirect labeling may use a bridging moiety or linker (e.g. antibody, oligomer, or other compound), which is directly or indirectly labeled, which may amplify a signal. Labels include any detectable moiety, e.g., radionuclide, ligand such as biotin or avidin, enzyme, enzyme substrate, reactive group, chromophore (detectable dye, particle, or bead), fluorophore, or luminescent compound (bioluminescent, phosphorescent, or chemiluminescent label). Preferred chemiluminescent labels include acridinium

5 ester ("AE") and derivatives thereof (US Pat. Nos. 5,656,207, 5,658,737, and 5,639,604). Preferred labels are detectable in a homogeneous assay in which bound labeled probe in a mixture exhibits a detectable change compared to that of unbound labeled probe, e.g., stability or differential degradation, without requiring physical separation of bound from unbound forms (e.g., US Pat. Nos. 5,283,174, 5,656,207, and 5,658,737). Methods of synthesizing labels, attaching labels to nucleic  
10 acids, and detecting labels are well known (e.g., Sambrook *et al.*, *Molecular Cloning, A Laboratory Manual*, 2nd ed. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989), Chapt. 10; US Pat. Nos. 5,658,737, 5,656,207, 5,547,842, 5,283,174, and 4,581,333).

An array refers to multiple components arranged in a two-dimensional or three-dimensional format to allow similar or identical method steps to be performed on the components substantially  
15 simultaneously. Examples of arrays are well known and include high-density microarrays or gene chips that contain 10 to thousands of oligonucleotides attached to a support in predetermined configuration. Such arrays allow performance of assay steps on all the oligonucleotides in different positions under the same conditions, e.g., hybridization of nucleic acids in a sample applied to the array or detection of specific sequences.

20 Sample refers to a specimen that may contain an analyte of interest, e.g., microbe, virus, nucleic acid such as a gene, or components thereof, which includes nucleic acid sequences in or derived from an analyte. Samples may be from any source, such as biological specimens or environmental sources. Biological specimens include any tissue or material derived from a living or dead organism that may contain an analyte or nucleic acid in or derived from an analyte. Examples of  
25 biological samples include respiratory tissue, exudates (e.g., bronchoalveolar lavage), biopsy, sputum, peripheral blood, plasma, serum, lymph node, gastrointestinal tissue, feces, urine, or other fluids, tissues or materials. Examples of environmental samples include water, ice, soil, slurries, debris, biofilms, airborne particles, and aerosols. Samples may be processed specimens or materials, such as obtained from treating a sample by using filtration, centrifugation, sedimentation, or adherence to a  
30 medium, such as matrix or support. Other processing of samples may include treatments to physically or mechanically disrupt tissue, cellular aggregates, or cells to release intracellular components that include nucleic acids into a solution which may contain other components, such as enzymes, buffers, salts, detergents and the like.

"Consisting essentially of" is used to mean that additional component(s), composition(s) or  
35 method step(s) that do not materially change the basic and novel characteristics of an isothermal

5 amplification method that uses universal sequences and TS sequences as described herein may be included in the compositions or methods. Such characteristics include the structures of TSU oligonucleotides, including complexes of multiple TSU oligonucleotides as described herein and the ability of the methods to detect one or more analytes or target nucleic acids in a sample by associating one or more universal sequences with the respective target sequences, amplifying in a substantially isothermal *in vitro* condition at least one universal sequence that serves as a surrogate for an analyte or target nucleic acid, and detecting a response resulting from amplification of the universal sequence to indicate the presence of at least one analyte in the assayed sample. Any component(s), composition(s), or method step(s) that have a material effect on the basic characteristics of the claimed compositions and/or methods fall outside of this term.

15 Preferred embodiments of the disclosed methods use aspects of isothermal amplification systems that are generally referred to as transcription associated amplification methods, which have been previously described in detail (US Pat. Nos. 5,399,491 and 5,554,516, Kacian et al.; US Pat. No. 5,437,990, Burg et al.; PCT Nos. WO 88/01302 and WO 88/10315, Gingeras et al.; US Pat. No. 5,130,238, Malek et al.; US Pat. Nos. 4,868,105 and 5,124,246, Urdea et al.; PCT No. WO 95/03430, Ryder et al.; and US 2006-0046265 A1, Becker et al.). Examples include transcription mediated amplification (TMA) and nucleic acid sequence based amplification (NASBA). Typically, transcription-associated amplification uses an RNA polymerase to produce multiple RNA transcripts from a nucleic acid template by using a series of steps that employ an RNA polymerase, a DNA polymerase, deoxyribonucleoside triphosphates, ribonucleoside triphosphates, a template complementary amplification oligonucleotide that includes a promoter sequence, and optionally one or more other oligonucleotides, which may serve as primers. Preferred disclosed embodiments are based on TMA (US Pat. Nos. 5,399,491 and 5,554,516) or one-primer transcription-associated amplification (US 2006-0046265 A1), although a person of ordinary skill in the art will understand that other amplification methods based on polymerase mediated extension of oligonucleotide sequences may be used with the compositions and/or method steps described herein.

35 Methods disclosed herein use three basic steps in a universal transcription-associated amplification reaction. First, a target capture (TC) step includes hybridizing one or more TSU primers (which may be in a linked complex) to the target nucleic acid and capturing the hybridization complex that includes the target and the primer(s) from a mixture which separates the target nucleic acid from other sample components. A target capture mixture may include multiple TSU primers, each type

5 specific for a different target nucleic acid that may be present in a sample mixture. During the TC step, only those TSU primers that are specific for a target nucleic acid that is present in the sample mixture will be bound to a target and carried into the subsequent amplification steps, because TSU primers specific for other targets that are not present in the sample will remain in solution phase and be discarded or washed away with other sample components before amplification begins using the  
10 captured target nucleic acids. Thus, extraneous oligonucleotides that might otherwise result in interference or competition for resources during amplification are eliminated before the amplification steps begin. The captured target-TSU primer complex is used in an isothermal amplification reaction which is described as a first phase and a second phase of amplification. In the first phase of amplification, an initiation step extends the TSU primer attached to the target nucleic acid strand by  
15 enzymatic *in vitro* nucleic acid synthesis which links a universal sequence region of the TSU primer to an initial amplicon made from the target strand which serves as a template. For example, if the target strand is RNA, the TSU primer hybridizes to the RNA and serves as an initiation site for synthesis of the cDNA strand that includes the U sequence present on the TSU primer. In the second phase of amplification, subsequent synthetic steps in the reaction use the initial amplicons, which include the U  
20 sequence incorporated into the product in the initial phase, and amplify the initial and subsequent amplicons by using universal primers that hybridize to the universal sequences and are extended enzymatically by using amplicons as templates. In some embodiments, two universal sequences are introduced into the initial amplified products of the isothermal amplification reaction and those universal sequences are the targets of subsequent amplifications that use primers that contain complementary  
25 universal sequences to make more amplicons from the captured target sequence. In other embodiments, one universal sequence is introduced into the initial amplified products and in the second amplification phase steps, primers include one with a universal sequence specific for the introduced universal sequence and another target specific primer (TSP) that is specific for a sequence contained in the target nucleic acid strand or a complementary strand. In some embodiments,  
30 universal primers are provided in a reagent that is mixed with the captured hybridization complexes that include the target strand and TSU primer, in which the reagent also provides one or more other components used in *in vitro* nucleic acid synthesis (e.g., nucleotide triphosphates, enzymes, cofactors and the like) in the second phase.

Oligonucleotides are disclosed for use preferred embodiments of the universal transcription  
35 associated amplification methods that include: (1) a target specific capture oligomer (which may be

5 referred to as a capture probe), (2) a target-specific universal (TSU) promoter primer or TSU promoter provider, (3) a target-specific universal (TSU) non-promoter primer, (4) a linker oligonucleotide that may be referred to as an S-oligonucleotide which serves to link TSU primers in a complex that is hybridized via a portion of one TSU oligonucleotide to the target strand, (5) a universal promoter primer (which may be referred to as UP1), and (6) a universal non-promoter primer (which may be referred to as  
10 UP2).

In some embodiments, two TSU primers are linked together into a complex that is then hybridized to a target strand by using hybridization of a TS sequence in a TSU primer to a complementary sequence on the target strand. Such linking of TSU primers may be mediated by hybridization of the TSU primers to a linking oligonucleotide, which is sometimes referred to as an S-oligonucleotide due to its serpentine shape when it non-covalently joins two TSU primers in a three-oligonucleotide complex, in which a first end sequence of the S-oligonucleotide that is complementary to and hybridized to part of a first TSU primer and a second end sequence of the S-oligonucleotide is complementary to and hybridized to part of a second TSU primer. In some embodiments, a TSU promoter primer sequence may be linked to a TSU non-promoter primer sequence without use of a S-oligonucleotide linker. For example, a TSU promoter primer sequence and TSU non-promoter primer sequence may be synthesized as a single oligonucleotide in which both functional sequences are covalently linked, either directly or indirectly, such as by using an intervening spacer oligonucleotide sequence or a non-nucleotide covalent linker compound. In other embodiments, the two TSU oligonucleotide sequences may be synthesized as separate oligonucleotides that are joined covalently  
25 by subsequently ligating them together directly or indirectly, e.g., by use of a random linker sequence. In embodiments in which multiple TSU oligonucleotides are linked non-covalently into a complex they may be synthesized as separate oligonucleotides and then joined to a single support, e.g., via binding pair members attached to the support, or the separate TSU oligonucleotides may contain complementary sequences that are directly hybridized to link the two functional TSU oligonucleotides into a complex. For example (shown below in "Embodiment a"), a first TSU oligonucleotide is synthesized to contain, in a 5' to 3' orientation, a 5' promoter sequence (P), a middle universal sequence (U1), and a 3' target specific sequence (TS1), and a second TSU oligonucleotide is synthesized to contain a 5' sequence complementary to the promoter sequence (P'), a middle universal sequence (U2), and a 3' target specific sequence (TS2). Alternatively (shown below in "Embodiment  
30 b"), the second TSU oligonucleotide may be without the U2 sequence to contain a 5' sequence  
35

complementary to the promoter sequence (P') and a 3' target specific sequence (TS2). When the two TSU oligonucleotides are mixed under hybridization conditions, they form a directly hybridized (DH) complex of TSU oligonucleotides as diagrammed below, where vertical lines (|||) indicate the hybridization of the complementary P and P' sequences.

Embodiment aEmbodiment b

3' – TS1 – U1 – P – 5'

3' – TS1 – U1 – P – 5'

|||

|||

5' – P' – U2 – TS2 – 3'

5' – P' – U2 – TS2 – 3'

A version of Embodiment a is illustrated schematically in FIG. 17 in which the two TSU oligonucleotides are shown in a hybridization complex that is hybridized to a target strand via the TS1 sequence of a first TSU primer which is hybridized via the complementary P' and P sequences to the second TSU oligonucleotide, which is a TSU promoter provider oligonucleotide with a blocked 3' end.

Alternatively, two TSU primers may be linked together covalently into a complex that is then hybridized to a target strand by using hybridization of a TS sequence in a TSU primer to a complementary sequence on the target strand. FIG. 18 illustrates such an embodiment. This embodiment shows two TSU oligonucleotides joined covalently via a non-nucleotide linker ( $-C_9-C_9-$ ) to form a complex made up of a TSU promoter provider that includes a blocked 3' end, and TS2, U2 and promoter (P) sequences in a 3' to 5' orientation linked to a TSU primer that includes U1 and TS1 sequences in a 5' to 3' orientation. This complex provides one extendable 3' terminus in the complex that hybridizes to a target strand via the TS1 sequence of the TSU primer. FIG. 18 also shows, hybridized to the target, a blocker oligonucleotide and a TC probe, hybridized to the target via its TS sequence. Many methods of making covalently linked primers to make a TSU primer complex are envisioned. For example, coupling after the 2 different oligos (primer and promoter primer or provider) are synthesized by using an aldehyde/hydrazine coupling pair. Other coupling pairs may be used, e.g. a carboxyl and an amine, condensed using standard carbodiimide chemistry. Alternatives for making covalently linked TSU primer complexes include constructing the entire complex on the DNA synthesizer. For example, by using standard 3' to 5' synthesis of a TSU primer, incorporation of spacers (e.g., non-nucleotide linkers or nucleotide linkers, such as poly-T), 5' to 3' synthesis of the TSU promoter primer or provider oligonucleotide by using reverse polarity phosphoramidites, and finishing the synthesis by adding a 3' blocker structure, e.g., a C added in 3' to 5' orientation. Other alternatives use the same basic strategy, but start with the TSU T7 promoter primer or provider oligonucleotide and

5 end with the non-promoter TSU primer.

Embodiments of the amplification oligonucleotides may be used in method steps in which the TSU oligonucleotides do not form a hybridization complex or covalently linked complex of multiple functional sequence regions. That is, amplification oligonucleotides may be provided in solution phase as individual oligonucleotides or mixtures of oligonucleotides in which the individual amplification  
10 oligonucleotides function in the method steps without first forming a complex of multiple amplification oligonucleotides independent of the target nucleic acid.

In some embodiments, only one TSU oligonucleotide is used in the initial amplification phase in combination with a target specific primer (TSP) that does not contain a universal (U) sequence. For example, a TSU promoter primer or TSU promoter provider oligonucleotide may be used in  
15 combination with a TS primer, or in another example, a TSU primer may be used in combination with a promoter primer or promoter provider oligonucleotide that does not contain a U sequence. That is, only one TSU oligonucleotide is used in the initial amplification phase to introduce a U sequence into an amplicon made during in the initial phase and a TS primer is used as an initiation point for enzymatic synthesis of the initial complementary strand made from the target strand or to serve as a primer to  
20 make a strand complementary to the strand made from the target strand. In an embodiment that uses only one TSU oligonucleotide, one universal primer specific for the universal sequence introduced by the TSU oligonucleotide is used in the second phase of amplification. That is, a single universal sequence serves as the surrogate or tag sequence for that target during the second phase of amplification.

25 In certain embodiments in which the promoter sequence in a TSU promoter primer or promoter provider oligonucleotide is one recognized by a bacteriophage T7 RNA polymerase, the TSU promoter primer or provider may be referred to as a "TSU T7 primer" or "TSU T7 provider" oligonucleotide which may be distinguished from a TSU non-promoter primer oligonucleotide (referred to as a "TSU non-T7 primer"), and a universal primer (UP1) that includes a T7 promoter sequence may be referred to as  
30 "T7-UP1 primer" which is distinguished from a universal primer (UP2) that does not contain a promoter sequence (referred to as a "non-T7-UP2 primer").

Table 1 summarizes various combinations of oligonucleotides that may be used in certain embodiments of universal transcription associated amplification methods described and illustrated herein. Only oligonucleotides used in a target capture step and amplification steps are listed in Table 1  
35 because amplicons may be detected by a variety of means (e.g., intercalating chemicals), which do

5 not all require additional oligonucleotides (e.g., detection probes), but those skilled in the art will appreciate that one or more detection probe oligonucleotides may be used in a complete assay that detects amplicons made by these methods. For simplicity, Table 1 uses "TMA" to refer to a transcription mediated amplification method that uses two amplification oligonucleotides that serve as primers for a single target in an initial phase of amplification (i.e., two oligonucleotides that each have a  
10 3' end that is extended enzymatically), whereas "rTMA" is used to refer to a single-primer transcription mediated amplification method that uses only one amplification oligonucleotide that serves as a primer (i.e., has a 3' end that is extended enzymatically) for each analyte in the initial phase in which other oligonucleotides included in the reaction are not extended enzymatically (see US 20060046265) in the reaction.

15 Embodiments of compositions and steps included in amplification methods described herein are illustrated by the figures.

Referring to FIG. 1, oligonucleotides used in methods disclosed herein are schematically drawn. At the top, a hybridization complex is illustrated that is made up of a TSU promoter primer linked non-covalently to the S-oligonucleotide which is linked non-covalently to the TSU non-promoter primer. In this complex, the TSU promoter primer is diagramed at the top as including a 5' promoter sequence (P, solid line), a middle universal sequence, U1 (dashed line), and a 3' target-specific sequence, TS1 (double line). The S-oligonucleotide is shown as an S-shaped curve (dotted line) having a 5' region that includes sequence U1' that is complementary to the universal sequence U1 of the TSU promoter primer and a 3' region that includes sequence U2' that is complementary to the  
20 universal sequence U2 of the TSU non-promoter primer. The TSU non-promoter primer is diagramed at the bottom of the complex includes a 5' universal sequence, U2 (dashed line) and a 3' target-specific sequence, TS2 (double line). Hybridization between the universal sequences of the TSU primers and the complementary sequences of the S-oligonucleotide forms the complex. Under the complex that contains the TSU primers is shown the target-specific capture oligonucleotide which is diagramed as having a 5' target-specific region, TS3 (double line), and a 3' moiety that is a member of a specific binding pair (triple line), which in some embodiments is a homopolymeric nucleic acid sequence. Next is shown the universal promoter primer (UP1) which is diagramed as having a 5' promoter sequence region (solid line) and a 3' universal sequence region, U1 (dashed line). Next is a diagram of the universal non-promoter primer (UP2) which is shown as a universal sequence, U2 (dashed line).

35 In preferred embodiments, target capture and amplification oligonucleotides are provided in a

5 minimum of reagents, to minimize the number of addition steps required to perform an assay. In a preferred embodiment, two reagent mixtures are provided as follows. In a first reagent mixture, referred to as a Target Capture Reagent (TCR), the TSU primers (e.g., TSU-T7 primer and TSU non-T7 primer) and all cofactors needed for their specific attachment to the desired target sequences are included (e.g., appropriate salts and buffers for hybridization when mixed with a sample that contains the target  
10 nucleic acids). The TCR also includes all of the oligonucleotides used in the target capture step, e.g., a capture probe specific for each desired target or a non-specific capture probe, a support to capture the capture probe attached to the target nucleic acid, and any intermediary oligonucleotides used in target capture, such as an immobilized probe on the support. A second reagent mixture, referred to as an Amplification Reagent (AR), provides only one set of universal primers, the universal promoter  
15 primer and the universal non-promoter primer, in addition to compounds used in *in vitro* nucleic acid synthesis, e.g., nucleotide triphosphates (NTPs, dNTPs), salts, buffering agents, enzyme cofactors, and enzyme(s).

In use, the TCR is mixed with a sample that contains the intended target nucleic acids. The TCR that contains target capture oligonucleotides and TSU primer allows all of the introduced  
20 oligonucleotides to simultaneously hybridize specifically to their respective complementary sequences for each intended target nucleic acid in the sample. By including the TSU primers and the target capture oligonucleotides in the first reagent which is mixed with the sample, a complex is formed that is made up of the target nucleic acid, the TSU primers hybridized to the target nucleic acid, and the capture oligonucleotide hybridized to a separate sequence of the target nucleic acid. Then the  
25 complex is attached to the support and separated from other sample components, including primers that are not bound to their intended target nucleic acid, thus limiting the nucleic acids carried into the amplification step to the desired targets which are already linked to their specific TSU primers. When the separated complex, attached or detached from the support, is mixed with the amplification reagent that contains the components needed for synthesis (e.g., NTPs, salts, buffering agents) and the  
30 universal primers, the target nucleic acid is already hybridized to the TSU primers allowing the initial synthesis to occur to produce a product that contains a universal sequence complementary to the universal primers (i.e., the universal promoter primer and the universal non-promoter primer). Then the universal primers may immediately hybridize to the complementary universal sequences present in the initial synthetic products, allowing the amplification reaction to continue without an additional step to  
35 introduce the universal set of primers into the reaction mixture. The universal primers also preclude

5 introducing into the reaction mixture target-specific sequences which may interact with other primer sequences, either intermolecularly or intramolecularly, which can lead to artifacts during subsequent synthetic steps of the amplification reaction.

An embodiment diagramed in FIG. 2 illustrates the target capture phase of the universal isothermal amplification method that involves specific binding of a target nucleic acid in the sample to its respective TSU primers and to its respective target-specific capture oligonucleotide. FIG. 2, 1, illustrates a target capture reagent (TCR) that is a mixture of multiple different TSU primer complexes (each containing target specific sequences, TSa, TSb, and TSc, which are specific for the different targets, a, b, and c). The TCR also contains the target-specific capture oligonucleotides for each of the potential targets, with the 3' member of the binding pair shown as a poly-A sequence. The TSU primer complexes are shown as a TSU promoter primer linked via an S-oligonucleotide to a TSU non-promoter primer, and the capture oligomers are shown as a solid line and a poly-A region, both substantially as shown in FIG. 1. For each set of TSU primer complexes and capture oligomers specific for a target nucleic acid, the target-specific regions are labeled as TSa, TSb, or TSc. The TCR also contains a support with an attached immobilized moiety that binds specifically to the capture oligomers (see FIG. 2, 3.). In FIG. 2, 2., the sample which contains a target nucleic acid (Target a) is mixed with the TCR, which allows binding of the target specific sequence of the TSa capture probe to bind to its complementary sequence in Target a, and the target specific sequence of the promoter primer in the TSU primer complex to bind to its complementary sequence in Target a. The poly-A sequence of the TSa capture probe binds to its complementary poly-T sequence of the immobilized probe attached to the support, which allows the captured Target a with the TSa TSU primer complex to be retrieved from the mixture with the support (see FIG. 2, 3.). The waste products of the target capture step, following separation of the immobilized complexes on the supports, include the unbound TSU primer complexes (TSUb and TSUc primer complexes, see FIG. 2, 4.), thereby removing them from the captured target nucleic acid that is used in a subsequent amplification process.

FIG. 3 illustrates a TSU primer complex, such as shown in FIG. 2 (3.), in more detail. The target strand is in a capture complex made up of the target strand, a capture probe that contains a 5' target specific sequence (TS3) that hybridizes specifically to a complementary target sequence (TS3') and a 3' poly-A sequence, shown hybridized to an immobilized probe that is a complementary poly-T sequence which is attached to a support. Vertical lines (| | | |) are used to indicate hybridization between some of the complementary sequence regions. The target strand is also attached to a TSU

5 primer complex by hybridization between the target's TS1' sequence region and the complementary target specific sequence region (TS1) of the TSU promoter primer in the TSU primer complex. The TSU primer complex is made up of the TSU non-promoter primer hybridized at its U2 sequence region to the complementary U2' sequence region of the S-oligonucleotide, which has a 3' blocked end ( $\ominus$ ), and the 5' region of the S-oligonucleotide is hybridized at its U1' sequence region to the

10 complementary U1 sequence region in the TSU promoter primer that includes a 5' promoter sequence region (P) and a 3' TS1 region. The target strand contains a target specific sequence region (TS2) which is identical to the target specific sequence region (TS2) of the TSU non-promoter primer. All of the target specific regions of the target strand (TS1', TS2 and TS3') are independent sequences in the target strand.

15 FIG. 4 illustrates a preferred embodiment of a TSU primer complex, similar to one illustrated in FIG. 3, in which the upper strand is a TSU non-promoter primer made up of a 3' TS2 region and a 5' universal sequence region, U2(+), which is hybridized to a 3' complementary U2' sequence region of the S-oligonucleotide, which has a 3' blocked end made up of a 3' to 3' C linkage. The S-oligonucleotide contains an abasic spacer that links the 3' U2' sequence region to the 5' U1' sequence region which is the complement of the U1(-) sequence region in the TSU promoter primer, to which it is

20 hybridized. The TSU promoter primer includes a 5' promoter sequence (P) and a 3' target specific sequence region (TS1) that flank an internal U1 region. Preferred embodiments of this type of S-oligonucleotide include as the spacer an abasic compound, e.g., (C9)<sub>2</sub> or (C9)<sub>3</sub> that is covalently joined to the flanking U1' and U2' sequences.

25 Although FIG. 2 illustrates only three different TSU primer complexes and capture probes (labeled TSUa, TSUb, and TSUc for Targets a, b and c, respectively) and only one target nucleic acid (Target a), it will be appreciated that many different TSU complexes and capture oligonucleotides, each specific for its own respective target nucleic acid, may be included in a TCR. And a sample may include many different target nucleic acids, all of which may be selectively removed from other sample

30 components. Thus, by including additional TSU primer complexes and probes in a TCR, but using substantially the same steps illustrated in FIG. 2, one or more different targets with attached TSU primers and capture oligonucleotides each bound specifically to their respective targets, may be separated from the mixture by using one or more supports that bind to one or more target-primer complexes selectively. For example, different size particles may be used as supports, each with a

35 different immobilized probe that selectively binds a target specific capture probe, so that each desired

5 target present in a single sample may be selectively removed by size separating the supports with their attached captured target and TSU primer complexes. Although FIG. 2 illustrates capture probes that include poly-A regions to hybridize to immobilized poly-T sequences, those skilled in the art will appreciate that members of any specific binding pair may be used to capture a target nucleic acid to a support, and different binding pair members may be used to selectively isolate different targets from a complex sample mixture. For example, referring to FIG. 2, the TSUa primer complexes specific to Target a, could be separated from the mixture by using a TSa capture probe that contains a ligand for receptor a in which receptor a is associated with the support as the immobilized probe. And, for example, Targets a, b, and c all contained in one sample could be associated with their respective TSU primers and separated from other sample components by using different combinations of binding pair members (BPM) on the capture probes (BPMa1, BPMb1, and BPMc1, respectively) which bind to immobilized probes via a specific binding pair partner (BPMa2, BPMb2, and BPMc2, respectively), to capture individually the targets, either all to the same support or to supports specifically for one or more targets determined by the second binding pair partner(s) associated with the support(s). For example, a capture probe for Target a associated with BPMa1 of avidin selectively removes Target a from the sample by using an immobilized probe having a BPMa2 of biotin attached to a first support, whereas in the same TCR, a capture probe for Target b is associated with a BPMb1 of an Fab fragment which selectively removed Target b by using an immobilized probe having a BPMa2 of the ligand for the Fab fragment attached to a second support, where the first and second supports are separable by standard methodologies. Supports with attached complexes that include the desired target nucleic acids may be separated from the other components in the mixture, including other sample components, such as cell debris, organelles, proteins, lipids, carbohydrates, other nucleic acids, and from unbound primers and capture probes. Any of a variety of well known ways may be used to separate supports with attached complexes from other components in the mixture, e.g. by centrifugation, filtration, gravity separation, magnetic separation of magnetized materials, aspiration, and the like. Thus, following target capture, only TSU primers bound to their respective targets are carried into the amplification phase of the assay because unbound oligonucleotides are separated from the targets during the target capture phase. Additional washing step(s) may be included in the target capture phase to wash supports with the attached targets and primer complexes, thus further purifying the captured target nucleic acids with attached TSU primers from other sample components and unbound oligonucleotides before the amplification phase.

5           Next, amplification is initiated by using the TSU primers specific for the intended target nucleic acids, i.e., primers carried into the amplification mixture with the captured complex that includes the target nucleic acid strand linked by hybridization to its corresponding TSU primer(s). In some preferred embodiments, the TSU primers carried into the amplification phase are in a TSU primer complex made up of a TSU promoter primer, S-oligonucleotide, and TSU non-promoter primer for the intended target  
10 (see FIG. 1 and FIG. 2). Other TSU primers specific for other analytes that were absent from the sample, and therefore not captured, are discarded in the target capture stage and are substantially absent from the amplification reaction mixture. Thus, the initial synthetic step in amplification relies on TSU primers attached specifically to the intended target nucleic acids present in at initial amplification phase. Because the TSU primers are already linked specifically to their intended target nucleic acid  
15 sequences, amplification initiates efficiently when other reaction components (e.g., enzymes and co-factors, synthetic substrates) are mixed with the captured target and its attached TSU primer or primer complex. The 3' end of the TSU promoter primer is extended synthetically as illustrated in FIG. 5 which shows the product that results from a first synthetic step in the initial amplification phase, in which the 3' end of the TSU promoter primer, hybridized at its TS1 sequence to the TS1' sequence of the target  
20 strand, has been synthetically extended to make a first strand cDNA. For simplicity, the other components of a TSU primer complex (the S-oligonucleotide and TSU non-promoter primer) have not been illustrated in FIG. 5, but it will be understood that the entire TSU primer complex may be attached to the RNA template strand during this synthetic step. Synthesis that initiates from the TSU promoter primer on the RNA template strand uses an RNA directed DNA polymerase or a reverse transcriptase  
25 (RT) enzyme supplied in the amplification reaction mixture to synthesize a complementary DNA (cDNA) strand. A preferred RT is one that includes RNase H activity to degrade an RNA target/template strand, although the RNA dependent DNA polymerase activity and the RNA degradation activity may be supplied by different enzymes in the amplification reaction mixture. The synthesized cDNA strand contains a sequence TS2' which is complementary to the TS2 sequence in  
30 the target/template strand. Following synthesis of the cDNA, degradation of the RNA template strand occurs from the RNase H activity in the reaction mixture, resulting in a single strand DNA that contains a 5' promoter sequence, the U1 sequence and the TS1 sequence, all supplied by the TSU promoter primer, and a 3' sequence that contains sequence complementary to the RNA template strand, including the TS2' sequence which is 3' of the TS1, U1 and P sequences. This resulting cDNA strand  
35 is shown in FIG. 6.

5           The first strand cDNA then binds to the TSU non-promoter primer by hybridization between the TS2' sequence of the cDNA and the complementary TS2 sequence of the TSU non-promoter primer, which was carried into the amplification reaction mixture as part of the TSU primer complex bound to the captured target nucleic acid. In preferred embodiments, the isothermal amplification conditions maintain the TSU non-promoter primer in a TSU primer complex (i.e., linked via the S-oligonucleotide to the TSU promoter primer) during the initial cDNA synthesis step and then the 3' TS2 portion of the TSU non-promoter primer in the complex hybridizes to the cDNA strand. Such embodiments are advantageous because they make use of efficient kinetics of hybridization that performs substantially as intramolecular hybridization because the TS2 and TS2' sequences are in close proximity due to the maintained structure of the TSU primer complex joined to the cDNA. Referring to FIG. 7, the 3' end of the TSU non-promoter primer hybridized the cDNA strand via hybridization of the TS2 and TS2' sequences is enzymatically extended by a DNA polymerase using the cDNA as a template strand to synthesize a second strand of DNA. For simplicity, FIG. 7 shows the TSU non-promoter primer without the other components of the TSU primer complex as described above, but those components may be maintained during synthesis of the second strand DNA. The second strand DNA includes a 5' universal sequence (U2) and TS2 sequence, both contributed by the TSU non-promoter primer, a DNA strand extended from the 3' end of the TSU primer, which includes a TS1' sequence and universal sequence U1' (both complementary to the TS1 and U1 sequences, respectively, of the cDNA and the TSU promoter primer), and a 3' sequence complementary to the promoter sequence (P) of the TSU promoter primer. The resulting structure is a substantially dsDNA that contains a functional promoter sequence for its respective RNA polymerase enzyme.

Continuing the initial phase of isothermal amplification, as shown in FIG. 8, the RNA polymerase (RNA Pol) specific for the promoter sequence binds to the functional promoter and initiates transcription from the substantially dsDNA, to make multiple RNA transcripts. These transcripts include a 5' U1 sequence, followed by the TS1 sequence, additional target-specific sequence located between the TS1 and TS2' sequences, the TS2' sequence, and a 3' U2' sequence. The RNA transcripts contain target specific sequences flanked by a first universal sequence (U1), and a second universal sequence (U2'), which differ from each other (one such transcript is illustrated in FIG. 9).

In the second phase of amplification, universal primers (UP1 and UP2 of FIG. 1) are used to make additional RNA transcripts in a continuous cycle of isothermal amplification, using RNA transcripts as templates for synthesis of additional amplification products or amplicons. Preferred

embodiments use the universal primers in an isothermal amplification reaction similar to TMA or NASBA reactions. In a first step of the second phase of amplification, a universal non-promoter primer (UP2), which consists essentially of a U2 sequence complementary to the 3' U2' sequence of the RNA transcripts produced in the first phase of amplification, hybridizes to the initial RNA transcripts (see FIG. 9). The 3' end of the UP2 primer is extended synthetically in an enzymatic isothermal reaction as illustrated in FIG. 10, in which the RNA transcripts from the initial phase of amplification enter the second phase at the lower left. The RT enzyme binds and initiates cDNA synthesis from the 3' end of the UP2 primer by using the RNA directed DNA polymerase activity and the transcript as a template. Following the dark arrows in FIG. 10 illustrates the steps in the second phase of amplification. The RNA template strand in the duplex with the cDNA is degraded by RNase H activity, allowing the cDNA to hybridize at the U1' sequence to the complementary U1 sequence of the universal promoter primer (UP1). The RT binds to the 3' end of the UP1 primer and initiates second strand DNA synthesis by using the DNA directed DNA polymerase activity and the cDNA strand as a template strand. The resulting dsDNA contains a functional promoter sequence and, on each strand, two universal sequences flanking the target specific sequences. RNA polymerase (RNA Pol) specific for the promoter sequence binds to the functional promoter and makes 100 to 1000 transcripts (RNA amplicons) that are identical structurally to the initial RNA transcripts made in the first phase of amplification. The additional transcripts serve as templates for more iterations of the process. The RNA transcripts made in the second phase of amplification become available for use in the amplification process when they are made, i.e., no denaturation step is required, thus efficiently amplifying the universal and target specific sequences in a continuous isothermal process. RNA transcripts made during the second phase of the isothermal amplification process may be detected during the reaction (i.e., in real time) or at a designated end point of the reaction (e.g., a specific time after beginning the amplification reaction or when amplification substantially terminates due to exhaustion of substrates present in the reaction).

The RNA amplicons may be detected by using well known detection methods which may detect simply an increase in nucleic acid concentration or may detect selected amplified sequences. For example, detection may specifically detect one or more of the universal sequence(s) or subsequence(s) thereof, or a target specific sequence(s) or a subsequence thereof, or a contiguous sequence that combines portions of universal and target specific sequences. Preferably, a detection step that uses a probe for detection of amplicons allows homogeneous detection, i.e., detection of the

hybridized probe without removal of unhybridized probe from the mixture (e.g., US Pat. Nos. 5,639,604 and 5,283,174, Arnold Jr. et al.). In preferred embodiments that detect the amplified product near or at the end of the second phase of amplification, a linear probe is used to provide a detectable signal that indicates hybridization of the probe to the amplified product. In preferred embodiments that detect the amplified product in real time, the probe is preferably a probe in which signal production is linked to the presence of the target sequence, such as a molecular beacon, molecular torch, or hybridization switch probe, that is labeled with a reporter moiety that is detected when the probe binds to amplified product. Such a probe may include a label, e.g., a fluorophore attached to one end of the probe and an interacting compound, e.g., a quencher attached to another location of the probe to inhibit signal production from the label when the probe is in a "closed" conformation that indicates it is not hybridized to the amplified product, whereas detectable signal is produced when the probe is in "open" conformation that indicates it is hybridized to the amplified product. Various probe structures and methods of using them have been described previously (e.g., US Pat. Nos. 5,118,801 and 5,312,728, Lizardi et al., US Pat. Nos. 5,925,517 and 6,150,097, Tyagi et al., US Pat. Nos. 6,849,412, 6,835,542, 6,534,274, and 6,361,945, Becker et al., US Patent Publication No. 2006-0068417, Becker et al., and WO2006/093892, Arnold Jr.).

The methods of target capture and amplification that uses at least one universal sequence described herein may be performed in a variety of different ways. In some preferred embodiments, all of the steps are performed substantially in a liquid phase, i.e., one in which most or all of the steps occur with the components in the reactions being present in substantially aqueous media. For example, the steps of target capture may be performed in a substantially liquid aqueous mixture that allows hybridization of the capture probe to the target nucleic acid and the capture probe to an immobilized probe in solution phase by using immobilize probes attached to small particles or beads that are mixed or suspended in the solution phase. Similarly, in some preferred embodiments, all of the amplification steps are performed by having all of the amplification components (e.g., substrates, templates, enzymes and cofactors) in a solution phase for the entire reaction. The detection step that detects a signal resulting from the presence of amplified products may also be performed in a substantially aqueous solution phase (e.g., as described in US Pat. Nos. 5,639,604 and 5,283,174, Arnold Jr. et al.). In other preferred embodiments, one or more of the steps in an assay that includes target capture, amplification and detection steps may be performed substantially attached to a solid phase, such as a support matrix or particle, to compartmentalize or localize detection of a particular

5 analyte of interest. Such embodiments are advantageous because amplification products may be localized, e.g., temporally or spatially, for separate detection of signals resulting from the presence of one or more selected analytes present in a sample. This is particularly useful when a sample may contain multiple different analytes that are all treated in substantially the same reagent mixtures during target capture, amplification and/or detection steps, but for which separate detection of signals  
10 resulting from the presence of amplified products for each analyte is desired.

Referring to FIG. 11, two preferred embodiments are illustrated that allow assay steps to be performed attached to a support. Both embodiments use a combination of TSU primers (TSU promoter primer and TSU non-promoter primer sequences) that are attached via members of a specific binding pair to a support. The TSU primers in both embodiments provide target specific sequences  
15 (TS1 and TS2) and universal sequences (U1 and U2) as described earlier in this disclosure. And both embodiments use universal primers (UP1 and UP2) in the second phase of amplification as described earlier in this disclosure. In contrast to the embodiments that use a TSU primer complex that includes an S-oligonucleotide (e.g., as shown in FIG. 3), the TSU primers of these two embodiments are physically linked by being attached to a support. In FIG. 11, Embodiment 1, the TSU promoter primer and TSU non-promoter primer sequences are linked to a support via a first binding pair member  
20 (BPM1) that binds specifically with a second binding pair member (BPM2) attached to the support. This may be accomplished by synthesizing a single oligonucleotide that contains all of the structural elements of the TSU promoter primer and TSU non-promoter primer sequences in the appropriate order (e.g., 3'-TS2-U2-5'-5'-P-U1-TS1-3') with a BPM1 element associated with the synthetic  
25 oligonucleotide, or by synthesizing two oligonucleotides (TSU promoter primer sequence and TSU non-promoter primer sequence) which are then attached to the same BPM2 moiety via a BPM1 moiety associated with the primers. In FIG. 11, Embodiment 2, the TSU promoter primer oligonucleotide and TSU non-promoter primer oligonucleotide are linked to the same support via a first binding pair member (BPM1) associated with each primer that binds specifically but independently with a second  
30 binding pair member (BPM2) attached to the support. In both embodiments, the TSU primers are maintained in close proximity by being bound to the same support. Because the TS1 sequence of the TSU promoter primer binds with a complementary sequence in the target nucleic acid strand (TS1'), the TSU primer may function as a capture probe to selectively bind and separate the intended target nucleic acid from a sample mixture, by using the support to separate the TSU primer-target complex  
35 from other sample components. Then, the TSU primer-target complex attached to the support and

5 mixed with amplification reaction components (e.g., substrates, enzymes, cofactors) serves as a primer-template complex in the initial phase of amplification substantially as described earlier in this disclosure except that the support substitutes for the S-oligonucleotide in providing the TSU non-promoter primer in close proximity to the cDNA synthesized from the initial TSU primer-target complex. The RNA transcripts from the first phase of amplification then serve as templates for the second phase  
10 of amplification by using the UP1 and UP2 universal primers substantially as described in this disclosure (referring to FIG. 10).

The supports in both embodiments shown in FIG. 11 may be used to localize the amplification and detection steps, temporally or spatially or both for specific analytes of interest. For example, if three different analytes (A1, A2, A3) are present in a sample, the three different target nucleic acids  
15 (T-A1, T-A2, T-A3) may be captured in a single target capture step by using three different TSU primers attached to different supports or different locations of one support, each TSU primer specific for its respective analyte by use of different TS1 sequences (TS-A1, TS-A2, TS-A3), each specific for one of the targets. Spatial separation of may result, e.g., when a single support is used to which the TSU primer complexes are attached at different predetermined loci, such as in an array. Other  
20 embodiments that achieve spatial separation include different wells or containers of a multi-chambered device which contain TSU primer complexes in a predetermined pattern or a random pattern, such as achieved by dispensing a known amount of solution in which one or more support particles are suspended at a predetermined probability, e.g., a dilution at which an average of one or fewer individual supports are deposited at a locus on or in a well or chamber. Spatial separation may also  
25 be achieved by selectively separating each of the supports into separate chambers or sections of a device before performing the amplification step by using a physical characteristic of the support to which each of the different TSU primers is attached. For example, TSU primers having different TS1 sequences (TS-A1, TS-A2, TS-A3) may be attached to different particular supports that are separable based on size, density, ligand binding capabilities, magnetic properties and the like, so that the  
30 different supports with their attached TSU primer-target complexes may be spatially separated before performing amplification steps that all use the same reagents, including the same universal primers. The amplified product detected at a particular spatial location in the detecting step indicates whether a particular analyte was present in the sample, and the cumulative detection results of all of the locations may indicate that more than one analyte was present in the sample, and may provide a quantitative or  
35 proportional measurement of each analyte present in the sample. For example, if an array of 100

5 chambers is used in which three different TSU primer-target complexes (i.e., TS-A1, TS-A2, TS-A3 primers) are spatially separated to produce an average of one TSU primer-target complex per locus before performing amplification steps, and the detection step results in 10 chambers positive for the TS-A1 primer, 30 chambers positive for the TS-A2 primer, and 50 chambers positive for the TS-A3 primer, then the results indicate that the sample contained all three analytes A1, A2 and A3, in a ratio  
10 for A1:A2:A3 of 1:3:5.

Similarly, temporal separation may be used to amplify products from different target nucleic acids and detect the amplified products. For either embodiment of FIG. 11, using the model system of three different analytes (A1, A2, A3) present in a sample, the three different target nucleic acids (T-A1, T-A2, T-A3) may be captured in a single target capture step by using three different TSU primer  
15 complexes attached to supports, each TSU primer complex specific for its respective analyte by use of different TS1 sequences (TS-A1, TS-A2, TS-A3). Amplification in the first and second phases is performed substantially as described previously herein, except that at different times during the amplification a detection measurement is made for each of the amplified products, e.g., at a first time (T1) for the A1 product, at a second time (T2) for the A2 product, and at a third time (T3) for the A3  
20 product, which each product results in a different detectable signal such as fluorescence at a different wavelength. Thus, positive signals detected only at T1 and T3 indicate that the sample contained only analytes A1 and A3, and did not contain A2. In other embodiments, temporal detections may be made at sequential times over an extended time range during the amplification reaction, e.g., at T1, T4 and T7 for A1, at T2, T5 and T8 for A2, and at T3, T6 and T9 for A3, and the cumulative results may  
25 indicate both the presence and relative amounts of each of the analytes present in a sample. For example if a positive signal is detected at T1, T4 and T7 it indicates for A1 is present in the sample, and a positive signal is detected at T8 it indicates that A2 is present in the sample, and a positive signal is detected at T6 and T9 it indicates that A3 is present in the sample. Amplification for each of the analytes is expected to proceed at approximately the same rate due to use of the same conditions  
30 and universal primers in the second phase of amplification. Thus the relative amount of amplified product and the resulting earliest time of signal detection for each amplified product provides an indication of the proportional amount of each of the analytes present in the sample. Based on the model system results above in which signal for A1 is detected before signal for A3, which is detected before signal for A2, the relative of amounts of each of the analytes in the sample are A1 greater than  
35 A3 greater than A2.

5           A combination of spatial and temporal separations may be used in an assay to amplify and selectively detect amplified products from more than one analyte in a reaction, to allow detection of amplified products for an analyte at discrete locations and times. For example, spatial separation may involve use of an array of TSU primer complexes attached to a support at predetermined loci combined with temporal separation by detecting signals at different time points from each or selected groups of  
10       loci to detect amplification products resulting from an amplification reaction performed on the array. In another embodiment, TSU primer complexes attached to particulate supports may be suspended in solution phase of an amplification reaction mixture for some portions of the amplification reaction and then sedimented or attracted to a surface in a random or non-random pattern (spatial separation) for detection of signal from the localized amplification products made during other selected times during  
15       the amplification reaction (temporal separation) so that the resulting series of cumulative patterns of detectable signals provide information on both the presence and relative amounts of analyte(s) present in the sample. Those skilled in the art will appreciate that a wide variety of spatial, temporal, and combined spatial and temporal separations may be used to selectively detect amplification products resulting from amplification reactions that include multiple analytes (i.e., multiplex reactions).

20           Those skilled in the art will also appreciate that other embodiments are encompassed by the the general principles of the assays disclosed herein. That is, assays that include a target capture step to separate a target nucleic acid from a sample and attach an initial TSU primer to the selected target nucleic acid, followed by an isothermal amplification reaction that is characterized by two phases, in which the first phase introduces universal sequences into products made from the target nucleic acid,  
25       and the second phase uses those universal sequences for further production of amplification products, which are detected in the final stage of the assay. The target capture step includes attachment of an initial TSU primer that contains a first universal sequence attaches to the target nucleic acid. The target capture step is followed by an initial phase of isothermal amplification that uses the initial TSU primer and a second TSU primer, which contains a second universal sequence, to produce RNA  
30       transcripts that contain the first universal sequence and the complementary sequence of the second universal sequence, which flank a target specific sequence. This is followed by a second phase of isothermal amplification in which the RNA transcripts made in the first phase are amplified by using a continuous process of making additional RNA transcripts by using universal primers that bind specifically to the universal sequences (or their complements) introduced by using the initial TSU and  
35       second TSU primers. The final detection step detects a signal resulting from the amplified products

5 made during the second phase of isothermal amplification to indicate that the target nucleic acid selected in the target capture step was present in the tested sample. These general assay steps may be used with a variety of different primers of different sequences which can be readily designed by those skilled in the art of molecular biology in view of the general structural features of the primers described herein.

10 Other embodiments of isothermal amplification methods that use universal sequences may use fewer TSU primers and universal primers compared to the embodiments described above, while retaining features characteristic of the method such as attachment of a TSU primer to the target nucleic acid during the target capture step and but performing isothermal amplification steps by using a combination of universal and target specific primers. For example, an embodiment may use only one  
15 initial TSU promoter primer which hybridizes to the target nucleic acid during the target capture step and is extended synthetically to introduce a single universal sequence into the cDNA and later into the RNA transcripts made during the first phase of isothermal amplification, so that the second phase of amplification uses only a single universal primer combined with one or more target specific primers to make the amplification products that are detected to indicate the presence of the analyte(s) in the  
20 tested sample. FIG. 12 illustrates two embodiments (Embodiment 1, upper, and Embodiment 2, lower) to compare difference in the (A.) target capture (TC) step with initial primer attachment and (B.) primers used in the second phase of amplification. Referring to FIG. 12, Embodiment 1 in the TC step attaches to the target strand a TSU primer complex that includes both a TSU promoter primer and a TSU non-promoter primer linked by an S-oligonucleotide as described earlier herein, where the target specific portion of the TSU promoter primer binds to a complementary sequence in the target strand to link a  
25 universal sequence (U1) to the cDNA that will be made by extending the 3' end of the TSU promoter primer in the first phase of isothermal amplification, as described earlier herein. In contrast, Embodiment 2 in the TC step attaches to the target strand only a TSU promoter primer which is hybridized to via its target specific portion to a complementary sequence in the target strand to link a  
30 U1 sequence to the cDNA that will be made by extending the 3' end of the TSU promoter primer, as described above. In Embodiment 1, the first phase of amplification will continue as described earlier with reference to FIGs. 5 to 8, in which the TSU non-promoter primer with its universal sequence will be used to make the second DNA strand, so that the RNA transcripts made in the first phase of amplification will contain two universal sequences. In Embodiment 2, instead of using a TSU non-  
35 promoter primer, a target specific non-promoter primer is hybridized to a complementary sequence in

5 the cDNA and extended synthetically to make the second strand DNA, so that the RNA transcripts made in the first phase of amplification contain only one universal sequence. Referring to FIG. 12, B., in the second phase of isothermal amplification for Embodiment 1 (upper portion), two universal primers, a universal promoter primer (UP1) and universal non-promoter primer (UP2), are used to make RNA amplicons as described earlier with reference to FIG. 10. In contrast, in Embodiment 2, of  
10 FIG. 12, B., the second phase of isothermal amplification uses only one universal promoter primer (UP1) combined with a target specific primer (TSP). Referring to FIG. 13, in the second phase of isothermal amplification, RNA amplicons are made by using synthetic steps similar to those described above, but by using the TSP (instead of UP2) to initiate synthesis of the cDNA using the RNA transcripts as templates (starting at lower left in FIG. 13.). That is, in this embodiment, no U2 or U2'  
15 universal sequences are present in the reaction.

An embodiment that uses a single TSU primer and a target specific primer may be used in assays that make use of the TSU primer attached to a support, similar to those embodiments described above with reference to FIG. 11. FIG. 14 schematically depicts a TSU promoter primer oligonucleotide made up of a promoter sequence (P), a universal sequence (U1) and a target specific  
20 sequence (TS1) which is attached to a support via a first binding pair member (BPM1) which binds specifically to a second binding pair member (BPM2) attached to the support. The TSU promoter primer is used in the first phase of amplification substantially as described above with reference to FIG. 12 (Embodiment 2). For the second phase of amplification, a mixture containing a universal promoter primer (UP1) and a target specific primer (TSP) is used, as shown in FIG. 14, using the steps as  
25 described above and diagramed in FIG. 13, to amplify the RNA transcripts. In one preferred embodiment, a TSU promoter primer attached to a support (as in FIG. 14) may be used to capture the target nucleic acid strand to which it hybridizes by using its TS1 sequence that is complementary to a sequence (TS1') in the target strand. Alternatively, an embodiment that uses a single TSU primer attached to a support may be used in combination with a TC step that uses a capture complex (as in  
30 FIG. 12, A.) that includes a support, an immobilized probe and a target specific capture probe, as described in detail previously. In an embodiment that uses a TSU promoter primer attached to a support as the means for separating the target nucleic acid from other sample components, then the TSU promoter primer serves essentially as the capture probe and as the primer for initiation of cDNA synthesis when the complex that includes the support and the TSU promoter primer hybridized to the  
35 target strand is mixed with other amplification reagents. In an embodiment that performs a TC step

5 that uses a capture complex made up of a capture probe hybridized to the target strand and bound to the immobilized probe attached to the support, then the TSU promoter primer hybridized to the target strand and attached to another support acts as the primer for initiation of cDNA synthesis when the complex is mixed with other amplification reagents. In both embodiments, the TSU primer attached to a support may be used to separate amplification products spatially, temporally, or as a combination of spatial and temporal separation as described above with reference to FIG. 11, except that the second phase of isothermal amplification relies on using a TSP instead of a universal primer (UP2).

Embodiments such as those described with reference to FIGs. 12 (Embodiment 2), 13 and 14, that use a TSU promoter primer in combination with a target specific primer (TSP) are advantageous in a number of applications. For example, in assays for detection of one or more species or isolates that share a common target sequence (TS1') that is conserved among the different targets, a TSP may be included for each of the different targets by making the TSP sequence specific for each target. For example, a TS1' sequence that occurs in 16S or 23S rRNA sequence of many members of a genus (e.g., *Mycobacterium*) may be used to design a TSU promoter primer that contains a TS1 sequence that will bind to the target 16S or 23S rRNA from all of the intended targets in the genus. Then, for each of the intended target species included in the genus targets (e.g., *M. tuberculosis*, *M. avium*, *M. abscessus*, *M. africanum*, *M. asiaticum*, *M. avium*, *M. bovis*, *M. celatum*, *M. chelonae*, *M. flavescens*, *M. fortuitum*, *M. gastri*, *M. gordonae*, *M. haemophilum*, *M. intracellulare*, *M. interjectum*, *M. intermedium*, *M. kansasii*, *M. malmoense*, *M. marinum*, *M. non-chromogenicum*, *M. paratuberculosis*, *M. phlei*, *M. scrofulaceum*, *M. shimodei*, *M. simiae*, *M. smegmatis*, *M. szulgai*, *M. terrae*, *M. triviale*, *M. tuberculosis*, *M. ulcerans* or *M. xenopi*) a TSP specific for each member is designed and used in the isothermal amplification reaction to make amplified products specific for each target species, which may be individually detected by using standard probe hybridization or size separation methods. In another example, related viral targets, such different human papillomavirus (HPV) types may be detected in a single reaction mixture designing a TSU promoter primer that binds via its TS1 sequence to a common sequence (TS1') present in all of the desired HPV types to be detected (e.g., HPV types 16, 18, 31, 33, 35, 45, 51, 56, 58, 59 and 68). Thus, the initial cDNA made from the TSU promoter primer will be synthesized for each of the intended target HPV types present in the sample using HPV mRNA in the E6/E7 gene target sequence. Then, for amplification and detection of individual HPV types of interest, a TSP is designed for each target (e.g., one each for HPV16 and HPV18) or for a combination of related targets (e.g. one specific for both HPV 16 and HPV18), i.e., each TSP binds

5 specifically to a sequence of its intended HPV type(s) only. Each TSP specific for its target type is used in the isothermal amplification reaction to make amplified products specific for the selected target types and the amplified products are individually detected by using standard methods (hybridization, size separation, sequencing) to identify the HPV type(s) present in the tested sample. Embodiments such as these are particularly useful for multiplex reactions, in which more than one selected target is present in a sample and is amplified to produce a detectable amplified product that is distinguishable from other amplified products, so that a signal from each amplified product present in the reaction mixture indicates the target analytes that were present in the tested sample.

Another application for which embodiments that use a single universal sequence provided by a TSU primer combined with multiple target specific primers (TSP) are useful is for detecting different forms of related genetic sequences or products. For example, cancers may be correlated with the presence of certain genetic translocations or translocation breakpoints (e.g., chronic myelogenous leukemia (CML) associated with translocations between human chromosomes 9 and 22 in the *abl* gene of chromosome 9 and the "breakpoint cluster region" or *bcr* gene of chromosome 22). To detect different types of translocations, an embodiment of the methods described herein uses a TSU primer in which the TS1 sequence is specific for a target sequence in a genetic sequence or mRNA of one of the translocation members (e.g., *abl* gene) that is common to many different cancer-associated translocations, and therefore can amplify sequences from many different translocations independent of the breakpoint. To amplify and detect specific translocations that are associated with cancers or have particular prognostic value, a variety of different TSPs are designed (e.g., different *bcr* sequences), each one specific for amplifying a particular sequence associated with a cancer-associated translocation, where the amplified sequence may be detected specifically using standard methods (e.g., probe hybridization, sequencing, or size of amplicon). A sample suspected of containing nucleic acid (DNA or RNA) that has a diagnostic translocation sequence is then amplified using the TSU promoter primer that amplifies many translocations in the target and with the many different TSPs, preferably in a single or a few multiplex reactions, and the amplified products are detected specifically to provide diagnostic or prognostic information based on the particular translocation sequences that are amplified and detected.

Similarly, embodiments that use a single universal sequence provided by a TSU primer and multiple target specific primers (TSP) are useful for detecting different forms of related genetic sequences that occur in different expression products of a gene (e.g., PCA3 gene associated with

5 prostate cancer; see US Pat. 7,008,765, Bussemakers et al.). Such different expression products may result from different splicing events in RNA transcripts, where some spliced RNAs are diagnostic of a disease or provide prognostic value, such as whether a cancer tissue is benign or malignant. In such embodiments, a TSU promoter primer is designed to contain a TS1 sequence that is specific for a TS1' sequence contained in all or many forms of the differentially spliced RNA, and the multiple TSPs are  
10 designed to each amplify only one form of the differentially spliced RNAs. Following amplification using the TSU promoter primer and the TSPs, preferably in a single multiplex reaction mixture, the amplified products are detected in a way that distinguishes them to provide information on the particular form(s) of spliced RNA present in the tested sample.

Other embodiments that use a single universal sequence provided by a TSU primer and  
15 multiple target specific primers (TSP) are useful for detecting mutations in genetic sequences that provide diagnostic or prognostic information, such as by detecting the presence of one or more sequences that result in drug resistance. For example, a number of HIV-1 mutations are associated with the viral infection being resistant to treatment with particular drugs (e.g., see US Pat. 6,582,920, Yang et al.). To detect one or more drug resistance mutations in a single reaction, the TSU primer is  
20 designed to contain a TS1 sequence that is complementary to HIV-1 mRNA that is common to HIV-1 strains and isolates, independent of whether the strain or isolate contains a drug resistance mutation. The multiple TSPs are designed to amplify a particular sequence that contains a mutation associated with drug resistance. In some embodiments the TSPs are specific for the drug resistance mutations themselves, whereas in other embodiments, the TSPs are specific for a sequence that does not  
25 contain the drug resistance mutation *per se*, but which amplifies a product that contains the drug resistance mutation. The TSU promoter primer is used with the multiple TSPs, preferably in a single multiplex reaction, to amplify products that provide information on whether a drug resistance mutation was present in the nucleic acid of the tested sample. For example, for embodiments in which the TSPs are specific for each of the drug resistance mutations to be detected, the presence or absence of the  
30 distinguishable amplified products indicates which mutations are present in the tested sample. In other embodiments in which the TSPs are specific for a sequence that does not contain the drug resistance mutation *per se*, but which amplifies a product that contains the drug resistance mutation(s), then standard methods of detecting the mutation(s) are used, e.g., probe hybridization including on an array, sequencing, or size separation, including mass spectrometry.

35 Testing of embodiments that use TSU primers, TSU primer complexes and universal primers,

5 in the isothermal amplification methods as described herein has been performed and amplified products have been successfully detected for viral targets and genetic sequences associated with cancer markers, such as prostate specific antigen (PSA; US Pat. 6,551,778, Harvey et al.) and PCA3 sequences.

10 Those skilled in the art of molecular biology will appreciate that TSU oligonucleotides as described herein do not require any specific sequences to function, so long as the chosen sequences fulfill the functional requirements of the TSU oligonucleotide. That is, no single sequence is required for any functional portion of a TSU oligonucleotide, e.g., no particular primer is required for a TSU promoter primer or promoter provider, so long as the TSU oligonucleotide contains sequences for all of the functional portions needed for its function for the embodiment for which it is intended as disclosed  
15 herein. Similarly, a TSU primer that does not contain a promoter sequence does not require any particular sequence so long as it contains a U sequence and a TS sequence that allows it to function for the embodiment for which it is intended as disclosed herein. Similarly, no particular sequence is required for an S-oligonucleotide, a covalently linked oligonucleotide made up of two TSU oligonucleotide sequences, or for two TSU oligonucleotides that are directly hybridized to each other  
20 via complementary sequences, so long as the appropriate sequences for each functional portion are included as described for the embodiments disclosed herein. Universal primers similarly do not require a particular sequence but instead are chosen to contain sequences that perform with the U sequence(s) chosen for the TSU oligonucleotides as described herein. For example, a universal promoter primer or promoter provider oligonucleotide contains a promoter sequence and a U sequence  
25 that functions in the methods described herein, where the U sequence of the universal primer and the U sequence of the TSU promoter oligonucleotide are usually identical, although a U sequence in the universal primer may vary from the U sequence of the TSU oligonucleotide at 1 to 3 nt positions and still perform in the methods disclosed herein. Similarly, the universal primer does not rely on any particular sequence but is selected to be identical to the universal sequence of the TSU non-promoter  
30 primer with which it is used, but U sequence in the universal primer may vary from the U sequence of the TSU primer at 1 to 3 nt positions and still function in the disclosed methods. Promoter sequences are typically the same in all TSU promoter primers or promoter providers used in an assay for multiple targets because that simplifies other reaction components (i.e., a single RNA polymerase is used), but different promoter sequences that function with the same or different RNA polymerases may be used.  
35 Those skilled in the art will appreciate that many different sequences may be incorporated into TSU

5 oligonucleotides, S-oligonucleotides, and universal primers that fall within the scope of the compositions described herein, which those skilled in the art of nucleic acid amplification are capable of selecting based on the descriptions of the structural and functional features of the oligonucleotides as described herein, where functionality may be demonstrated by using routine testing methods.

10 Embodiments of the compositions and methods described herein may be further understood by the examples that follow. Method steps used in the examples have been described herein and the following information describes typical reagents and conditions used in the methods with more particularity. Those skilled in the art of nucleic acid amplification will appreciate that other reagents and conditions may be used that will not substantially affecting the process or results so long as guidance provided in the description above is followed. For example, although transcription mediated  
15 amplification (TMA) methods are described that use a promoter primer or promoter provider oligonucleotide and a non-promoter primer in an initial phase of amplification, other methods of transcription associated nucleic acid amplification *in vitro* that rely on primer extension could be modified to use the TSU oligonucleotides as described herein to make amplified products by using universal primers, i.e., the methods are not limited to TMA-based embodiments. Those skilled in the  
20 art of molecular biology will also understand that the disclosed methods and compositions may be performed manually or in a system that performs one or more steps (e.g., pipetting, mixing, incubation, and the like) in an automated device or used in any type of known device (e.g., test tubes, multi-tube unit devices, multi-well devices such as 96-well microtitre plates, and the like).

Reagents typically used in the methods described in the examples include the following.  
25 Sample Transport Medium ("STM") contained 15 mM sodium phosphate monobasic, 15 mM sodium phosphate dibasic, 1 mM EDTA, 1 mM EGTA, and 3% (w/v) lithium lauryl sulfate (LLS), at pH 6.7. Specimen Dilution Buffer contained 300 mM HEPES, 3% (w/v) LLS, 44 mM LiCl, 120 mM LiOH, 40 mM EDTA, at pH 7.4. Target Capture Reagent (TCR) contained 250 mM HEPES, 310 mM lithium hydroxide, 1.88 M lithium chloride, 100 mM EDTA, at pH 6.4, and 250 µg/ml of magnetic particles (1  
30 micron SERA-MAG™ MG-CM particles, Seradyn, Inc. Indianapolis, IN) with (dT)<sub>14</sub> oligomers covalently bound thereto. TC Wash Solution contained 10 mM HEPES, 150 mM sodium chloride, 6.5 mM sodium hydroxide, 1 mM EDTA, 0.3% (v/v) ethanol, 0.02% (w/v) methyl paraben, 0.01% (w/v) propyl paraben, and 0.1% (w/v) sodium lauryl sulfate, at pH 7.5. Probe Reagent contained one or more labeled detection probes in a solution made up of either (1) 100 mM lithium succinate, 3% (w/v) LLS, 10 mM  
35 mercaptoethanesulfonate, and 3% (w/v) polyvinylpyrrolidone, or (2) 100 mM lithium succinate, 0.1%

5 (w/v) LLS, and 10 mM mercaptoethanesulfonate. Hybridization Reagent was either (1) 190 mM succinic acid, 17% (w/v) LLS, 100 mM lithium hydroxide, 3 mM EDTA, and 3 mM EGTA, at pH 5.1, or (2) 100 mM succinic acid, 2% (w/v) LLS, 100 mM lithium hydroxide, 15 mM aldrithiol-2, 1.2 M lithium chloride, 20 mM EDTA, and 3.0% (v/v) ethanol, at pH 4.7. Selection Reagent used to treat mixtures that use AE-labeled detection probes contained 600 mM boric acid, 182.5 mM sodium hydroxide, 1% (v/v) octoxynol (TRITON® X-100), at pH 8.5, and Detection Reagents used to elicit a chemiluminescent signal from AE-labeled probes included (1) Detect Reagent I made of 1 mM nitric acid and 32 mM hydrogen peroxide, and (2) Detect Reagent II (to neutralize pH) which was 1.5 M NaOH. Amplification reagent was a concentrated mixture that was mixed with other reaction components (target, oligonucleotides) to produce a mixture containing 47.6 mM Na-HEPES, 12.5 mM N-acetyl-L-cysteine, 15 2.5% TRITON™ X-100, 54.8 mM KCl, 23 mM MgCl<sub>2</sub>, 3 mM NaOH, 0.35 mM of each dNTP (dATP, dCTP, dGTP, dTTP), 7.06 mM rATP, 1.35 mM rCTP, 1.35 mM UTP, 8.85 mM rGTP, 0.26 mM Na<sub>2</sub>EDTA, 5% v/v glycerol, 2.9% trehalose, 0.225% ethanol, 0.075% methylparaben, 0.015% propylparaben, and 0.002% Phenol Red, at pH 7.5-7.6. Primers and/or probes may be added to the reaction mixture in the amplification reagent or separate from the amplification reagent. Enzymes used in amplification reaction mixtures were about 90 U/μl of MMLV reverse transcriptase (RT) and about 20 U/μl of T7 RNA polymerase per reaction (where 1 U of RT incorporates 1 nmol of dTTP in 10 min at 37°C using 200-400 micromolar oligo dT-primed polyA template, and 1 U of T7 RNA polymerase incorporates 1 nmol of ATP into RNA in 1 hr at 37°C using a T7 promoter in a DNA template).

A typical protocol for TMA reactions that detect results by using labeled probes at the end of the amplification reaction follows. The TMA reaction uses substantially the procedures described previously in detail (US Pat. Nos. 5,399,491 and 5,554,516, Kacian et al.). Briefly, a reaction mixture (e.g., 0.08 ml) containing amplification reagent, target nucleic acid, and amplification oligomers (e.g., 15 pmol of each oligomer per reaction) was mixed, covered with silicon oil (0.2 ml) to prevent evaporation, and incubated for 10 min at 62°C and then for 5 min at 42°C, and then the enzyme reagent (0.025 ml containing reverse transcriptase and T7 RNA polymerase) was added, and reaction mixtures were incubated for 60 min at 42°C. Following amplification, detection of the amplified products involved mixing the amplification mixture with an acridinium ester (AE) labeled detection probe oligomer specific for the amplification product (e.g., 0.1 pmol per reaction in 0.1 ml of probe reagent, or an amount previously determined to produce a maximum detectable signal in an acceptable range, such as up to 2,000,000 relative light units ("RLU") from hybridized labeled probe).

5 Mixtures of probe and amplified sequences were incubated to bind the probe to the amplified product and then treated to produce chemiluminescent signal from hybridized probes substantially as described (US Pat. Nos. 5,283,174 and 5,639,604). Briefly, the probe and amplified product mixtures were incubated for 20 min at 62°C, then cooled at room temperature about 5 min and selection reagent (0.25 ml) was added, mixed, incubated 10 min at 62°C and then at room temperature for 15 min to hydrolyze the AE label on unbound probes. Chemiluminescence from AE on bound probes was produced by adding detect reagent I, incubating, adding detect reagent II, and measuring chemiluminescence in a luminometer (e.g., LEADER®, Gen-Probe Inc., San Diego, CA).

A general protocol for TMA reactions that detect results in real time follows. The assay includes purification of target nucleic acids before amplification, amplification, and detection of the amplified products during amplification. Target capture is performed substantially as previously described in detail (US Pat. Nos. 6,110,678, 6,280,952, and 6,534,273, Weisburg et al.). Briefly, samples were prepared to contain known amounts of target RNA (*in vitro* transcripts ("IVT") present at a predetermined copy level per sample in a total volume of 0.2 ml of a 1:1 (v:v) mixture of water and sample transport medium). Each sample was mixed with 0.05 ml of TCR that typically contained 5 to 15 pmol of target capture oligomer (TCO) specific for the analyte nucleic acid to be captured (i.e., 3' target-specific binding region) and a 5' tail region (e.g., dT<sub>3</sub>A<sub>30</sub> sequence) for binding to the immobilized probe (e.g., poly-T oligomers attached to paramagnetic particles; 12.5 µg of particles with attached oligomers per reaction), 5 to 15 pmol of TSU primer and/or complex that includes TSU primer and TSU promoter primer or provider sequence for each analyte (for initial phase of amplification), and optionally 2 to 5 pmol of blocker oligomer (for rTMA amplification reactions). The mixtures were incubated for 25 to 30 min at 60 ± 1° C and then for 25 to 30 min at room temperature (20 to 25°C) to form hybridization complexes through which target nucleic acids were bound to the paramagnetic particles which were the isolated by using magnetic separation (e.g., KingFisher96™ magnetic particle processor, Thermo Fisher Scientific, Inc., Waltham, MA) and washed one time using TC wash solution. Particles were resuspended in 0.06 to 0.1 ml of amplification reagent and with amplification oligonucleotides used in the second phase of amplification (e.g., TS primer, universal primer(s), 3' blocked universal promoter provider). Detection probes (e.g., molecular beacon or molecular torch probes labeled with a fluorescent label compound) may be added with amplification oligonucleotides, or with addition of enzymes, or following addition of enzymes. Reaction mixtures were covered to prevent evaporation and incubated for 1 to 2 minutes at 42 ± 0.5°C. While keeping them at 42 ±

5 0.5°C, the mixtures were uncovered and mixed with 0.02 ml of enzyme reagent per mixture, covered again, and incubated for 30 to 90 minutes at  $42 \pm 0.5^\circ\text{C}$ , during which time fluorescence is measured at regular time intervals (e.g., every minute) which are referred to as "cycles" for data collection and display, which is typically a graph of detected fluorescence units versus time (cycles), from which a time of emergence of signal was determined (i.e., time at which fluorescence signal for a sample  
10 becomes positive over a background level, which is usually predetermined for the assay).

**Example 1: Universal TMA (uTMA) System for Detection of Multiple HPV Types**

This example shows the performance of an embodiment of universal isothermal amplification referred to as "half uTMA", in a system to detect at least 12 human papillomavirus (HPV) types associated with a high risk of developing cervical cancer (high-risk HPV types). The target was either  
15 200 or 1,000 copies/reaction (c/rxn) of a single *in vitro* transcript of the specified HPV type. Target capture, amplification and probe detection by using hybridization protection assay (HPA) which were all performed substantially as described earlier (US Pat. Nos. 6,110,678 and 6,534,273 for target capture, US Pat. Nos. 5,399,491 and 5,554,516 for TMA, and US Pat. Nos. 5,283,174 and 5,639,604 for HPV). The target capture mixture contained in the TC reagent 2 pmol each of target capture  
20 oligonucleotides of SEQ ID Nos. 28-32. The target capture mixture additionally contained 5 pmol each of HPV TSU T7 promoter primers of SEQ ID Nos. 1-9. Each of these primers contained the target-specific region, the sequence of the universal T7 primer, and a T7 promoter region. Amplification buffer contained reagents for performing TMA plus 15 pmol each of universal T7 primer of SEQ ID NO:33 and the TS (target-specific) non-T7 primers of SEQ ID Nos. 10-13.

25 During the target capture step, which includes hybridization at  $62^\circ\text{C}$ , the capture oligonucleotides and TSU T7 promoter primers hybridized to their specific *in vitro* transcripts; and all unhybridized primers were removed during the wash steps. After target capture, the magnetic beads with bound complex that includes the target strand and hybridized TSU primer were mixed with amplification reagent containing primers, RNA polymerase, reverse-transcriptase, dNTPs and NTPs,  
30 and then incubated at  $42^\circ\text{C}$  for 60 minutes. In the first step of the reaction (initial amplification phase), a cDNA transcription template is created which incorporates the universal T7 primer region and a HPV target-specific binding region. Amplification proceeds (in the second phase of amplification) by using the universal T7 promoter primer and a non-T7 primer specific for the target in the reaction. RNA amplicons were detected by HPA by using a mixture of target-specific acridinium ester (AE)-labeled  
35 probes of SEQ ID Nos. 20-27. All probes not hybridized to an amplicon target were hydrolyzed by

5 using the selection reagent during the HPA procedure and rendered non-chemiluminescent. Probes that were bound to amplicon target and remained protected from hydrolysis. HPA detection was performed by using the detection reagents, and the resulting chemiluminescent signals were measured and expressed in relative light units (RLU).

10 Table 1 shows RLU signals (average of 3 replicates) obtained for 12 high-risk HPV types, 4 low-risk HPV types, and negative reactions in which no target was added. A positive reaction was scored for RLU greater than 20,000. In this example, all high-risk HPV types were detected successfully at 200 c/rxn, except HPV 45 which was positive at 1,000 c/rxn. None of the low-risk HPV types tested gave a positive signal.

15 **Table 1**

| Group          | Target   | Avg RLU 200<br>c/rxn | Avg RLU 1,000<br>c/rxn |
|----------------|----------|----------------------|------------------------|
| A1             | HPV 16   | 3,125,124            | 3,335,360              |
|                | HPV 31   | 345,676              | 1,524,821              |
|                | HPV 35   | 2,948,726            | 3,207,962              |
| A2             | HPV 33   | 2,571,697            | 3,924,319              |
|                | HPV 58   | 922,123              | 4,270,230              |
| C1             | HPV 18   | 997,356              | 1,438,953              |
|                | HPV 45   | 12,839               | 579,850                |
|                | HPV 59   | 1,950,796            | 2,521,835              |
| C2             | HPV 39   | 2,466,025            | 2,452,492              |
|                | HPV 68   | 689,548              | 1,845,594              |
| D              | HPV 51   | 1,571,834            | 1,604,492              |
|                | HPV 56   | 1,015,787            | 775,501                |
|                |          | Avg 1 mil c/rxn      | Avg 10 mil c/rxn       |
| Low-risk types | HPV 6    | 9,431                | 9,790                  |
|                | HPV 11   | 9,839                | 9,644                  |
|                | HPV 42   | 9,805                | 9,628                  |
|                | HPV 43   | 9,683                | 9,714                  |
|                | Negative | 7,612                |                        |

**Example 2: Sensitivity of Universal TMA System for Detection of High-risk HPV Types**

This example shows the performance of an embodiment of universal isothermal amplification referred to as a "full uTMA" in a system that includes two universal sequences to detect 12 high-risk HPV virus types. The target was either 200 or 2,000 copies/reaction of a single *in vitro* transcript of the specified HPV type. Target capture, amplification and HPA detection steps were all performed substantially as described in Example 1 except that different TSU primer combinations were used. The target capture mixture contained 2 pmol each of TC oligonucleotides of SEQ ID NOs. 28, 29, 30, 31

5 and 32. The target capture mixture additionally contained S-oligonucleotide TSU primer complexes designed to detect the 12 high-risk HPV types. The TSU primer complexes were formed by hybridizing 5 pmol of TSU T7 promoter primer with 10 pmol of S-oligonucleotide of SEQ ID NO:35 and 15 pmol of the corresponding TSU non-T7 primer. The S-oligonucleotide primer complexes consisted of the S-oligonucleotide of SEQ ID NO:35 in hybridization complexes with the following combinations of TSU T7 promoter primer plus TSU non-T7 primer: SEQ ID Nos. 1 plus 14, SEQ ID Nos. 2 plus 14, SEQ ID Nos. 3 plus 14 (the same TSU non-T7 primer was used for 3 TSU T7 primers directed to a related group of HPV types), SEQ ID Nos. 4 plus 15, SEQ ID Nos. 5 plus 16, SEQ ID Nos. 6 plus 17, SEQ ID Nos. 7 plus 18, SEQ ID Nos. 8 plus 15, and SEQ ID Nos. 9 plus 15 (the same TSU non-T7 primer was used for both TSU T7 primers directed to a related group of HPV types). Each TSU T7 promoter primer contained the target-specific region, the sequence of the universal T7 primer, and a T7 promoter region. Each TSU non-T7 primer contained the target-specific region and the sequence of the universal non-T7 primer. After each S-oligonucleotide primer complex was formed separately, they were combined in the target capture mix. Amplification buffer contained 15 pmol of universal T7 promoter primer of SEQ ID NO:33 and universal non-T7 primer of SEQ ID NO:34.

20 During target capture hybridization at 62°C, the capture oligonucleotides and TSU T7 promoter primers of the S-oligonucleotide primer complexes hybridized to their specific *in vitro* transcripts; and all unhybridized primers and S-oligonucleotide primer complexes were removed during the wash steps. After target capture, the magnetic beads with bound target/primer complexes were mixed with amplification reagent containing universal primers, RNA polymerase, reverse-transcriptase, dNTPs and NTPs, and then incubated at 42°C for 60 minutes. In the first step of the amplification reaction a cDNA transcription template was created which incorporates the universal T7 primer region and a universal non-T7 primer binding region and then amplification proceeded by using the universal T7 and non-T7 primers. RNA amplicons were detected by HPA as described above using a mixture of target-specific AE-labeled probes of SEQ ID Nos. 20 to 27. All probes not hybridized to an amplicon target were hydrolyzed during the HPA procedure and rendered non-chemiluminescent. Probes that were bound to amplicon target and remained protected. HPA detection was performed as described above, and the resulting chemiluminescent signal was measured and expressed in relative light units (RLU).

Table 2 shows signals (average of 3 replicates) obtained for 12 high-risk HPV types, and negative reactions with no target added. A positive reaction was scored for RLU greater than 20,000. In this example, all high-risk HPV types were detected successfully at 200 c/rxn, except HPV 31 which

5 was positive at 2,000 copies per reaction. In other experiments (data not shown), low-risk HPV types were not detected.

**Table 2**

|    | Group | Target   | Avg RLU/200 c/rxn |             |
|----|-------|----------|-------------------|-------------|
|    |       |          | 200 c/rxn         | 2,000 c/rxn |
| 10 | A1    | HPV 16   | 32,620            | 209,397     |
|    |       | HPV 31   | 17,123            | 84,653      |
|    |       | HPV 35   | 28,542            | 217,063     |
|    | A2    | HPV 33   | 22,276            | 797,309     |
|    |       | HPV 58   | 236,932           | 1,383,602   |
| 15 | C1    | HPV 18   | 103,672           | 964,766     |
|    |       | HPV 45   | 324,981           | 1,329,859   |
|    |       | HPV 59   | 29,254            | 202,631     |
|    | C2    | HPV 39   | 100,941           | 1,376,088   |
|    |       | HPV 68   | 162,030           | 943,088     |
| 20 | D     | HPV 51   | 241,543           | 1,132,808   |
|    |       | HPV 56   | 447,408           | 483,658     |
|    |       | Negative | 10,312            |             |

**Example 3** Detection of HPV RNA from Clinical Samples Using a uTMA System

25 This example shows that the "full uTMA" system as described in example 2 is capable of detecting HPV RNA from cervical swab or scraping samples preserved in alcohol-based liquid media (CYTYC™). The procedure was performed as described in Example 2, except that 100 µl of the liquid media sample was added to 500 µl of target capture mixture in the target capture reaction.

30 The presence of both high- and low-risk HPV was determined by HPV DNA PCR and visualized as bands following separation by agarose gel electrophoresis. Identity of any HPV viral RNA present in the samples was confirmed by DNA sequencing. Samples that produced greater than 20,000 RLU using the full uTMA system, were scored as positive. Table 3 shows the correlation between HPV type and full uTMA amplification results. Positive PCR that resulted in highly visible bands were scored as "+", weak bands as "+/-", and negative results (no visible band) as "-" (and "nd" means not determined).

35 The full uTMA HPV system used in this example was not optimized for sensitivity or specificity, but correctly scored 29 of 34 cervical samples in this study. Samples 6 and 26 were probably not detected because of low amounts of HPV RNA.

5

Table 3

| Sample # | PCR Result | HPV type by sequencing | Targeted high-risk HPV | uTMA result |
|----------|------------|------------------------|------------------------|-------------|
| 10       | 1          | HPV 59                 | yes                    | +           |
|          | 2          | HPV 16                 | yes                    | +           |
|          | 3          | HPV 66                 | no                     | -           |
|          | 4          | HPV 61                 | no                     | -           |
|          | 5          | HPV 18                 | yes                    | +           |
|          | 6          | HPV 18                 | yes                    | -           |
| 15       | 7          | HPV 16                 | yes                    | +           |
|          | 8          | mixed                  | yes                    | +           |
|          | 9          | 70                     | no                     | -           |
|          | 10         | HPV 81                 | no                     | -           |
|          | 11         | mixed                  | yes                    | +           |
|          | 12         | HPV 16                 | yes                    | +           |
| 20       | 13         | HPV 33                 | yes                    | +           |
|          | 14         | HPV 58                 | yes                    | +           |
|          | 15         | HPV 31                 | yes                    | +           |
|          | 16         | HPV 18                 | yes                    | +           |
|          | 17         | nd                     | nd                     | -           |
|          | 18         | nd                     | no                     | -           |
| 25       | 19         | HPV 54                 | no                     | -           |
|          | 20         | nd                     | no                     | -           |
|          | 21         | nd                     | no                     | -           |
|          | 22         | nd                     | no                     | -           |
|          | 23         | HPV 59                 | yes                    | +           |
|          | 24         | HPV 16                 | yes                    | +           |
| 30       | 25         | HPV 81                 | no                     | -           |
|          | 26         | HPV 68                 | yes                    | -           |
|          | 27         | HPV 68                 | yes                    | +           |
|          | 28         | HPV 53                 | no                     | -           |
|          | 29         | HPV 16                 | yes                    | +           |
|          | 30         | HPV 62                 | no                     | ++++        |
| 35       | 31         | HPV 58                 | yes                    | +           |
|          | 32         | HPV 16                 | yes                    | +           |
|          | 33         | HPV 58                 | yes                    | +           |
|          | 34         | HPV 16                 | yes                    | -           |

**Example 4: Detection of PCA3 RNA in uniplex and multiplex modes using reverse standard TMA**

45 In this example, reverse TMA was performed in a standard, i.e., non-universal, format (RS-TMA). The assay was performed in either the uniplex mode, where the only oligonucleotides required for target capture, amplification and detection of PCA3 were included, or the multiplex mode, where oligonucleotides required for target capture, amplification and detection of both PCA3 and PSA were included. The assay was performed substantially equivalently to the general protocol described above. Specifically, PCA3 *in vitro* transcript (IVT; SEQ ID NO:62) was spiked into water/STM (1:1) at 10<sup>6</sup>, 10<sup>4</sup>

or  $10^2$  copies per reaction. For samples run in the uniplex mode, 5 pmol PCA3 TC probe (SEQ ID NO:53), 2 pmol PCA3 blocker (SEQ ID NO:51), and 5 pmol of PCA3 Non-T7 (NT7) primer (SEQ ID NO:49) were spiked into TCR, and 15 pmol of PCA3 Non-T7 (NT7) primer (SEQ ID NO:49), 10 pmol of PCA3 T7 promoter provider (SEQ ID NO:50) and 12 pmol PCA3 molecular torch (SEQ ID NO:52) were spiked into amplification reagent (amounts given here and later in this and other examples are per reaction, unless indicated otherwise). For samples run in the multiplex mode, in addition to the PCA3 oligomers listed above, 5 pmol PSA TC probe (SEQ ID NO:60), 2 pmol PSA blocker (SEQ ID NO:58) and 5 pmol of PSA NT7 primer (SEQ ID NO:56) were also spiked into TCR, and 15 pmol of PSA NT7 primer (SEQ ID NO:56), 10 pmol of PSA T7 promoter provider (SEQ ID NO:57) and 12 pmol PSA molecular torch (SEQ ID NO:59) were spiked into amplification reagent. For each sample, either 3 or 4 replicates were performed.

After the assay was completed, plots of fluorescence versus time were prepared for each condition (Figure 19) and average emergence times were determined (Table 4).

**Table 4**

| PCA3 amount | Emergence time (min) |           |
|-------------|----------------------|-----------|
|             | Uniplex              | Multiplex |
| $10^6$      | 8.5                  | 12.5      |
| $10^4$      | 11.5                 | >80       |
| $10^2$      | 14.5                 | >80       |

These results demonstrate that the RS-TMA readily detected PCA3 RNA in a uniplex mode. However, in a multiplex mode (PSA specific oligonucleotides present in addition to the PCA3 specific oligonucleotides present in the uniplex mode), detection of PCA3 was severely hampered. In fact,  $10^2$  and  $10^4$  copies of PCA3 were undetectable under the conditions of the assay. This illustrates the problem that exists with multiplex amplification reactions known in the art.

These results further demonstrate the ability of RS-TMA to quantitate target level, as amount of PCA3 was directly related to the emergence time. One drawback of the RS-TMA method is the small difference in emergence times between relatively large copy level differences of PCA3 (i.e., 3 minutes difference in emergence time between 100-fold differences in PCA3 copy level). This diminishes the ability of the RS-TMA method to accurately discriminate between small differences (e.g., 3-fold) in copy levels.

5 **Example 5: Detection of PCA3 RNA in uniplex and multiplex modes using reverse universal (half) TMA**

10 In this example, reverse TMA was performed in a universal (half) TMA format (RUh-TMA). In this format, a target-specific universal NT7 primer (TSU NT7) containing a specific target binding region and a universal region at the 5' end of the oligonucleotide is bound to target in the target capture step. Excess TSU-NT7 is washed away. A TSU-NT7 is included in the target capture step for each analyte to be detected in a multiplex assay. In the amplification reaction, a universal NT7 primer (same sequence as the universal sequence of all the TSU-NT7 primers) is added and is used as the NT7 primer in the amplification of all the analytes to be detected in a multiplex reaction. Also in the amplification reaction, a target specific T7 promoter provider (TS-T7) is added for each target to be detected in a multiplex assay. A schematic representation of this format is given in Figure 15.

15 The assay was performed substantially equivalently to the protocol described in Example 4 above, with the exceptions described below. Specifically, a PCA3 TSU-NT7 primer (5 pmol; SEQ ID NO:48) and PSA TSU-NT7 primer (5 pmol; SEQ ID NO:55) were spiked into TCR instead of the PCA3 and PSA TS-NT7 primers, respectively, cited in Example 4. Further, a universal NT7 primer (15 pmol; SEQ ID NO:64) was spiked into the amplification reaction instead of the PCA3 TS-NT7 primer in the  
20 uniplex mode and instead of both the PCA3 and PSA TS-NT7 primers in the multiplex mode. All other conditions were the same as those given in Example 5. After the assay was completed, average emergence times were determined (Table 5).

**Table 5**

| 25 | PCA3 amount     | Emergence time (min) |         |           |         |
|----|-----------------|----------------------|---------|-----------|---------|
|    |                 | Uniplex              |         | Multiplex |         |
|    |                 | RS-TMA               | RUh-TMA | RS-TMA    | RUh-TMA |
|    | 10 <sup>6</sup> | 7.0                  | 8.0     | 11.5      | 9.5     |
|    | 10 <sup>4</sup> | 10.0                 | 12.0    | >80       | 11.5    |
| 30 | 10 <sup>2</sup> | 14.0                 | 17.5    | >80       | 24.0    |

35 These results demonstrate that the RUh-TMA format readily detected PCA3 RNA. In the uniplex mode, emergence times are somewhat later than the corresponding emergence times obtained with the RS-TMA format. This is favorable in relation to quantitation, and helps to solve the problem with RS-TMA cited in Example 4 (i.e., diminished ability of the RS-TMA method to accurately discriminate between small differences (e.g., 3-fold) in copy levels). In the multiplex mode, the

5 interferences observed in the RS-TMA system are largely overcome, resulting in ready detection of all levels of PCA3 RNA tested.

**Example 6: Detection of PCA3 RNA in uniplex and multiplex modes using reverse universal (full) TMA (RUf-TMA) in the S-oligo format**

10 In this example, reverse TMA was performed in a universal (full) TMA format (RUh-TMA). In universal (full) TMA, amplification is initiated with a TSU-NT7 and a TSU-T7 provider, and subsequent rounds of amplification are driven by a universal NT7 primer and a universal T7 provider. In order to provide each target with the primer and provider required for initiation, yet include only a universal primer and provider in the amplification reaction, a TSU NT7 primer and a TSU T7 provider are joined  
15 together, this complex is bound to target in the target capture step (via hybridization of the target specific region of the TSU-NT7 to the target) and excess complex is washed away. In amplification, the TSU-NT7 primer is extended, and after digestion of the target via RNase H, the target specific region of the TSU-T7 provider that is joined to the TSU-NT7 primer binds to the cDNA and amplification is initiated. Amplification then continues using the universal NT7 primer and T7 provider that are in the  
20 amplification reagent.

In the S-oligo mode of RUf-TMA described in this example, the TSU-NT7 primer and TSU-T7 provider are joined via hybridization of both to an intervening "S-oligo" as shown schematically in Figure 16. This S-oligo complex is pre-formed for each analyte to be included in a multiplex assay, then all are added to TCR in the manner that NT7 primers are added in the RS- and RUh-TMA formats  
25 described above.

The assay in this example was performed substantially equivalently to the protocol described in Example 4 above, with the exceptions described below. Specifically, the multiplex portion of the assay contained the oligonucleotides required for target capture, universal amplification and real time detection of not only PCA3 and PSA, but also AMACR. PCA3 S-oligo complex was prepared by  
30 mixing 5 pmol of PCA3 TSU-NT7 primer (SEQ ID NO:48), 7.5 pmol S-oligo (SEQ ID NO:66) and 10 pmol PCA3 TSU-T7 provider (SEQ ID NO:50; in this case, the TS- and TSU-T7 providers are one and the same in water/STM/TCR (1/1/0.5). Further, PSA S-oligo complex was prepared by mixing 5 pmol of PSA TSU-NT7 primer (SEQ ID NO:55), 7.5 pmol S-oligo (SEQ ID NO:66) and 10 pmol PSA TSU-T7 provider (SEQ ID NO:57). AMACR S-oligo complex was prepared by mixing 5 pmol of AMACR TSU-  
35 NT7 primer (SEQ ID NO:36), 7.5 pmol S-oligo (SEQ ID NO:66) and 10 pmol AMACR TSU-T7 provider (SEQ ID NO:37). The mixtures were incubated at room temperature for 30 minutes to allow the

complexes to form. PCA3 and PSA TC probes and blockers were spiked into TCR as in Example 5. Additionally, AMACR TC probe (5 pmol; SEQ ID NO:40) and AMACR blocker (2 pmol; SEQ ID NO:38) were also spiked into TCR. PCA3 and PSA S-oligo complexes (5 pmol each) were spiked into TCR instead of PCA3 and PSA TS-NT7 primers, respectively. AMACR S-oligo complex (5 pmol) was also spiked into TCR. PCA3 and PSA molecular torches were spiked into amplification reagent as in Example 5. Additionally, AMACR molecular torch (12 pmol; SEQ ID NO:39) was also spiked into amplification reagent. Universal NT7 primer (15 pmol; SEQ ID NO:64) and universal T7 provider (10 pmol; SEQ ID NO:65) were spiked into the amplification reagent instead of the TS-NT7 primer(s) and TS-T7 provider(s). All other conditions were the same as those given in Example 4.

After the assay was completed, average emergence times were determined (Table 6).

**Table 6**

| PCA3 amount | Emergence time (min) |           |
|-------------|----------------------|-----------|
|             | Uniplex              | Multiplex |
| $10^6$      | 18.1                 | 20.2      |
| $10^4$      | 23.4                 | 25.4      |
| $10^2$      | 34.5                 | 36.5      |

These results demonstrate that the RUf-TMA format in the S-oligo mode readily detected PCA3 RNA. In the uniplex mode, emergence times are significantly later and the time between different copy levels is significantly greater than the corresponding values obtained with the RS-TMA format. These features are very favorable in relation to quantitation, and helps to solve the problem with RS-TMA cited in Example 5 (i.e., diminished ability of the RS-TMA method to accurately discriminate between small differences (e.g., 3-fold) in copy levels). In the multiplex mode, the interferences observed in the RS-TMA system are largely overcome, resulting in ready detection of all levels of PCA3 RNA tested.

**Example 7: Detection of PCA3 RNA in uniplex and multiplex modes**

In this example, reverse TMA was performed in a universal (full) TMA format (RUh-TMA) very similar to that described in Example 6. However, instead of via an S-oligo complex, TSU NT7 primer and TSU T7 provider were joined together using a Directly Hybridized-oligo (DH-oligo) complex. In this mode, the TSU NT7 primer and TSU T7 provider are directly hybridized to one another, with no intervening sequence as in the S-oligo complex. Figure 17 depicts an example of a DH-oligo complex,

5 in this case with binding occurring via the T7 promoter region of the T7 provider.

The assay in this example was performed substantially equivalently to the protocol described in Example 6, with the exceptions described below. Specifically, PCA3 DH-oligo complex was prepared by mixing 5 pmol of PCA3 DH-TSU-NT7 primer (SEQ ID NO:54) and 5 pmol PCA3 TSU-T7 provider (SEQ ID NO:50) in water/STM/TCR (1/1/0.5). Further, PSA DH-oligo complex was prepared by mixing 5 pmol of PSA DH-TSU-NT7 primer (SEQ ID NO:61) and 5 pmol PSA TSU-T7 provider (SEQ ID NO:57). The mixtures were incubated at room temperature for 30 minutes to allow the complexes to form. TC probes and blockers were spiked into TCR as in Example 6, but PCA3 and PSA DH-oligo complexes (5 pmol each) were spiked into TCR instead PCA3 and PSA S-oligo complexes, respectively. All other conditions were the same as those given in Example 6, except that the total amplification volume was 0.04 mL instead of 0.08 mL (0.03 mL amplification reagent and 0.01 mL enzyme reagent). After the assay was completed, average emergence times were determined (Table 7).

**Table 7**

| 20 | PCA3 amount     | Emergence time (min) |           |
|----|-----------------|----------------------|-----------|
|    |                 | Uniplex              | Multiplex |
|    | $5 \times 10^6$ | 49.5                 | 50.5      |
|    | $5 \times 10^5$ | 43.0                 | 44.0      |
|    | $5 \times 10^4$ | 36.5                 | 37.5      |
| 25 | $5 \times 10^3$ | 30.0                 | 31.0      |
|    | $5 \times 10^2$ | 24.5                 | 24.5      |

These results demonstrate that the RUf-TMA format in the DH-oligo mode readily detected PCA3 RNA. In the uniplex mode, emergence times are significantly later and the time between different copy levels is significantly greater than the corresponding values obtained with the RS-TMA format. These features are very favorable in relation to quantitation, and helps to solve the problem with RS-TMA cited in Example 4 (i.e., diminished ability of the RS-TMA method to accurately discriminate between small differences (e.g., 3-fold) in copy levels). In the multiplex mode, the interferences observed in the RS-TMA system are largely overcome, resulting in ready detection of all levels of PCA3 RNA tested. Plots of emergence time versus PCA3 copy levels for both the uniplex and multiplex assays yielded excellent correlation factors (uniplex  $R^2 = 1.000$ ; duplex  $R^2 = 1.000$ ),

5 demonstrating the quantitative nature of these assays.

**Example 8: Detection of PCA3 RNA in uniplex and multiplex modes using reverse universal (full) TMA (RUf-TMA) in the CL-oligo format**

10 In this example, reverse TMA was performed in a universal (full) TMA format (RUf-TMA) very similar to that described in Example 6. However, instead of via an S-oligo complex, TSU NT7 primer and TSU T7 provider were joined together using a covalently linked-oligo (CL-oligo) complex. In this mode, the TSU NT7 primer and TSU T7 provider are covalently linked to one another at the 5'-ends of each oligomer. A variety of methods can be utilized to achieve such a linking. An example of one possible scheme is shown schematically in Figure 18. In this case, the NT7 primer and T7 provider are  
15 joined 5' to 5' with 2 C9 linkers between the 2 oligomers.

The assay in this example was performed substantially equivalently to the protocol described in Example 6 above, with the exceptions described below. Specifically, the multiplex portion of the assay contained the oligonucleotides required for target capture, universal amplification and real time detection of not only PCA3 and PSA, but also AMACR and CAP2. CL-oligos for each analyte were  
20 prepared generally as follows: NT7 primers and T7 providers were synthesized using standard phosphoramidite reagents (Sigma Aldrich), except for those listed below, using an Expedite DNA synthesizer (Applied Biosystems, Foster City, California). The T7 provider was synthesized with a 5'-aldehyde (specialty phosphoramidite from SoluLink, San Diego, California) and a reverse polarity dC (specialty Control Pore Glass (CPG) reagent from Biosearch Technologies). The NT7 primer was  
25 synthesized with a 5' C6 amino linker (Glen-Research). Both oligos underwent cleavage and deprotection using standard conditions. A bifunctional spacer was then attached to the NT7 primer via incubation with Hydrazine-NHS ester (SoluLink) at room temperature for 2 hours in 100mM phosphate buffer (pH 7.40) containing 150 mM NaCl. The reaction mixture was then precipitated with sodium acetate (pH 5.1) and the pellet was dissolved in 100mM MOPS buffer (pH 4.8) containing a 10%  
30 excess of the 5'aldehyde-modified T7 provider. This mixture was left overnight at room temperature and subsequently desalted and purified by PAGE.

SEQ ID numbers of oligonucleotides used to construct the CL-oligo complexes are in Table 8.

**Table 8**

|    | Analyte | Oligo           |           |
|----|---------|-----------------|-----------|
|    |         | Type            | SEQ ID No |
| 5  |         |                 |           |
| 10 | PCA3    | TSU NT7 primer  | 48        |
|    |         | TSU T7 provider | 50        |
|    | PSA     | TSU NT7 primer  | 55        |
|    |         | TSU T7 provider | 57        |
| 15 | AMACR   | TSU NT7 primer  | 36        |
|    |         | TSU T7 provider | 37        |
|    | CAP2    | TSU NT7 primer  | 42        |
| 20 |         | TSU T7 provider | 43        |

PCA3 and PSA TC probes and blockers were spiked into TCR as in Example 7, but PCA3 and PSA DH-oligo complexes were replaced with PCA3 and PSA CL-oligo complexes (5 pmol each), respectively. Additionally, AMACR TC probe (5 pmol; SEQ ID NO:40), AMACR blocker (2 pmol, SEQ ID NO:38), CAP2 TC probe (5 pmol; SEQ ID NO:46) and CAP2 blocker (2 pmol, SEQ ID NO:44) were also spiked into TCR. Further, in addition to the oligonucleotides listed in Example 7, AMACR molecular torch (12 pmol; SEQ ID NO:39) and CAP2 molecular torch (12 pmol; SEQ ID NO:45) were also spiked into the amplification reagent. All other conditions were the same as those given in Example 7. After the assay was completed, average emergence times were determined (Table 9).

**Table 9**

|    | PCA3 amount     | Emergence time (min) |           |
|----|-----------------|----------------------|-----------|
|    |                 | Uniplex              | Multiplex |
|    | 10 <sup>6</sup> | 35.0                 | 35.5      |
| 35 | 10 <sup>4</sup> | 49.0                 | 48.5      |
|    | 10 <sup>2</sup> | 59.0                 | 59.5      |

These results demonstrate that the RUf-TMA format in the CL-oligo mode readily detected

PCA3 RNA. In the uniplex mode, emergence times are significantly later and the time between different copy levels is significantly greater than the corresponding values obtained with the RS-TMA format. These features are very favorable in relation to quantitation, and helps to solve the problem with RS-TMA cited in Example 5 (i.e., diminished ability of the RS-TMA method to accurately discriminate between small differences (e.g., 3-fold) in copy levels). In the multiplex mode (quadruplex in this example), the interferences observed in the RS-TMA system are largely overcome, resulting in ready detection of all levels of PCA3 RNA tested.

#### SEQUENCE LISTING IN ELECTRONIC FORM

- 10        This description contains a sequence listing in electronic form in ASCII text format. A copy of the sequence listing in electronic form is available from the Canadian Intellectual Property Office. The sequences in the sequence listing in electronic form are reproduced in the following Table.

SEQUENCE TABLE

<110> GEN-PROBE INCORPORATED

<120> METHODS AND COMPOSITIONS FOR NUCLEIC ACID AMPLIFICATION

<130> 82022-82

<140> PCT/US2007/088473

<141> 2007-12-20

<150> 60/871,451

<151> 2006-12-21

<160> 68

<170> PatentIn version 3.3

<210> 1

<211> 80

<212> DNA

<213> Artificial

<220>

<223> Synthetic oligonucleotide

<400> 1

|                                                                   |    |
|-------------------------------------------------------------------|----|
| aatttaatac gactcactat agggagagtt tgtatgtctg ttgctattat gtctagtcta | 60 |
| cgtgtgtgct ttgtacgcac                                             | 80 |

<210> 2

<211> 80

<212> DNA

<213> Artificial

<220>

<223> Synthetic oligonucleotide

<400> 2

|                                                                    |    |
|--------------------------------------------------------------------|----|
| aatttaatac gactcactat agggagagtt tgtatgtctg ttgctattat gtctaatacta | 60 |
| cttgtgtgct ctgtacacac                                              | 80 |

<210> 3

<211> 78

<212> DNA

<213> Artificial

<220>

<223> Synthetic oligonucleotide

<400> 3

|                                                                   |    |
|-------------------------------------------------------------------|----|
| aatttaatac gactcactat agggagagtt tgtatgtctg ttgctattat gtctacgcct | 60 |
| cacatttaca acaggacg                                               | 78 |

<210> 4

<211> 77  
 <212> DNA  
 <213> Artificial  
  
 <220>  
 <223> Synthetic oligonucleotide  
  
 <400> 4  
 aatttaatac gactcactat agggagagtt tgtatgtctg ttgctattat gtctacaatg 60  
 tagtaattag ctgtggc 77  
  
 <210> 5  
 <211> 78  
 <212> DNA  
 <213> Artificial  
  
 <220>  
 <223> Synthetic oligonucleotide  
  
 <400> 5  
 aatttaatac gactcactat agggagagtt tgtatgtctg ttgctattat gtctagcaca 60  
 ccacggacac acaaagga 78  
  
 <210> 6  
 <211> 82  
 <212> DNA  
 <213> Artificial  
  
 <220>  
 <223> Synthetic oligonucleotide  
  
 <400> 6  
 aatttaatac gactcactat agggagagtt tgtatgtctg ttgctattat gtctaggata 60  
 gtgtgtccat aaacagctgc tg 82  
  
 <210> 7  
 <211> 76  
 <212> DNA  
 <213> Artificial  
  
 <220>  
 <223> Synthetic oligonucleotide  
  
 <400> 7  
 aatttaatac gactcactat agggagagtt tgtatgtctg ttgctattat gtctaccgtc 60  
 tggctagtag ttgatg 76  
  
 <210> 8  
 <211> 78  
 <212> DNA  
 <213> Artificial  
  
 <220>  
 <223> Synthetic oligonucleotide

<400> 8  
 aatttaatac gactcactat agggagagtt tgtatgtctg ttgctattat gtctacggag 60  
 cttcaattct gtaacacg 78

<210> 9  
 <211> 79  
 <212> DNA  
 <213> Artificial

<220>  
 <223> Synthetic oligonucleotide

<400> 9  
 aatttaatac gactcactat agggagagtt tgtatgtctg ttgctattat gtctacgtat 60  
 gttgttttagc ttgtctagc 79

<210> 10  
 <211> 21  
 <212> DNA  
 <213> Artificial

<220>  
 <223> Synthetic oligonucleotide

<400> 10  
 gtgacagctc agatgaggat g 21

<210> 11  
 <211> 16  
 <212> DNA  
 <213> Artificial

<220>  
 <223> Synthetic oligonucleotide

<400> 11  
 cgacgagccg aaccac 16

<210> 12  
 <211> 19  
 <212> DNA  
 <213> Artificial

<220>  
 <223> Synthetic oligonucleotide

<400> 12  
 gaccttgtat gtcacgagc 19

<210> 13  
 <211> 22  
 <212> DNA  
 <213> Artificial

<220>

<223> Synthetic oligonucleotide

<400> 13  
gacagctcag aggaggagga tg 22

<210> 14  
<211> 38  
<212> DNA  
<213> Artificial

<220>  
<223> Synthetic oligonucleotide

<400> 14  
acagcagtac aaatggcagg acagctcaga ggaggagg 38

<210> 15  
<211> 40  
<212> DNA  
<213> Artificial

<220>  
<223> Synthetic oligonucleotide

<400> 15  
acagcagtac aaatggcagg tgacagctca gatgaggatg 40

<210> 16  
<211> 35  
<212> DNA  
<213> Artificial

<220>  
<223> Synthetic oligonucleotide

<400> 16  
acagcagtac aaatggcagg acgagccgaa ccaca 35

<210> 17  
<211> 42  
<212> DNA  
<213> Artificial

<220>  
<223> Synthetic oligonucleotide

<400> 17  
acagcagtac aaatggcagg acgagctgaa ccacagcgtc ac 42

<210> 18  
<211> 38  
<212> DNA  
<213> Artificial

<220>

<223> Synthetic oligonucleotide

<400> 18

acagcagtac aaatggcagg accttgatg tcacgagc

38

<210> 19

<211> 41

<212> DNA

<213> Artificial

<220>

<223> Synthetic oligonucleotide

<400> 19

acagcagtac aaatggcagg acagctcaga ggaggaggat g

41

<210> 20

<211> 23

<212> RNA

<213> Artificial

<220>

<223> Synthetic oligonucleotide

<400> 20

cagcuggaca agcagaaccg gac

23

<210> 21

<211> 21

<212> RNA

<213> Artificial

<220>

<223> Synthetic oligonucleotide

<400> 21

ggccagaugg acaagcaca c

21

<210> 22

<211> 25

<212> RNA

<213> Artificial

<220>

<223> Synthetic oligonucleotide

<400> 22

guaguagaaa gcucagcaga cgacc

25

<210> 23

<211> 22

<212> RNA

<213> Artificial

<220>

<223> Synthetic oligonucleotide

<400> 23

gaccuuagaa cacuacagca gc

22

<210> 24

<211> 23

<212> RNA

<213> Artificial

<220>

<223> Synthetic oligonucleotide

<400> 24

gauugcgagc cuuacagcag cug

23

<210> 25

<211> 21

<212> DNA

<213> Artificial

<220>

<223> Synthetic oligonucleotide

<400> 25

ccgaccatgc agttaatcac c

21

<210> 26

<211> 21

<212> DNA

<213> Artificial

<220>

<223> Synthetic oligonucleotide

<400> 26

gcgtgaccag ctaccagaaa g

21

<210> 27

<211> 21

<212> DNA

<213> Artificial

<220>

<223> Synthetic oligonucleotide

<400> 27

gccacagcaa gctagacaag c

21

<210> 28

<211> 61

<212> DNA

<213> Artificial

<220>

<223> Synthetic oligonucleotide

<400> 28

gcucauaaca guggagguca guugccuctt taaaaaaaaa aaaaaaaaaa aaaaaaaaaa 60  
a 61

<210> 29

<211> 55

<212> DNA

<213> Artificial

<220>

<223> Synthetic oligonucleotide

<400> 29

acagcgcccu gcccaacgac cctttaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaa 55

<210> 30

<211> 62

<212> DNA

<213> Artificial

<220>

<223> Synthetic oligonucleotide

<400> 30

gugcacagau cagguagcuu guagggucgt taaaaaaaaa aaaaaaaaaa aaaaaaaaaa 60  
aa 62

<210> 31

<211> 60

<212> DNA

<213> Artificial

<220>

<223> Synthetic oligonucleotide

<400> 31

gcacaggucu ggcaauuugu auggccgttt aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 60

<210> 32

<211> 59

<212> DNA

<213> Artificial

<220>

<223> Synthetic oligonucleotide

<400> 32

ggucuugac aucugugaca ccuauttta aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 59

<210> 33

<211> 55

<212> DNA

<213> Artificial

<220>  
 <223> Synthetic oligonucleotide

<400> 33  
 aatttaatac gactcactat agggagagtt tgtatgtctg ttgctattat gtcta 55

<210> 34  
 <211> 19  
 <212> DNA  
 <213> Artificial

<220>  
 <223> Synthetic oligonucleotide

<400> 34  
 acagcagtac aaatggcag 19

<210> 35  
 <211> 48  
 <212> DNA  
 <213> Artificial

<220>  
 <223> Synthetic oligonucleotide

<220>  
 <221> misc\_structure  
 <222> (28)..(29)  
 <223> non-nucleotide spacer (-CH<sub>2</sub>CH<sub>2</sub>O--)<sub>3</sub> between nt 28 and 29

<220>  
 <221> misc\_structure  
 <222> (48)..(48)  
 <223> 3' end blocked by 3' C covalently joined in 3' to 5' orientation

<400> 35  
 tagacataat agcaacagac atacaaacct gccatttgta ctgctgtc 48

<210> 36  
 <211> 54  
 <212> DNA  
 <213> Artificial

<220>  
 <223> Synthetic oligonucleotide

<400> 36  
 gtcatatgcg acgatctcag ccaggagatt cagcggggca tacggattct cacc 54

<210> 37  
 <211> 76  
 <212> DNA  
 <213> Artificial

<220>

<223> Synthetic oligonucleotide

<220>

<221> misc\_structure

<222> (76)..(76)

<223> 3' C is blocked by use of 3' DMT dC cpg structure

<400> 37

aattttaatac gactcactat agggagacca caacgggttt ctgccgggta gctggccacg 60  
atatcaacta tttggc 76

<210> 38

<211> 35

<212> RNA

<213> Artificial

<220>

<223> Synthetic oligonucleotide

<220>

<221> misc\_structure

<222> (35)..(35)

<223> 3' end is blocked by 3' C covalently joined in 3' to 5' orientation

<400> 38

gcagaagcuu ccugacuggc caaauccacu cagcc 35

<210> 39

<211> 27

<212> RNA

<213> Artificial

<220>

<223> Synthetic oligonucleotide

<220>

<221> misc\_structure

<222> (5)..(6)

<223> 9-carbon non-nucleotide linker is between nt 5 and 6

<400> 39

cugccaauuu uugagagaac acggcag 27

<210> 40

<211> 55

<212> DNA

<213> Artificial

<220>

<223> Synthetic oligonucleotide

<220>

<221> misc\_structure

<222> (55)..(55)

<223> 3' end is blocked by 3' C covalently joined in 3' to 5' orientation

<400> 40  
gcagcacauc cgaccgcuug ctttaaaaaa aaaaaaaaaa aaaaaaaaaa aaaac 55

<210> 41  
<211> 81  
<212> DNA  
<213> Artificial

<220>  
<223> Synthetic oligonucleotide

<400> 41  
tctccctata gtgagtcgta ttaaattgtc atatgcgacg atctcagcca ggagattcag 60  
cggggcatac ggattctcac c 81

<210> 42  
<211> 43  
<212> DNA  
<213> Artificial

<220>  
<223> Synthetic oligonucleotide

<400> 42  
gtcatatgcg acgatctcag ctttgtctct aattgaccat gtc 43

<210> 43  
<211> 67  
<212> DNA  
<213> Artificial

<220>  
<223> Synthetic oligonucleotide

<220>  
<221> misc\_structure  
<222> (67)..(67)  
<223> 3' terminus blocked by 3' DMT dC cpg structure

<400> 43  
aatttaatac gactcactat agggagacca caacggtttc aaggaagtga caatagatta 60  
tataggc 67

<210> 44  
<211> 23  
<212> RNA  
<213> Artificial

<220>  
<223> Synthetic oligonucleotide

<220>  
 <221> misc\_structure  
 <222> (23)..(23)  
 <223> 3' terminal end is blocked by terminal C is covalently joined in  
 3' to 5' orientation

<400> 44  
 cuauugucac uuccuugagu auc 23

<210> 45  
 <211> 22  
 <212> RNA  
 <213> Artificial

<220>  
 <223> Synthetic oligonucleotide

<220>  
 <221> misc\_structure  
 <222> (17)..(18)  
 <223> 9-carbon non-nucleotide linker is between nt 17 and 18

<400> 45  
 ccacuugcga uguuuuaagu gg 22

<210> 46  
 <211> 57  
 <212> DNA  
 <213> Artificial

<220>  
 <223> Synthetic oligonucleotide

<220>  
 <221> misc\_structure  
 <222> (57)..(57)  
 <223> 3' terminal end is blocked by C is covalently joined in 3' to 5'  
 orientation

<400> 46  
 cguucacuau uggucucugc auucttttaa aaaaaaaaaa aaaaaaaaaa aaaaaaac 57

<210> 47  
 <211> 70  
 <212> DNA  
 <213> Artificial

<220>  
 <223> Synthetic oligonucleotide

<400> 47  
 tctccctata gtgagtcgta ttaaattgtc atatgcgacg atctcagctt tgtctcta 60  
 tgaccatgtc 70

<210> 48  
 <211> 47  
 <212> DNA  
 <213> Artificial  
  
 <220>  
 <223> Synthetic oligonucleotide  
  
 <400> 48  
 gtcatatgcg acgatctcag ggctcatcga tgacccaaga tggcggc 47  
  
 <210> 49  
 <211> 27  
 <212> DNA  
 <213> Artificial  
  
 <220>  
 <223> Synthetic oligonucleotide  
  
 <400> 49  
 ggctcatcga tgacccaaga tggcggc 27  
  
 <210> 50  
 <211> 64  
 <212> DNA  
 <213> Artificial  
  
 <220>  
 <223> Synthetic oligonucleotide  
  
 <220>  
 <221> misc\_structure  
 <222> (64)..(64)  
 <223> 3' end is blocked by use of 3' DMT dC cpg structure  
  
 <400> 50  
 aatttaatac gactcactat agggagacca caacgggtttt aatgtctaag tagtgacatg 60  
 tttc 64  
  
 <210> 51  
 <211> 26  
 <212> RNA  
 <213> Artificial  
  
 <220>  
 <223> Synthetic oligonucleotide  
  
 <220>  
 <221> misc\_structure  
 <222> (26)..(26)  
 <223> 3' terminal C is covalently joined in 3' to 5' orientation  
  
 <400> 51  
 ugucacuacu uagacauuau auuguc 26

<210> 52  
 <211> 27  
 <212> RNA  
 <213> Artificial  
  
 <220>  
 <223> Synthetic oligonucleotide  
  
 <220>  
 <221> misc\_structure  
 <222> (21)..(22)  
 <223> 9-carbon non-nucleotide linker is between nt 21 and 22  
  
 <400> 52  
 cgcuuccugu guguguggua ugaagcg 27  
  
 <210> 53  
 <211> 59  
 <212> DNA  
 <213> Artificial  
  
 <220>  
 <223> Synthetic oligonucleotide  
  
 <400> 53  
 aucuguuuuc cugcccaucc uuuaagttta aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 59  
  
 <210> 54  
 <211> 74  
 <212> DNA  
 <213> Artificial  
  
 <220>  
 <223> Synthetic oligonucleotide  
  
 <400> 54  
 tctccctata gtgagtcgta ttaaattgtc atatgcgacg atctcagggc tcatcgatga 60  
 cccaagatgg cggc 74  
  
 <210> 55  
 <211> 42  
 <212> DNA  
 <213> Artificial  
  
 <220>  
 <223> Synthetic oligonucleotide  
  
 <400> 55  
 gtcatatgcg acgatctcag gctgtggctg acctgaaata cc 42  
  
 <210> 56  
 <211> 22  
 <212> DNA  
 <213> Artificial

<220>  
 <223> Synthetic oligonucleotide

<400> 56  
 gctgtggctg acctgaaata cc 22

<210> 57  
 <211> 71  
 <212> DNA  
 <213> Artificial

<220>  
 <223> Synthetic oligonucleotide

<220>  
 <221> misc\_structure  
 <222> (71)..(71)  
 <223> 3' terminal C is blocked by use of 3' DMT dC cpg structure

<400> 57  
 aatttaatac gactcactat agggagacca caacggtttc cactgcatca ggaacaaaag 60  
 cgtgatcttg c 71

<210> 58  
 <211> 24  
 <212> RNA  
 <213> Artificial

<220>  
 <223> Synthetic oligonucleotide

<220>  
 <221> misc\_structure  
 <222> (24)..(24)  
 <223> 3' terminal C is covalently joined in 3' to 5' orientation

<400> 58  
 gaugcagugg gcagcuguga ggac 24

<210> 59  
 <211> 24  
 <212> RNA  
 <213> Artificial

<220>  
 <223> Synthetic oligonucleotide

<220>  
 <221> misc\_structure  
 <222> (19)..(20)  
 <223> 9-carbon non-nucleotide linker is between nt 19 and 20

<400> 59  
 ugugucuuca ggaugaaaca caca 24

<210> 60  
 <211> 60  
 <212> DNA  
 <213> Artificial  
  
 <220>  
 <223> Synthetic oligonucleotide  
  
 <220>  
 <221> misc\_structure  
 <222> (60)..(60)  
 <223> 3' terminal C is covalently joined in 3' to 5' orientation  
  
 <400> 60  
 cgaacuugcg cacacacguc auuggattta aaaaaaaaaa aaaaaaaaaa aaaaaaaaaac 60  
  
 <210> 61  
 <211> 69  
 <212> DNA  
 <213> Artificial  
  
 <220>  
 <223> Synthetic oligonucleotide  
  
 <400> 61  
 tctccctata gtgagtcgta ttaaattgtc atatgcgacg atetcaggct gtggctgacc 60  
 tgaataacc 69  
  
 <210> 62  
 <211> 557  
 <212> DNA  
 <213> Human  
  
 <400> 62  
 tttaccatct gaggccacac atctgctgaa atggagataa ttaacatcac tagaaacagc 60  
 aagatgacaa tataatgtct aagtagtgac atgtttttgc acatttccag cccctttaaa 120  
 tatccacaca cacaggaagc acaaaaggaa gcacagaggt aagtgcctta taaagcactc 180  
 aattttctact cagaaatttt tgatggcctt aagttcctct actcgtttct atccttccta 240  
 ctcactgtcc tcccgggaatc cactaccgat tttctatttc ttgcctcgta ttgtctgact 300  
 ggctcacttg gatttatctc acggagtctg gattttctac ccgggctcac ctccgtccct 360  
 ccatatttgt cctccacttt cacagatccc tgggagaaat gcccggccgc catcttgggc 420  
 catcgatgag cctcgccctg tgcttggtcc cgcttgtgag ggaaggacat tagaaaatga 480  
 attgatgtgt tccttaaagg atgggcagga aaacagatcc tgttgtggat atttatttga 540  
 acgggattac agatttg 557  
  
 <210> 63  
 <211> 30  
 <212> DNA  
 <213> Artificial  
  
 <220>  
 <223> Synthetic oligonucleotide  
  
 <400> 63  
 atgtccaagt gtcatatgcg acgatctcag 30

<210> 64  
 <211> 20  
 <212> DNA  
 <213> Artificial  
  
 <220>  
 <223> Synthetic oligonucleotide  
  
 <400> 64  
 gtcatatgacg acgatctcag 20  
  
 <210> 65  
 <211> 40  
 <212> DNA  
 <213> Artificial  
  
 <220>  
 <223> Synthetic oligonucleotide  
  
 <220>  
 <221> misc\_structure  
 <222> (40)..(40)  
 <223> 3' terminal C is covalently joined in 3' to 5' orientation  
  
 <400> 65  
 aatttaatac gactcactat agggagacca caacggtttc 40  
  
 <210> 66  
 <211> 43  
 <212> DNA  
 <213> Artificial  
  
 <220>  
 <223> Synthetic oligonucleotide  
  
 <220>  
 <221> misc\_structure  
 <222> (20)..(21)  
 <223> two 9-carbon non-nucleotide linkers are between nt 20 and 21  
  
 <220>  
 <221> misc\_structure  
 <222> (43)..(43)  
 <223> 3' terminal C is covalently joined in 3' to 5' orientation and  
  
 <400> 66  
 ctgagatcgt cgcataatgac aaaccggtgt ggtctcccta tac 43  
  
 <210> 67  
 <211> 27  
 <212> DNA  
 <213> Artificial  
  
 <220>  
 <223> Synthetic oligonucleotide

<220>  
<221> promoter  
<222> (1)..(27)

<400> 67  
aatttaatac gactcactat agggaga

27

<210> 68  
<211> 28  
<212> DNA  
<213> Artificial

<220>  
<223> Synthetic oligonucleotide

<220>  
<221> promoter  
<222> (1)..(28)

<400> 68  
gaaattaata cgactcacta tagggaga

28

## CLAIMS:

1. A method of amplifying a target nucleic acid comprising the steps of:
  - a. mixing a target nucleic acid with a target specific universal (TSU) primer complex made up of
    - i. a TSU promoter oligonucleotide comprising a 5' promoter sequence, an internal first universal sequence (U1), and a 3' first target specific sequence (TS1) that binds specifically to a target sequence contained in a target nucleic acid, wherein the TSU promoter oligonucleotide is a TSU promoter primer oligonucleotide that has a 3' terminus that is capable of being extended by a polymerase, directly or indirectly joined to
    - ii. a TSU non-promoter primer oligonucleotide comprising a 5' second universal sequence (U2) and a 3' second target specific sequence (TS2) which is different from the TS1,
      - wherein the TSU promoter primer oligonucleotide is joined to the TSU non-promoter primer oligonucleotide via:
        - A. a covalent linkage,
        - B. a non-covalent linkage of members of a binding pair to join the TSU promoter primer oligonucleotide and the TSU non-promoter primer oligonucleotide to a support, wherein one member of the binding pair is present on the TSU promoter primer oligonucleotide or the TSU non-promoter primer oligonucleotide and the other member of the binding pair is attached to the support,
        - C. a hybridization complex between a first sequence on the TSU promoter primer oligonucleotide and a second sequence on the TSU non-promoter primer oligonucleotide that is complementary to the first sequence on the TSU promoter primer oligonucleotide, or
        - D. a hybridization complex that includes an S-oligonucleotide that contains a first sequence complementary to a sequence in the TSU promoter primer oligonucleotide and a second sequence complementary to a sequence in the TSU non-promoter primer oligonucleotide,
  - b. hybridizing the TSU promoter primer oligonucleotide of the TSU primer complex to a target sequence in the target nucleic acid via the TS1 sequence in the TSU promoter primer,

- c. isolating the target nucleic acid with hybridized TSU complex away from unhybridized TSU primer complexes and other sample components,
  - d. synthetically extending the 3' terminus of the TS1 by using a polymerase *in vitro* nucleic acid synthesis in which the target nucleic acid is a template to make a first cDNA strand,
  - e. hybridizing the TSU non-promoter primer oligonucleotide of the TSU primer complex to the first cDNA strand by specific hybridization of the TS2 sequence to its target sequence contained in the first cDNA strand,
  - f. synthetically extending the 3' terminus of the TS2 sequence hybridized to the first cDNA strand by a polymerase *in vitro* nucleic acid synthesis to make a second DNA strand, thereby making a substantially double-stranded DNA that contains a functional promoter sequence and the U1 sequence,
  - g. enzymatically transcribing RNA transcripts from the functional promoter sequence of the substantially double-stranded DNA to make RNA transcripts that contain a 5' U1 region sequence, a TS1 sequence, a complement of the second target specific sequence (TS2'), and a 3' universal sequence that is complementary to the U2 sequence (U2'),
  - h. hybridizing a universal primer oligonucleotide (UP2) that contains a universal sequence U2 to the RNA transcript at the U2' sequence,
  - i. synthetically extending the 3' terminus of the UP2 by enzymatic *in vitro* nucleic acid synthesis to make a cDNA strand,
  - j. hybridizing a universal promoter primer oligonucleotide (UP1) that contains a universal sequence U1 to the cDNA made in the previous step at the U1' sequence,
  - k. synthetically extending at least the 3' terminus of the DNA strand made in step i, by enzymatic *in vitro* nucleic acid synthesis to make a functional promoter, and
  - l. transcribing multiple RNA transcripts from the functional promoter, which transcripts are amplification products that may serve as templates for further enzymatic *in vitro* nucleic acid synthesis.
2. A method of amplifying a target nucleic acid comprising the steps of:
- a. mixing a target nucleic acid with a target specific universal (TSU) complex made up of
    - i. a TSU promoter oligonucleotide comprising a 5' promoter sequence, an internal first universal sequence (U1), and a 3' first target specific sequence (TS1) that binds specifically to its target sequence, wherein the TSU promoter oligonucleotide is a TSU promoter provider oligonucleotide

that has a blocked 3' terminus that is incapable of being extended by a polymerase, directly or indirectly joined to

- ii. a TSU non-promoter primer oligonucleotide comprising a 5' second universal sequence (U2) and a 3' second target specific sequence (TS2) which is different from the TS1,
  - wherein the TSU promoter provider oligonucleotide is joined to the TSU non-promoter primer oligonucleotide via:
    - A. a covalent linkage,
    - B. a non-covalent linkage of members of a binding pair to join the TSU promoter provider oligonucleotide and the TSU non-promoter primer oligonucleotide to a support, wherein one member of the binding pair is present on the TSU promoter provider oligonucleotide or the TSU non-promoter primer oligonucleotide and the other member of the binding pair is attached to the support,
    - C. a hybridization complex between a first sequence on the TSU promoter provider oligonucleotide and a second sequence on the TSU non-promoter primer oligonucleotide that is complementary to the first sequence on the TSU promoter provider oligonucleotide, or
    - D. a hybridization complex that includes an S-oligonucleotide that contains a first sequence complementary to a sequence in the TSU promoter provider oligonucleotide and a second sequence complementary to a sequence in the TSU non-promoter primer oligonucleotide,
- b. hybridizing the TSU non-promoter primer oligonucleotide of the TSU complex to a target sequence in the target nucleic acid via the TS2 sequence in the TSU non-promoter primer,
- c. optionally hybridizing a blocker oligonucleotide to a sequence on the target nucleic acid, wherein said blocker comprises a blocked 3' terminus to prevent extension of the blocker by a polymerase and wherein the blocker oligomer is hybridized to the target nucleic acid at a position to terminate polymerase extension of the TSU non-promoter primer,
- d. isolating the target nucleic acid with hybridized TSU complex away from unhybridized TSU primer complexes and other sample components,

e. synthetically extending the 3' terminus of the TSU non-promoter primer hybridized to the target nucleic acid by using a polymerase *in vitro* nucleic acid synthesis in which the target nucleic acid is a template to make a first cDNA strand,

f. hybridizing the TSU promoter provider oligonucleotide of the TSU complex to the first cDNA strand by specific hybridization of the TS1 sequence in the TSU promoter provider oligonucleotide to a target sequence contained in the first cDNA strand,

g. synthetically extending the 3' terminus of the first cDNA by using the TSU promoter provider as a template to make a substantially double-stranded DNA that contains a functional promoter sequence and the U1 sequence,

h. enzymatically transcribing RNA transcripts from the functional promoter sequence to make RNA transcripts that contain a 5' U1 region sequence, a TS1 sequence, a complement of the second target specific sequence (TS2'), and a 3' universal sequence that is complementary to the U2 sequence (U2'),

i. hybridizing a universal primer oligonucleotide (UP2) that contains a universal sequence U2 to the RNA transcript at the U2' sequence,

j. synthetically extending the 3' terminus of the UP2 by enzymatic *in vitro* nucleic acid synthesis to make a cDNA strand,

k. hybridizing to the U1' sequence a universal promoter oligonucleotide (UP1) that contains a promoter sequence, a universal sequence U1, and a 3' blocked end to the cDNA made in step j,

l. synthetically extending the 3' terminus of the DNA strand made in step j using the UP1 oligonucleotide as a template to make a functional double-stranded promoter using enzymatic *in vitro* nucleic acid synthesis, and

m. transcribing multiple RNA transcripts from the functional promoter, which transcripts are amplification products that may serve as templates for further enzymatic *in vitro* nucleic acid synthesis.

3. The method of claim 1 or 2, wherein the TSU promoter oligonucleotide is directly joined to the TSU non-promoter oligonucleotide via the covalent linkage.

4. The method of claim 3, wherein the covalent linkage is formed via a polynucleotide linker sequence.

5. The method of claim 3, wherein the covalent linkage is formed via a non-nucleotide abasic linker compound.
6. The method of claim 1 or 2, wherein the TSU promoter oligonucleotide is directly joined to the TSU non-promoter oligonucleotide via the hybridization complex between the first sequence on the TSU promoter oligonucleotide and the second sequence on the TSU non-promoter primer oligonucleotide that is complementary to the first sequence on the TSU promoter oligonucleotide.
7. The method of claim 1 or 2, wherein the TSU promoter oligonucleotide is indirectly joined to the TSU non-promoter oligonucleotide via the hybridization complex that includes the S-oligonucleotide.
8. The method of any one of claims 1 to 7, further comprising a step of detecting the amplification products to indicate the presence of an analyte in the sample from which the target nucleic acid was isolated.
9. The method of claim 8, wherein the detection step is performed using a probe that is complementary to an amplification product; or, wherein the detection step is a real time detection step; or, wherein the detection step is a quantitative detection step.
10. The method of any one of claims 1 to 9, wherein said isolating step comprises hybridizing a target capture oligomer to a target nucleic acid and separating the bound target nucleic acid from other components in the sample; or wherein said isolating step comprises hybridizing a target capture oligomer to a target nucleic acid, and further hybridizing the target specific sequence one of a TSU promoter oligonucleotide or a TSU non-promoter oligonucleotide to the target nucleic acid and separating the bound target nucleic acid from other components in the sample.
11. The method of any one of claims 1 to 10, wherein the amplification is a multiplex amplification reaction.

12. The method of claim 11, wherein at least a detection step is performed for two or more different amplification products in spatially separated reaction wells, wherein one of the reaction wells detects a different amplification product than does another.

13. The method of claim 12, wherein said spatially separated reaction wells further comprise amplification oligomers for increasing the amount of amplification product present in said wells.

14. A composition comprising:

a TSU promoter oligonucleotide that includes a 5' promoter sequence, an internal first universal sequence (U1), and a 3' first target specific sequence (TS1) that binds specifically to a target sequence contained in a target nucleic acid, wherein the TSU promoter oligonucleotide is a TSU promoter primer that has a 3' terminus that is capable of being extended by a polymerase, or is a TSU promoter provider oligonucleotide that has a blocked 3' terminus that is incapable of being extended by a polymerase,

a TSU non-promoter primer oligonucleotide made up of a 5' second universal sequence (U2) and a 3' second target specific sequence (TS2) which is different from the TS1, and

a means for directly or indirectly joining the TSU promoter oligonucleotide to the TSU non-promoter primer oligonucleotide, thereby forming a target specific universal (TSU) primer complex, wherein said joining means is selected from

a covalent linkage,

a non-covalent linkage of members of a binding pair to join the TSU promoter oligonucleotide and the TSU non-promoter primer oligonucleotide to a support, wherein one member of the binding pair is present on the TSU promoter oligonucleotide or the TSU non-promoter primer oligonucleotide and the other member of the binding pair is attached to the support,

a hybridization complex between a first sequence on the TSU promoter oligonucleotide and a second sequence on the TSU non-promoter primer that is complementary to the first sequence on the TSU promoter oligonucleotide, and

a hybridization complex that includes an S-oligonucleotide that contains a first sequence complementary to a sequence in the TSU promoter oligonucleotide and a second sequence complementary to a sequence in the TSU non-promoter primer oligonucleotide.

15. The composition of claim 14, wherein the means for directly joining the TSU promoter oligonucleotide to the TSU non-promoter primer oligonucleotide is the covalent linkage.
16. The composition of claim 15, wherein the covalent linkage is formed via a polynucleotide linker sequence.
17. The composition of claim 15, wherein the covalent linkage is formed via a non-nucleotide abasic linker compound.
18. The composition of claim 14, wherein the means for indirectly joining the TSU promoter oligonucleotide to the TSU non-promoter primer oligonucleotide is the non-covalent linkage of members of the binding pair to join the TSU promoter oligonucleotide and the TSU non-promoter primer oligonucleotide to the support.
19. The composition of claim 14, wherein the means for directly joining the TSU promoter oligonucleotide to the TSU non-promoter primer oligonucleotide is the hybridization complex between the first sequence on the TSU promoter oligonucleotide and the second sequence on the TSU non-promoter primer that is complementary to the first sequence on the TSU promoter oligonucleotide.
20. The composition of claim 14, wherein the means for indirectly joining the TSU promoter oligonucleotide to the TSU non-promoter primer oligonucleotide is the hybridization complex that includes the S-oligonucleotide.
21. The composition of claim 20, wherein the S-oligonucleotide contains a first sequence complementary to the universal sequence in the TSU promoter oligonucleotide and the S-oligonucleotide contains a second sequence complementary to the universal sequence in the TSU non-promoter primer oligonucleotide.
22. The composition of claim 20, wherein the S-oligonucleotide is made up of (1) a first terminal region sequence that is complementary to the U1 sequence of the TSU promoter primer and (2) a second

terminal region sequence that is complementary to the U2 sequence of the TSU non-promoter primer, and (3) a linking moiety that links the first and second terminal region sequences.

23. The composition of claim 22, wherein the linking moiety is a non-nucleic acid chemical compound that covalently links the first and second terminal region sequences.

24. The composition of any one of claims 14 to 23, further comprising a target specific capture oligonucleotide that contains a sequence that hybridizes specifically to a sequence in the target nucleic acid of the TSU promoter oligonucleotide and the TSU non-promoter primer at a sequence that is different from the sequence in the target nucleic acid that hybridizes to the TS sequence of the TSU promoter oligonucleotide or the TS sequence of the TSU non-promoter primer, and contains a means for binding the target nucleic acid to a support.

25. The composition of any one of claims 14 to 24, further comprising a universal promoter primer made up a 5' promoter sequence and a 3' universal sequence that is the same as the universal sequence of the TSU promoter oligonucleotide.

26. The composition of any one of claims 14 to 24, further comprising a universal primer made up a universal sequence that is the same as the universal sequence of the TSU non-promoter primer oligonucleotide.

27. The composition of any one of claims 14 to 24, further comprising at least one universal promoter primer made up of a 5' promoter sequence and a 3' U1 sequence and at least one target specific primer (TSP) made up of a sequence that is complementary to a sequence contained in an RNA transcript made from a double stranded DNA that contains a cDNA sequence made from synthetic extension of the 3' end of the TSU promoter primer oligonucleotide.

28. The composition of any one of claims 14 to 27, further comprising a blocker oligonucleotide that hybridizes specifically to a sequence in a target nucleic acid strand that is different than the sequence that the TS sequence of the TSU promoter oligonucleotide or the TS sequence of the TSU non-promoter

primer oligonucleotide binds to in the target nucleic acid strand, wherein the blocker oligonucleotide has a 3' blocked terminus that is not capable of being extended by a polymerase.






**FIG. 1**

FIG. 2


1. TCR containing TSU primers & capture probes



2. Mix with Sample that contains Target



4. Discard unbound TSU primer complexes



3. Retrieve the captured target and TSU primer complex




FIG. 3




FIG. 4






**FIG. 5****FIG. 6**



**FIG. 7****FIG. 8**

FIG. 9




FIG. 10




FIG. 11





FIG. 12

A. TC with TSU Primer      B. Second Phase


Embodiment 1



Embodiment 2



FIG. 13








FIG. 17




FIG. 18




FIG. 19

